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Summary
Endothelin-1 (ET-1) was found to be a complete mitogen in Rat-1 
fibroblasts and therefore the signalling pathways which might mediate its action 
were investigated. ET-1 stimulated both sustained phosphatidylinositol 4,5- 
bisphosphate (PtdIns(4,5)P2) and phosphatidylcholine (PtdCho) hydrolysis. 
The rank order of potency for both pathways stimulated by a range of ET 
isopeptides was the same for both responses (ET-1 -  ET-2 > ET-3) suggesting 
that the same receptor controls both signalling pathways. PtdCho hydrolysis 
occurred kinetically downstream of Ptdlns(4,5)p2 hydrolysis by a 
phospholipase D-catalysed mechanism apparently involving both protein kinase 
C-dependent and -independent means of activation.
The regulation of ET-l-stimulated PtdIns(4,5)P2 hydrolysis was 
investigated and compared with the response to another mitogen for Rat-1 cells, 
lysophosphatidic acid (LPA). The ET-l-stimulated generation of Ins(l,4,5)P3 
was biphasic consisting of a transient Ca2+-independent phase and a sustained 
Ca2+-dependent phase while the response to LPA was transient. The effect of 
non-hydrolysable guanine nucleotide analogues on both ET-1- and LPA- 
stimulated inositol phosphates accumulation was investigated in permeabilized 
cells. GTP[S] significantly potentiated the response to LPA but had little effect 
on the ET-1 response. Similarly, LPA enhanced the GTP[S]-stimulated 
response while ET-1 had little effect. In contrast, GDP[S] inhibited the 
accumulation of inositol phosphates in response to stimulation with ET-1 alone 
or in combination with GTP[S] to similar extents. GDP[S] only inhibited the 
response to LPA alone to a small extent but the degree of inhibition was greater 
when LPA was used in combination with GTP[S]. The differences in the 
regulation of PtdIns(4,5)P2 hydrolysis by ET-1 and LPA wars.also demonstrated 
by the ability of PMA to inhibit inositol phosphates accumulation in response to 
LPA but not ET-1 in permeabilized and intact cells.
Binding studies were performed with [125I] ET-1 on membranes from 
Rat-1 cells to characterize the ET receptor on Rat-1 cells. [125I] ET-1 bound to a 
single class of binding sites in a saturable manner and with high affinity (Kp ~ 
2nM). The degree of dissociation of bound [125I] ET-1 was very little 
suggesting a tight association between agonist and receptor. Competition 
binding experiments with ET isopeptides yielded the same rank order of potency 
(ET-1 ~ ET-2 > ET-3) as was obtained for PtdIns(4,5)P2 and PtdCho 
hydrolysis. These results suggested an ET-l-selective receptor, perhaps similar 
to the previously characterised ETa receptor subtype.
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Chapter 1
Introduction
1
1.1. The cell cycle.
The cell cycle is the period during which a cell undergoes the events
necessary for successful cell division and depending on cell type may take up to 
30h to complete. It consists of a number of phases'known as Gj (the gap before
DNA replication), S phase (when chromosomes are replicated), G2 (gap after 
DNA replication) and M phase (when the replicated chromosomes are segregated
into two daughter cells). Cell proliferation is a tightly controlled process and in 
vivo many cells are in a quiescent state termed G q with unreplicated DNA.
Cells may enter the G j phase starting either from a G q nonproliferating quiescent
state or from the previous cell cycle.
Extracellular factors in the form of growth factors or mitogenic hormones
determine whether a quiescent cell will begin to proliferate and also whether a 
normal proliferating cell in Gj will continue to traverse the cycle or revert to
quiescence (reviewed in Pardee, 1989). After entry into S phase, however, the 
cell cycle events depend largely on intracellularly triggered events, and the 
control regulating the onset of M phase is now believed to be mainly dependent 
on the protein kinase product of the cdc 2 gene, p34cdc 2 jn fact, activation of 
cdc2 kinase is now believed to be the common mechanism which regulates 
progression of all eukaryotic cells through the cell cycle (Draetta and Beach, 
1988; reviewed in Lewin,1990; Nurse, 1990 and Draetta, 1990). Levels of 
p34crfc 2 ^  fairly constant throughout the cell cycle but its kinase activity 
fluctuates dramatically. In G1 it is unphosphorylated and inactive. As cells 
proceed through S phase into G2 it becomes progressively phosphorylated on 
threonine and tyrosine residues. Dephosphorylation of both phosphotyrosine 
and phosphothreonine residues causes activation of the enzyme before onset of 
M phase. The enzyme is also regulated by interaction with a class of proteins 
termed cyclins whose levels vaiy through the cell cycle. A number of proteins 
have been shown to be phosphorylated in vitro by cdc2 kinase, for example 
Histone HI, RNA polymerase and p60c_,yrc.
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The use of clonal cell lines has greatly facilitated the analysis of the early 
events induced by growth factors. These cell lines can be made quiescent by 
either withdrawing serum growth factors from the culture medium or by 
allowing the cells to reach confluency so that all the available growth factors are 
depleted and the cells are contact inhibited. By re-adding serum or defined 
growth factors, quiescent cells are stimulated to re-enter the cell cycle and thus 
early biochemical events in response to the growth stimulus can be investigated. 
Regulation of cell proliferation is defective in cancer cells and therefore the 
identification of an altered process in a cancer or transformed cell would suggest 
that it is important in growth control and provide a potential site for therapeutic 
intervention
Multiple regulatory pathways have been proposed in several systems for
the control of entry into S phase. For example, in Balb/c 3T3 mouse fibroblasts
two distinctive steps have been proposed; "competence" is achieved by a brief
exposure to platelet-derived growth factor (PDGF) but "progression" requires
the continuous presence of epidermal growth factor (EGF) and somatomedin C
or insulin (O’ Keefe and Pledger, 1983). Other studies have shown that after a 
certain stage in Gj cells become "committed" to division and complete the cycle
in a growth factor-independent manner (Zetterberg and Larson, 1985).
1.2. Early growth factor-stimulated events.
Since the initiation of DNA synthesis is a late event, occurring 10-15h after 
the addition of a mitogen, attention has focused on the initial cellular responses 
associated with a mitogenic stimulus and their importance in the later 
proliferative response. It has become evident that an increasing list of growth- 
promoting agents acting on different types of cells elicit a common pleiotypic 
response (Fig. 1.1). These early growth factor-stimulated events include (1) a
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rise in intracellular pH (pH*) due to activation of the amiloride-sensitive Na+/H+ 
antiporter, (2) a transient rise in cytoplasmic Ca2+, (3) the phosphorylation of a 
common set of proteins, (4) an increase in c-fos and c-myc mRNA (reviewed 
in Rozengurt 1985 and 1986).
1.2.1. pHj changes
Stimulation of a rise in cytoplasmic pH (pHj) has been reported to be a
common response in the activation of many quiescent cell types. Growth 
promoting agents such as serum, endothelin, EGF, a-thrombin, insulin, 
bombesin, PDGF, vasopressin, alone or in combination, have all been shown to 
induce a rapid rise in pHi of 0.1-0.3 pH units (Moolenaar et al., 1983; 
Pouyssegur etal., 1985; Hesketh etal., 1985,1988; Ives and Daniel, 1987; 
Simonson et al., 1989). Mitogenic stimuli which bypass membrane receptor 
activation such as the Ca2+ ionophore A23187 and the tumour promoter phorbol 
myristate acetate (PMA) can also induce an increase in cytoplasmic pH (Hesketh 
etal., 1985,1988; Ives and Daniel, 1987).
It is now clearly established that this cytoplasmic alkalinization results 
from growth factor activation of a membrane-bound amiloride-sensitve Na+/H+ 
antiporter which appears to result in a modification of the pHj sensitivity of the
exchanger (reviewed in Grinstein et al., 1989; Barber, 1991). The internal Na+ 
concentration is maintained by its efflux via the o/ojbain-sensitive Na+/K+ pump 
i.e. a Na+ cycle exists (Rozengurt, 1985). Considerable information exists 
which suggests that the activation of the antiporter is either essential or at least 
permissive for the development of the proliferative response. For example, in 
some systems proliferation can be induced by an exogenously imposed 
cytoplasmic alkalinization, inhibitors of Na+/H+ exchange can block cell growth 
and under certain conditions growth is impaired in mutant cells devoid of 
Na+/H+ exchange activity (Pouyssegur et al., 1985; reviewed in Grinstein,
1989). However, the importance of the antiporter to the processes leading to
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cellular proliferation remains controversial and a large body of evidence indicates 
that stimulation of the antiporter and the associated alkalosis are not by 
themselves sufficient to initiate cell growth and, in addition, cell proliferation can 
occur in the absence of alkalinization (see Grinstein, 1989 for further 
discussion).
1.2.2. Intracellular Ca2+ changes
In addition to pHj changes^ characteristic feature of many growth stimuli 
is that they induce increases in the intracellular free Ca2+ concentration ([Ca2+] j).
This was originally detected by measurement of 4^Ca2+ efflux; for example from
Swiss 3T3 cells following stimulation with serum, vasopressin and 
prostaglandin F2a  (Lopez-Rivas and Rozengurt, 1983; Smith and Smith, 1984).
This enhanced efflux was subsequently shown to be a consequence of
stimulating the release of calcium from intracellular reservoirs; for example,
stimulation of Swiss 3T3 cells with PDGF resulted in the loss of approximately
half of the calcium stored intracellularly within 5min (Frantz, 1985; reviewed in
Rozengurt, 1985).
The method most frequently used now to investigate Ca2+ responses in
cells is fluorescent dye analysis using dyes such as quin-2 or fura-2. An
increased fluorescence signal was seen in human fibroblasts loaded with quin-2
and stimulated with PDGF or EGF (Moolenaar et al., 1984) or Swiss 3T3 cells
loaded with quin-2 or fura-2 and stimulated with bombesin, PDGF, 
vasopressin, PGF2a, EGF, bradykinin or endothelin (Morris et al., 1984;
Hesketh et al., 1985; Ives and Daniel, 1987; Hesketh et al., 1988; Takuwa et 
al., 1989). Endothelin-stimulated [Ca2+]j increases were also observed in fura-2
loaded Rat-1 cells and A10 cells (Muldoon et al., 1989). Results from these and 
other studies also suggest that the increase in [Ca2+]j is due to the influx of
extracellular Ca2+ aswell as release from intracellular stores (Simonson et al.,
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1989; Ohnishi et al., 1989; see Meldolesi et al., 1991 for further discussion of 
Ca2+ influx).
The concentration of cytosolic free calcium is clearly very important for the 
control of many essential cellular responses and therefore the increases in 
[Ca2+]j observed with many growth factors and mitogenic peptides may have a
role to play in their mechanism of action.
1.2.3. Protein phosphorylation
A common consequence of mitogenic stimulation by different types of 
growth factors is the phosphorylation of numerous proteins on serine, threonine 
and tyrosine residues which may have important implications for the activity of 
many cellular proteins. It is now becoming clear that a number of elements 
involved in controlling cell division are regulated by changes in phosphorylation. 
As discussed above (Section 1.2.1), activation of the Na+/H+ antiporter
resulting in cytoplasmic alkalinization is believed to have a role to play in the
\
mitogenic response. It has now been shown by immunoprecipitation studies in 
hamster fibroblasts and A431 cells labelled with [^2P] orthophosphate that the 
antiporter is phosphorylated (~lmol of phosphate per mol of antiporter) in 
growing cells and that mitogenic stimulation of quiescent cells with EGF, 
thrombin, phorbol esters or serum stimulates phosphorylation of the antiporter 
on serine residues with a time course similar to that for the change in pHj. It was
suggested that the affinity of the antiporter for H+ is altered by phosphorylation
(Sardet et al., 1990).
Similarly, phosphorylation of the 40S ribosomal protein S6 is also
associated with cell activation. Stimulation of quiescent Swiss 3T3 cells with 
serum, EGF, PGF2a  or insulin resulted in the multiple phosphorylation of S6 at
serine residues. EGF, PGF2a  and insulin each induced phosphorylation of the 
same subset of tryptic peptides (eight out of the eleven phosphorylated by
6
serum) suggesting that they share a common regulatory pathway for the 
phosphorylation of S6 (Martin-Perez et al., 1984). Mitogen-activated S6 
kinases with a specificity for S6 have now been purified from several systems 
including Swiss 3T3 cells (Blenis et al., 1987; Jeno et al., 1988,1989). Distinct 
90kD and 70kD S6 kinases have been identified which are both activated by 
serine/threonine phosphorylation in response to mitogens (reviewed in Sturgill 
and Wu, 1991). Phosphorylation of S6 may play an important role in 
stimulating or facilitating increased rates of initiation of protein synthesis during 
the early mitogenic response.
A widely studied tyrosine-phosphorylated protein is pp42 which becomes 
phosphorylated after stimulation of fibroblasts by a number of diverse mitogens 
including EGF, PDGF, PMA, thrombin and insulin-like growth factor II. It is a 
serine/threonine-specific protein kinase and one of two phospho forms, pp42A, 
has now been shown to correspond to MAP (mitogen-activated protein) kinase 
(Rossomondo et al., 1989; reviewed in Thomas, 1992). Two forms of MAP 
kinase have now been purified from fibroblasts having Mr 42kD and 44kD and 
activation of both forms requires threonine and tyrosine phosphorylation which 
suggests that the enzyme could serve to integrate information from converging 
signal transduction pathways (Anderson et al., 1990). Supporting this, in 
CC139 hamster fibroblasts pertussis toxin was able to inhibit by -75% the 
thrombin-induced activation of MAP kinase and the tyrosine phosphorylation of 
the protein, but not that induced by fibroblast growth factor (FGF), indicating 
that the two agonists utilise different signalling pathways to stimulate these 
phosphorylations and to activate the enzyme (L'Allemain et al., 1991a). MAP 
kinase activating factors have been described in EGF-stimulated Swiss 3T3 cells 
and NGF-stimulated PC 12 cells but it is not clear whether they are molecules 
that accelerate the autophosphorylation reaction of the enzyme or kinases that 
independently phosphorylate and activate the enzyme (Ahn et al., 1991; Seger et 
al., 1991; Gomez and Cohen, 1991; reviewed in Thomas, 1992). A
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downstream function of MAP kinase may be to regulate S6 kinase as in vitro
insulin-stimulated MAP kinase will phosphorylate and reactivate S6 kinase II
(90kD) previously inactivated by phosphatase treatment (Sturgill et al., 1988).
In contrast, MAP kinase and 70kD S6 kinase have been shown to lie on distinct
signalling pathways (Ballou et al., 1991). In addition, MAP kinase has been
shown to phosphorylate the c-jun protein and has been suggested to positively
regulate the trans -acting activity of c-jun (Pulverer et al., 1991). As a result of
these studies, it has been suggested that MAP kinase has a key role in a kinase
cascade involved in the control of cell proliferation and may be a critical control 
element for the Gq to Gj transition (Sturgill and Wu, 1991; L'Allemain et al.,
1991b).
Many growth factors have also been shown to regulate Raf-1 kinase which 
is a 74kD serine/threonine kinase encoded by the cellular homologue of v-raf, 
the transforming gene of mouse sarcoma virus 3611 (reviewed in Li et al.,
1991). Mitogenic stimulation by a number of factors increased the kinase 
activity of Raf-1 and was accompanied by serine/threonine and tyrosine 
phosphorylation of the protein (Morrison et al., 1988; Blackshear et al., 1990). 
In PDGF-treated Balb 3T3 cells, Raf-1 tyrosine phosphorylation and kinase 
activity were increased and the Raf-1 protein directly associated with the ligand- 
activated PDGF receptor. It was suggested that the PDGF receptor directly 
activates Raf-1 kinase by phosphorylating it on tyrosine residues (Morrison et 
al., 1989). Raf-1 kinase has also been shown to be a substrate for MAP kinase 
in vitro (Anderson et al., 1991) while Raf-1 kinase kinase activity from HIR.5 
cell lysates was shown to comigrate with MAP kinase activities (Lee et al.,
1992). Perhaps, as has been proposed for MAP kinase, Raf-1 may be involved 
in integrating signals from different sources. When Raf-1 function was inhibited 
by expressing c-raf- 1 antisense RNA or kinase-defective c-raf-l mutants, the 
proliferation of normal NIH/3T3 cells was inhibited, as was serum- and PMA- 
stimulated DNA replication and raf -transformation. Proliferation and
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transformation by Ki- and Ha-ras oncogenes was also blocked (Kolch et al., 
1991). These results therefore support a role for Raf-1 in the proliferative 
response. In addition, microinjection of mutant c-raf proteins into G0-aiTested
NIH/3T3 cells induced DNA synthesis and morphological transformation (Smith 
etal., 1990).
Although this section has discussed the importance of phosphorylation 
reactions in the proliferative response, it is worth mentioning that 
dephosphorylation reactions probably also have a role to play. As was 
mentioned in section 1.1, cdc2 kinase is activated by dephosphorylation at 
threonine and tyrosine residues before onset of M phase. Thus, protein 
phosphatases may also have key roles in the regulation of cell function (reviewed 
in Tonks, 1990).
1.2.4. Transcription of immediate early genes
In addition to the events taking place in the cytosol described above, a 
common response to mitogenic stimuli is the transient expression of the cellular 
oncogenes c-fos, c-myc and c-jun.. These genes are transcribed in the absence 
of protein synthesis very early in the proliferative response (Greenberg and Ziff, 
1984; Ryder and Nathan, 1988; Takuwa et al., 1989; Simonson et a/., 1989). 
The enhanced expression of c-fos mRNA is detected first, usually within 
minutes of stimulation, while c-myc mRNA appears more slowly (Muller et al., 
1984; Rozengurt and Sinnett-Smith, 1987; Takuwa etal., 1989).
The rapid induction of expression of these early genes after mitogenic 
stimulation suggests that they have a primary role in mediating the growth 
response. Fos has been implicated as a trans -acting factor that is capable of 
stimulating gene expression, not by directly binding to DNA, but by interaction 
with the sequence-specific transcription factor c-Jun/AP-1 (pp44c~Jun ) which in 
turn recognises specific cis -elements (Curran and Franza, 1988; Chiu et al.,
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1988). Fos therefore acts as a "third messenger" that is involved in the 
transmission of signals elicited by cytoplasmic second messengers to the 
transcriptional machinery in the nucleus.
1.3. Mitogenic signal transduction pathways
It is unclear what governs the mitogenic potential of an agonist in a
particular cell type. However, from studying the responses of cells grown in
culture to growth factors and mitogenic hormones, a number of signal
transduction pathways have been implicated in the initiation of cell proliferation
(Fig. 1.1). As a result growth promoting agents have been divided into two
categories. One class binds to transmembrane surface receptors possessing an
intrinsic tyrosine kinase, activation of which is believed to initiate a series of
cellular events leading to DNA replication. The second class binds to G protein-
coupled receptors that activate multiple effector systems including enzymes
producing second messenger molecules e.g. adenylyl cyclase-catalysed
formation of cAMP, phospholipase C-catalysed hydrolysis of
phosphatidylinositol 4,5-bisphosphate, phospholipase C- and phospholipase D- 
catalysed hydrolysis of phosphatidylcholine, phospholipase A2-catalysed
generation of arachidonic acid (reviewed in Pouyssegur, 1990).
1.3.1 Receptor tyrosine kinases
Growth factors belonging to this class include epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor 
(FGF) and all bind to cell surface receptors that possess an intrinsic ligand- 
activated protein tyrosine kinase activity contained in the cytoplasmic domain 
(reviewed in Yarden and Ullrich, 1988; Ullrich and Schlessinger, 1990).
Ligand binding induces receptor oligomerization and leads to activation of the
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kinase function and enhanced ligand binding affinity. A common consequence 
of receptor activation is auto-phosphorylation. Two PDGF-dependent auto­
phosphorylation sites have been identified in the human PDGF receptor, one of 
which, tyr-751, appears to be involved in modulating the interactions between 
activated receptors and cellular proteins (Kazlauskas and Cooper, 1989). EGF 
receptor auto-phosphorylation sites also appear to modulate the interaction of 
activated EGF receptors with other proteins (Margolis et al., 1990). The 
tyrosine kinase domain is the most highly conserved portion of all receptor 
tyrosine kinase molecules and contains a consensus sequence that functions as 
part of the binding site for ATP. The kinase activity is essential for signal 
transduction and induction of cellular responses such as mitogensis and 
transformation ( Escobedo et al., 1988; Pandiella et a/., 1989; Margolis et al.,
1990). Receptor activation triggers numerous cellular responses including 
stimulation of Na+/H+ exchange, Ca2+ influx, inositol lipid turnover and gene 
expression (Kruijer et al., 1984; Hasegawa-Sasaki, 1985; Frick et al., 1988; 
Pandiella et al., 1989; see also Section 1.2.).
Several receptor tyrosine kinase substrates have been identified and include 
proteins which have been implicated in the control of proliferation. Both PDGF 
and EGF receptor activation can induce tyrosine phosphorylation of, and 
association with, phospholipase C-yl (PLCyl), GTPase activating protein 
(GAP), type 1 PI kinase and Raf-1 kinase (Kaplan et al., 1987; Morrison et al., 
1989; Margolis et al., 1989; Meisenhelder et al., 1989; Wahl et al., 1989; 
Kazlauskas et al., 1990; Kaplan et al., 1990; Todderud et al., 1990; Anderson et 
al., 1990; Ellis etal., 1990; Rhee, 1991). Binding of PLC-yl and GAP to 
activated growth factor receptors may be mediated via SH2 (src -homology 2) 
domains ( Anderson et al., 1990). Tyrosine phosphorylation of Raf-1 and PLC- 
yl has been shown to induce their activation (Morrison et al., 1990; Nishibe et 
al., 1990) and suggests an important role for these and the other associated 
proteins in mediating growth factor responses.
1.3.2. Adenylyl cyclase
Adenylyl cyclase catalyses the formation of cAMP from ATP which then 
activates cAMP-dependent protein kinase (protein kinase A). Receptors 
coupling to adenylyl cyclase (e.g.B-adrenergic) do so via guanine nucleotide 
binding proteins (G proteins) that mediate activation (Gs) or inhibition (Gj) of
the enzyme (reviewed in Levitzki, 1990). The role of cAMP as a second 
messenger in mediating the mitogenic response is controversial and it has been 
reported to have both positive and negative effects on proliferation (reviewed in 
Dumont et al., 1989; Wakelam, 1990)
In Swiss 3T3 cells cAMP has been shown to be a growth promoting 
signal; cholera toxin, at concentrations which increased cAMP, acted 
synergistically with serum, insulin, phorbol esters, EGF and FGF to stimulate 
DNA synthesis. The dose-dependency for inducing DNA synthesis and 
increasing cAMP were similar. Also, inhibitors of phosphodiesterase activity 
such as IBMX (1-methyl-3-isobutylxanthine) orRo-20-1724 potentiated the 
stimulation of DNA synthesis and the increase in cAMP (Rozengurt et al.,
1981). PDGF which is mitogenic in Swiss 3T3 cells also stimulated an increase 
in cAMP by a prostaglandin E-dependent mechanism (Rozengurt et al., 1983; 
the role of cAMP in initiating DNA synthesis in Swiss 3T3 cells is further 
discussed in Rozengurt, 1985). In addition, Swiss 3T3 cells expressing 
constitutively active GSa showed increased mitogenic sensitivity in response to 
forskolin associated with enhanced intracellular cAMP accumulation (Zachary et 
al., 1990). In S. cerevisae cAMP is the positive signal for growth elicited in 
response to a sufficient nutrient supply (Dumont et al., 1989 and references 
therein).
In contrast to this role for cAMP, it has been demonstrated that the cAMP 
level is higher in dense, non-proliferating fibroblast cultures than in growing 
cells and that cAMP levels drop when growth arrested cells are stimulated by 
mitogens (Froehlich and Rachmeler, 1972; Otten et al., 1972). In Rat-1
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fibroblasts and human fibroblasts, LPA (lysophosphatidic acid) -induced cell
proliferation appears to be mediated via an inhibition of adenylyl cyclase (van
Corven et al., 1989). Likewise, in 5-hydroxytryptamine-stimulated CHL
fibroblasts inhibition of adenylyl cyclase appears to be important for DNA
synthesis (Seuwen et al., 1988) while in human fibroblasts forskolin, a potent
stimulator of adenylyl cyclase, inhibited the stimulatory effect of PDGF on [^H]
thymidine incorporation with a dose dependency similar to that observed for
cAMP formation (Heldin et al., 1989).
The growth promoting and inhibiting effects of an increase in cAMP may
be due to the existence of two distinct isozymes of cAMP-dependent protein
kinase which differ in their regulatory subunits. Use of cAMP analogues
modified at either the C-8 position or the C-6 position has suggested the
involvement of the type II protein kinase in growth inhibition. Use of the
analogues inhibited the growth of a range of human cancer cell lines associated
with an increase in the cellular levels of the regulatory unit of the type II kinase
(Katsaros et al., 1987) while transformation of NIH 3T3 cells by Harvey murine
sarcoma virus was reversed (Tagliaferri et al., 1988). The different effects of
cAMP on proliferation may also be linked to the stage in the cell cycle. In Swiss
3T3 cells exposed to cholera toxin at different stages in the cell cycle, cAMP
appeared to be positively involved in the acquisition of the state of competence 
by quiescent cells (i.e. G0-Gj) but antagonistic to the onset of DNA replication
(i.e. Gj-S) in committed cells (Smets and van Rooy, 1987). The importance of
cAMP in cell growth regulation is, however, emphasized by the discovery of an 
altered Gs protein in a group of human growth hormone-secreting pituitary
adenomas with high intracellular cAMP levels (Vallar et al., 1987).
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1.3.3 Phosphoinositide hydrolysis
The phospholipase C-catalysed hydrolysis of phosphatidylinositol 4,5- 
bisphosphate (PtdIns(4,5)P2) is a major signalling pathway which has been
implicated in the control of cell proliferation (reviewed in Berridge, 1987; 
Whitman and Cantley, 1988; Wakelam, 1990). PtdIns(4,5)P2 is a quantitatively
minor inositol lipid largely confined to the inner leaflet of the plasma membrane 
which is hydrolysed to yield two second messengers, inositol 1,4,5- 
trisphosphate (Ins(l,4,5)P3> and sn -1,2-diacylglycerol (DAG). Ins(l,4,5)p3
mobilizes calcium from intracellular stores thus raising the intracellular free 
calcium concentration ([Ca2+] j), and DAG activates protein kinase C (PKC) in a
Ca2+ and phosphatidylserine-dependent manner (see section 1.4).
The role of increased [Ca2+]j as an early signal in mitogenesshas already
been discussed (section 1.2.2). Protein kinase C can phosphorylate many 
different cellular proteins. An important site of action is the Na+/H+ exchanger 
(section 1.2.1) and in mouse thymocytes and Swiss 3T3 fibroblasts PKC 
activation has been shown to cause an increase in intracellular pH (Hesketh et 
al., 1985). Therefore both messengers generated by PtdIns(4,5)P2 hydrolysis
can activate ionic events which have been implicated in the control of cell 
growth. PKC activation and increased [Ca2+]j have also been shown to be
involved in the expression of c-fos and c-myc (Rozengurt and Sinnett-Smith, 
1987; Kaibuchi et al., 1986), genes which are considered early signals in the 
mitogenic response (section 1.2.4).
However, there is no unequivocal evidence for the necessity of ion fluxes
or c-fos and c-myc expression for cell proliferation and other approaches have 
been used to determine the importanceof PtdIns(4,5)P2 hydrolysis in mitogensais* 
Microinjection of anti-PtdIns(4,5)P2 antibodies into NIH 3T3 cells abolished
DNA synthesis stimulated by PDGF and bombesin suggesting a crucial role for 
PtdIns(4,5)P2 hydrolysis for proliferation in response to these mitogens
(Matuoka, 1988). Injection of this antibody into ras -, src - or erb -transformed
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cells inhibited oncogene-induced cell proliferation (Fukami et al., 1988). 
Neomycin, which has been proposed to inhibit phospholipase C activity by 
selectively binding polyphosphoinositides, inhibited thrombin-induced 
mitogensis at doses similar to those necessary to block thrombin-stimulated 
incorporation of ^ 2P into phosphoinositides (Carney et al., 1985).
The importance of protein kinase C in the stimulation of cell proliferation is 
demonstrated by the fact that the enzyme is the target of action of the tumour 
promoting phorbol esters, e.g. PMA (Castagna et al., 1982; Niedel et al., 1983) 
and of teleocidin and debromoaplysia toxin (Fujiki et al., 1984). These 
compounds are generally accepted to act primarily by mimicking the function of 
DAG and, since they are not enzymatically removed, they cause sustained 
activation of PKC. Further evidence for a role for PKC in growth control comes 
from overexpression studies in rat fibroblasts. These cell lines show 
morphological changes and anchorage-independent growth in the presence or 
absence of PMA (Housey et al., 1988).
In addition to acting as a tumour promoter in vivo PMA can act as a 
mitogen or co-mitogen and mimic a number of the early events associated with 
mitogenic stimulation in a variety of cultured cell lines. Similarly, the calcium 
ionophores A23187 or ionomycin which mimic the Ca2+ branch of the inositol 
lipid signalling pathway appear to be co-mitogenic in some cell types and also 
appear to mimic early growth factor stimulated events (Whitman and Cantley,
1988 and references therein). The tumour promoter thapsigargin inhibits the 
endoplasmic reticulum Ca2+-ATPase resulting in a pronounced increase in the 
concentration of [Ca2+]j supporting the proposed role of Ca2+ in cell growth
(Thastrup et al.t 1990).
Prolonged treatment of many cell types with phorbol esters such as PMA 
results in down-regulation of protein kinase C (Rodriguez-Pene and Rozengurt, 
1984) and this technique has been used as a means of inhibiting mitogen- 
stimulated PKC activity. Mitogenic stimulation by vasopressin was inhibited in
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Swiss 3T3 cells treated with phorbol 12,13-dibutyrate (Collins and Rozengurt, 
1984). In Rat-1 cells, the ability of endothelin-1 to stimulate DNA synthesis and 
anchorage-independent growth was markedly reduced by the depletion of PKC 
induced by prolonged PMA treatment (Muldoon et al., 1990).
Further evidence which supports a role for PtdIns(4,5)P2 hydrolysis in
cell proliferation is the observation that cells transformed with various oncogenes 
show enhanced inositol lipid turnover as measured by elevated DAG or inosiol 
phosphates e.g. sis, erb -B,fes,fms, src, ros, abl, ras (Fieiscnman et al.,
1986; Wakelam et al., 1986; Whitman and Cantley, 1988 and references 
therein).
However, it is important to realise that there are many systems in which 
proliferation has been shown to occur in the absence of inositol lipid turnover 
e.g. EGF in Balb/c 3T3 cells (Besterman et al., 1986) or PDGF in C3H10T1/2 
fibroblasts (Hill et al., 1990). In addition, for some mitogens, activation of 
phosphoinositide turnover elicited many of the early signals generally associated 
with mitogenesis but was shown to be insufficient to stimulate or maintain 
continuous cell proliferation (Seuwen etal., 1990; Black and Wakelam, 1990). 
Cell growth is probably sustained by a variety of interconnected intracellular 
signals within which the importance of inositol lipid turnover can vary widely 
depending on the cell type and receptor stimulated (see Whitman and Cantley, 
1988 for further discussion of correlations and non-correlations between inositol 
lipid turnover and the regulation of cell proliferation).
1.3.4. Phosphatidylcholine hydrolysis
A variety of mitogens have now also been shown to stimulate the 
hydrolysis of phosphatidylcholine (PtdCho) which may be another source of 
second naessengers. PtdCho is hydrolysed by phospholipase C (PLC) to 
generate phosphocholine (PCho) and DAG and by phospholipase D (PLD)
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generating choline (Cho) and phosphatidic acid (PtdOH). PtdOH can be further 
metabolised to DAG by phosphatidate phosphohydrolase (PPH).
As discussed already (section 1.3.3), there is strong evidence for a role for
DAG-stimulated activation of PKC in mitogensis; however, there is increasing 
evidence for sources of the lipid other than PtdIns(4,5)P2 breakdown. Indeed, 
some PKC-mediated events such as increases in pHj (Bierman et al., 1990) and
phosphorylation of an 80kD phosphoprotein, the MARCKS protein (Takuwa et 
a!., 1991) persist long after Ins( 1,4,5)?3-stimulated [Ca2+]j elevation has
declined In Balb/c 3T3 cells microinjection of DAG but not Ins(l,4,5)P3 
stimulated mitogenesis (Suzuki-Sekimori et al., 1989).
A number of oncogenes (Lacal et al., 1987) and growth factors which do 
not stimulate inositol lipid hydrolysis are still able to increase cellular DAG 
content. The AA isoform of PDGF in vascular smooth muscle cells can 
stimulate DAG production and increase membrane associated PKC activity in the 
absence of Ins(l,4,5)P3 generation (Block etal., 1989; Sachinidis et al.,1990).
Similarly, EGF stimulation of IIC9 cells resulted in increased mass of DAG in 
the absence of phosphoinositide hydrolysis (Wright et al., 1990). In IIC9 
fibroblasts stimulated with a-thrombin (Wright et al., 1988) or Swiss 3T3 cells 
stimulated with bombesin (Cook et al., 1990) there was a biphasic generation of
DAG where the initial peak of DAG formation corresponded to transient 
Ins(l,4,5)P3 formation followed by a sustained second phase which was 
kinetically dissociated from Ins( 1,4,5)P3 accumulation and lasted for up to 4h
(Takuwa et al., 1991). The source of this sustained generation of DAG has been 
ascribed to hydrolysis of PtdCho based on fatty acid composition (Pessin and 
Raben, 1989).
Studies in a variety of cell types have shown that PMA can stimulate DAG 
formation (e.g. Cook etal., 1990). Phorbol ester-stimulated DAG accumulation 
occurs in the absence of inositol phosphate formation; in fact PMA inhibits 
receptor-stimulated inositol phosphates accumulation by a PKC-mediated,
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negative-feedback pathway (Brown etal., 1987; Cook and Wakelam, 1991a).
L
Such observations suggest that growth factors are able to stimulate DAG 
generation from a source other than inositol lipids and there has been increasing 
interest in the stimulated hydrolysis of PtdCho as a mitogenic signalling pathway 
(Cook and Wakelam, 1991b). Exogenous addition of PtdCho-hydrolysing PLC 
is sufficient to elicit a potent mitogenic response in Swiss 3T3 cells by a 
mechanism that is independent of PKC (Larrodera et al., 1990). Also, cells 
overexpressing PKC (31 show enhanced PLD activity and this may contribute to 
the growth abnormalities seen in these cells (Pai et al., 1991). In addition, rapid 
activation of PtdCho hydrolysis was observed in Ki-ras -transformed rat 
fibroblasts which also suggests a role in growth control (Lopez-Barahona et al.,
1990). PtdCho hydrolysis can also generate PtdOH which may itself function as 
a second messenger. In fact, it is now becoming clear that in some systems 
PLD-catalysed hydrolysis of PtdCho is a transient response (Martinson et al., 
1990; Plevin and Wakelam, 1992) and therefore may not be contributing 
significantly to sustained DAG formation suggesting that PtdOH may be the 
important messenger generated. PtdOH was shown to inhibit p21 ras GTPase 
activating protein (GAP) and stimulate a GTPase inhibiting protein which would 
tend to increase the proportion of RAS bound to GTP and therefore promote the 
biological activity of RAS. This suggests that PtdOH may be important in 
regulating the activity of the ras oncogene product (Tsai et al., 1989,1990). 
Both PtdOH and lyso-PtdOH can act as growth factors and have been shown to 
stimulate DNA synthesis in fibroblast cell lines (Moolenaar et al., 1986; van 
Corven et al., 1989; Knauss et al., 1990; van Corven et al., 1992). Whether 
PtdOH and lyso-PtdOH produced by stimulated lipid hydrolysis can actually 
leave the cell and act in an autocrine or paracrine manner remains to be
i
determined.
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1.4. Receptor coupled PtdIns(4,5)P2 hydrolysis
The phosphoinositides are a small group of membrane phospholipids 
which are unique in that their myo -inositol headgroup can be phosphorylated at 
multiple sites. They form a minor component of most, if not all, eukaryotic 
membranes. The three most predominant phosphoinositides are 
phosphatidylinositol (Ptdlns), phosphatidylinositol 4-monophosphate 
(PtdIns(4)P) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and
they interconvert via a series of successive phosphorylation and 
dephosphorylation reactions controlled by specific kinases and phosphatases. 
Binding of many agonists to their receptors leads to the activation of an inositol 
lipid-specific phospholipase C (Ptdlns-PLC), also known as phosphoinositidase 
C (PIC), which catalyses the hydrolysis of inositol phospholipids to generate 
inositol phosphates and sn -1,2-diacylglycerol (DAG). Hydrolysis of 
PtdIns(4,5)P2 generates a bifurcating pathway consisting of inositol 1,4,5- 
trisphosphate- (Ins(l,4,5)P3) mediated release of calcium from intracellular
stores and DAG activation of protein kinase C (PKC) (reviewed in Berridge, 
1987a and 1987b).
1.4.1. Ptdlns-PLCs
The phospholipase Cs are phosphodiesterases which hydrolyse the 
glycerophosphate bond of phospholipids (reviewed in Meldrum et al., 1991). 
From purification studies, immunological characterization and molecular 
cloning, it has been shown that numerous Ptdlns-PLCs exist in various tissues. 
From primary structure comparisons the superfamily of enzymes can be divided 
into four classes of isozymes, a , P, y and 8, with more than one enzyme of each 
type. A significant sequence homology exists in two regions shared by PLC-p, 
-7  and -8  which suggests that they may form a catalytic domain. In addition, 
members of the y class share regions of sequence homology with several other 
proteins in what are known as src -homology (SH) domains (Rhee et al., 1991).
19
Biochemical characterization has failed to clarify the relationship between 
enzymes of the PLC-a class and the other Ptdlns-PLC classes.
The way in which receptors couple to the different forms of Ptdlns-PLC is 
clearly of considerable interest. As discussed previously, receptors can be 
divided into two general categories based on the signalling pathways they 
employ, i.e. G protein-coupled receptors and receptors with intrinsic tyrosine 
kinase activity. Agonists employing both types of receptor have been shown to 
stimulate rLC-cataiysed hydrolysis of inositol lipids (see section 1.4.2 and 
1.4.3).
G proteins, which couple seven transmembrane domain receptors to 
effectors, are a highly conserved family of membrane associated, heterotrimeric 
proteins composed of a, p and y subunits. Agonist receptor activation 
stimulates the exchange of GTP for GDP bound to the a-subunit, thus causing 
the a-subunit with bound GTP to dissociate from Py and enabling it to stimulate 
the effector enzyme e.g. Ptdlns-PLC. An intrinsic GTPase activity hydrolyses 
GTP to GDP and as a result the a-subunit reassociates with py (reviewed in 
Gilman, 1987; Casey and Gilman, 1988).
Evidence exists that many receptors couple to Ptdlns-PLC via G proteins.
In some instances, coupling can be inhibited by pertussis toxin treatment which 
ADP-ribosylates the a-subunit of G j, the inhibitory G  protein which couples to
adenylyl cyclase, leading to its inhibition. This suggested a role for a Gj-like
protein in linking certain receptors to Ptdlns-PLC e.g. in HL60 cells stimulated
with fMet-Leu-Phe (Gierschik et al., 1989). However, there are also a large
number of receptor systems which operate via pertussis toxin-insensitive G 
proteins (reviewed in Meldrum et al., 1991) designated as Gp (Cockcroft,
1987). Recently a number of new pertussis toxin-insensitive a-subunits have
been identified using the polymerase chain reaction (PCR) technique 
(Strathmann et al., 1989; reviewed in Simon et al., 1991). Among these, G ^
and Ga l j are widely expressed and are highly homologous. It has been
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suggested that these a-subunits may be involved in pertussis toxin-insensitive
pathways coupling to Ptdlns-PLC (Strathmann and Simon, 1990). Indeed, a 
novel 42kD protein with sequence identity with the clone was purified and
shown to stimulate Ptdlns-PLC in a pertussis toxin-insensitive manner (Pang 
and Stemweis, 1990; Taylor et al., 1990; Smrcka et al., 1991). It was 
subsequently shown in reconstitution experiments that this G protein specifically 
activates PLC-pl and not the yl or 81 isozymes of Ptdlns-PLC (Taylor et al., 
1991; Martin et al., 1991, Wu et al., 1992).
The coupling of tyrosine kinase growth factor receptors to Ptdlns-PLC has 
been shown to occur by altemati#means (reviewed in Rhee, 1991). Studies in 
permeabilized cells have shown a lack of effect of guanine nucleotide analogues 
on growth factor-stimulated phosphoinositide hydrolysis suggesting a coupling 
mechanism independent of G proteins (Hasegawa-Sasaki, 1988; Cattaneo and 
Vincentini, 1989; Hapler etal., 1990). Furthermore, as was discussed 
previously (setion 1.3.1), Ptdlns-PLCy has been shown to associate with and be 
tyrosine phosphorylated by several tyrosine kinase receptor systems 
(Meisenhelder et al., 1989; Wahl et al., 1989). Binding of PLCy to activated 
growth factor receptors may be mediated via SH2 (src -homology 2) domains 
(Anderson et al., 1990) and tyrosine phosphorylation has been shown to activate 
PLCyl and result in its translocation to the plasma membrane (Nishibe et al., 
1990; Todderud et al., 1990). There is some evidence that the GTP binding 
protein p21ras together with GAP (GTPase activating protein) may be involved 
in modulating Ptdlns-PLCy within the cell. Microinjection of either PLCy or 
Ras protein induced DNA synthesis in NIH 3T3 cells; both responses were 
inhibited by co-injection of antibodies to Ptdlns-PLCy. In contrast, co-injection 
with a neutralizing antibody to Ras only inhibited the DNA systhesis induced by 
Ras and not by PLCy (Smith et al., 1990).
Thus the nature of coupling to the PLC-5 class of enzymes remains to be 
elucidated; perhaps it will involve a pertussis toxin-sensitive G protein.
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1.4.2. Ins(l,4,5)P3 and Ca2+
A common feature of calcium-mobilizing agonists is that they stimulate
inositol lipid turnover (reviewed in Michell, 1975; Berridge, 1987b; Berridge 
and Irvine, 1989). Ins(l,4,5)P3 was shown to be formed rapidly as a result of
stimulated PtdIns(4,5)P2 hydrolysis in blowfly salivary glands stimulated with
5-hydroxytryptamine (Berridge, 1983). The first direct evidence that 
Ins(l ,4,5)P3 functioned to mobilize intracellular calcium from a non-
mitochondrial store was obtained by adding purified Ins(l,4,5)p3 to
permeabilized pancreatic acinar cells (Streb et al., 1983).
Ins(l,4,5)P3 released calcium from a non-mitochondrial store which had
characteristics which suggested that it was the endoplasmic reticulum (Streb et 
al., 1984), but only part of this pool seems to be Ins(l,4,5)P3-sensitive.
Another candidate for the Ins(l,4,5)P3-sensitive calcium pool is the calciosome,
a small membrane vesicle which has some properties characteristic of the 
sarcoplasmic reticulum of muscle (Volpe et al., 1987). Of the inositol 
phosphates tested, only those having phosphates on the 4- and 5-position were 
capable of stimulating release of calcium, Ins(l,4,5)P3 being the most potent.
From these studies it appeared that two phosphates on the 4- and 5-positions are 
essential to stimulate the release of calcium whereas the phosphate at the 1- 
position functioned to enhance the affinity of the molecule for its receptor 
(Burgess et al., 1984; Irvine et al., 1984). In agreement with its role as a second 
messenger, Ins(l,4,5)P3 is generated rapidly after receptor activation, e.g. in
bombesin-stimulated Swiss 3T3 cells (Cook et al., 1990), and exerts its effect 
rapidly, e.g. in bradykinin stimulated NG115-401L cells InsP3 generation and
calcium release occur with similar time courses (Jackson et al., 1987).
To release calcium, Ins(l,4,5)P3 must bind to receptors that are linked to 
calcium channels connected with the Ins(l,4,5)P3-sensitive calcium pool. An 
Ins(l,4,5)P3-binding protein (Mr 260k) was isolated from rat cerebellar 
membranes (Supattapone et al., 1988) and immunocytochemical studies using a
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specific antibody on Purkinje cells revealed that this receptor was localized on 
the nuclear membrane and parts of the rough and smooth endoplasmic reticulum 
(Ross et al., 1989). The cloning of the cDNA for the Ins(l,4,5)P3 receptor
from a mouse cerebellum cDNA library has been reported together with its 
deduced amino-acid sequence (Furuichi etal., 1989). Purified Ins(l,4,5)P3
binding protein has been reconstituted into lipid vesicles; Ins(l,4,5)P3 and other
inositol phosphates stimulated calcium flux in the vesicles with potencies and 
specificities that matched their calcium releasing actions in intact cells, indicating 
that the purified Ins(l,4,5)P3 binding protein was a physiological receptor
responsible for calcium release (Ferris et al., 1989). These results also 
established that a single protein mediates both recognition of Ins(l,4,5)P3 and
the stimulation of calcium flux. From these studies it was also apparent that the 
Ins(l,4,5)P3 receptor showed similarities with the ryanodine receptor which
mediates calcium release from sarcoplasmic reticulum of skeletal muscle. 
Included among a number of shared features is the association of both receptors 
into tetrameric structures (Feruichi etal., 1989; Mignery et al., 1989; Takeshima 
et al., 1989). A characteristic feature of the Ins(l,4,5)P3 receptor is that it does
not desensitize. Any decline in the release of calcium can usually be attributed 
either to the rapid metabolism of Ins(l,4,5)P3 or to the transfer of the mobilized
calcium to an Ins(l,4,5)P3-insensitive pool (Stauderman, 1988; Taylor et al., 
1989).
Recent work has suggested that Ins(l,3,4,5)P4, which is generated from 
Ins(l,4,5)P3 via a 3-kinase activity, may also have a second messenger role.
The Ca2+-mediated sea urchin egg fertilisation envelope formation was shown to 
require microinjection of both Ins(l,4,5)P3 and Ins(l,3,4,5)P4 (Irvine and 
Moor, 1985). Similarly, both Ins(l,4,5)P3 and Ins(l,3,4,5)P4 were required to 
generate a Ca2+-activated K+ current in lacrimal acinar cells (Morris et al.,
1987; Changya et al., 1989). In addition to mobilizing intracellular calcium 
through Ins(l,4,5)P3, many agonists also stimulate influx of extracellular
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calcium. Although the mechanism and regulation of Ca2+ entry remains unclear 
Ins(l,3,4,5)P4 has been suggested to be involved in regulating this calcium 
entry in the simultaneous presence of Ins(l,4,5)P3 in some systems (Irvine et
al., 1988; Irvine, 1990). Irvine and colle&jues have suggested a coupled 
mechanism for receptor-stimulated Ca2+ control in which the Ins(l,4,5)P3- 
sensitive Ca2+ pool is reloaded by an Ins(l,3,4,5)P4-controlled process. An
Ins(l,3,4,5)P4- and Ca2+-sensitive Ca2+- and Mn2+-permeable channel has been
characterized in endothelial cells which is activated by an increase in cytoplasmic
Ca2+. Ins(l,3,4,5)P4 was shown to enhance the activity of the channel
(Liickhoff and Clapham, 1992). However, there have also been reports that
Ca2+ influx may occur independently of Ins(l,3,4,5)P4 (Penner et al., 1988;
Bird et al., 1991). Recently, a Ca2+ channel was characterized in mast cells
which is activated by depleting intracellular Ca2+ stores (Hoth and Penner,
1992). In PC12 cells two independently regulated mechanisms of Ca2+ influx
were demonstrated; one pathway was sustained by depletion of the intracellular
Ins(l,4,5)P3-sensitive Ca2+ store while the second pathway was dependent on
receptor-effector coupling via G protein(s) distinct from that (those) involved in
activation of Ptdlns-PLC (Clementi et al., 1992). A second messenger role for 
Ins(l ,3,4,5)P4 has also been proposed in inducing the sequestration of
intracellular Ca2+ (reviewed in Boynton etal., 1990).
In addition to their rapid formation, second messenger molecules also 
usually degrade quickly. There are a number of enzyme systems capable of 
removing Ins(l,4,5)P3 as soon as it is produced and the Ins(l,4,5)P3 generated
in response to agonist stimulation is often very transient in nature (e.g. Fu et al., 
1988; Cook et al., 1990). Ins(l,4,5)P3 is metabolized by two routes involving
InsP3-5-phosphatase which generates Ins(l,4)P2 or InsP3>3-kinase, a
Ca2+/calmodulin-sensitive enzyme, which generates Ins(l,3,4,5)P4 (reviewed in
Shears, 1989; Emeux and Takazawa, 1991). Purified InsP3 -3-kinase has been 
shown to be a substrate for protein kinase C with phosphorylation causing a
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decrease in its activity (Sim et al., 1990). Ins(l,4)P2 does not mobilize Ca2+ 
but, as discussed above, Ins(l,3,4,5)P4 may have a role in some cells in 
regulating Ca2+ influx (e.g. Cullen et al., 1990). Ins(l,3,4,5)P4 is a substate 
for the same 5-phosphatase that catalyses the dephosphorylation of Ins(l,4,5)P3 
and it is metabolised to the inactive Ins(l ,3,4)P3 (Connolly et al., 1987). 
Ins(l,3,4)P3 and Ins(l,4)P2 can be further dephosphorylated by a series of
enzymes to the monophosphate level. A single enzyme, an InsP] phosphatase,
can then dephosphorylate different isomers of InsPi (Gee et al., 1988), the final
product being inositol which can be reused in inositol lipid synthesis. InsPi
monophosphatase is sensitive to inhibition by lithium and this is often exploited
in measurements of phosphoinositide hydrolysis as it allows the accumulation of
total inositol phosphates consisting predominantly of InsPi (Berridge et al.,
1982). As well as these metabolic routes, levels of Ins(l,4,5)P3 in response to
stimulation are also subject to negative feedback inhibition via activation of 
protein kinase C. Swiss 3T3 cells in which protein kinase C had been down- 
regulated showed elevated basal and bombesin-stimulated production of inositol 
phosphates. Protein kinase C has been suggested to mediate this effect by 
uncoupling of bombesin-stimulated hydrolysis of PtdIns(4,5)P2 at the level of
the G protein (Brown et al., 1987; Brown et al., 1990).
1.4.3. DAG/Protein kinase C
Whereas Ins(l,4,5)P3 is released into the cytoplasm following activation
of Ptdlns-PLC, the neutral lipid sn -1,2-diacylglycerol (DAG) remains within
the plasma membrane where it functions as the physiological activator of protein
kinase C (PKC) (reviewed in Nishizuka, 1984 and 1986; Ganong etal., 1986).
In addition to DAG the enzyme requires calcium and phosphatidylserine. DAG 
is believed to activate PKC by lowering the Kj^ of the enzyme for Ca2+
(Kishimoto et al., 1980). Conversely, prior elevation of Ca2+ can enhance the
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activation of PKC by DAG (Dougherty and Niedel, 1986). During the activation 
of PKC the enzyme appears to be translocated from the cytosol onto the 
membrane (Kraft and Anderson, 1983; Farrar et al., 1985; Guy et al., 1986; 
Haller et al., 1990). However, this may also reflect a situation where the 
enzyme is plasma membrane associated and becomes more firmly bound through 
interaction with DAG. The importance of the DAG/PKC pathway in cell 
proliferation is illustrated by the fact that PKC has been identified as the cellular 
receptor for the tumour promoting phorbol esters (Castagna et al., 1982; Niedel 
etal., 1983; see section 1.3.3)
It is now clear that PKC is not a single enzyme but rather exists in multiple 
forms (Huang etal., 1986; Nishizuka, 1988; Kikkawa etal., 1989; Parker et al., 
1989). These proteins are derived both from multiple genes and from alternate 
splicing of single RNA transcripts, yet possess a primary structure containing 
conserved structural motifs with a high degree of sequence homology. There are 
at least seven subspecies of PKC; a, pi, pn and y PKC were initially isolated 
followed by 8, e and £ PKC which were isolated under low stringency 
conditions and have a structure closely related to but distinct from the species 
initially described. All species are composed of a single polypeptide chain, with 
each in the group of a, pi, pH and y  having four conserved regions designated 
C1-C4. The 8, e and £ subspecies lack the C2 region. The conserved regions 
Cl and C2 appear to include the regulatory domain but as yet the sites involved 
in Ca2+, DAG and phospholipid binding have not been identified with any 
certainty. The Cl domain has been shown to be important for binding phorbol 
esters and may therefore be the site of DAG regulation while the C2 region 
appears to play a role in the Ca2+-sensitfvity of the enzyme (Ono et al., 1989). 
The carboxyl-terminal half containing the regions C3 and C4 appears to be the 
protein kinase domain as it shows sequence homology with many other protein 
kinases. Also, the C3 region has an ATP-binding sequence (Kikkawa et al., 
1989).
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Using a combination of biochemical, immunological and cytochemical 
procedures with specific antibodies, a differential expression of PKC subspecies 
has been suggested (reviewed in Nishizuka, 1988; Kikkawa etal., 1989). For 
example, y PKC appears to be expressed solely in the brain and spinal cord and 
is not found in other tissues and cell types (Huang et al.y 1987). In contrast, a  
PKC is widely distributed in many tissues and cell types. In general, one cell 
type contains more than one subspecies of PKC.
The enzyme subspecies purified from tissues show subtle differences in 
their mode of activation and sensitivity to Ca2+. PKC isozymes a, P and y are 
markedly activated by phospholipids, DAG and Ca2+ while the 8, e and £ 
isozymes are activated to a lesser extent by phospholipids and DAG and are 
relatively Ca2+-independent (reviewed in Kikkawa et al., 1989; Parker et a l , 
1989; Schaap and Parker, 1990). The activation of a-, p -  and y-PKC by 
DAG and phosphatidylserine could also be potentiated by unsaturated fatty acids 
at physiologically relevant Ca2+ concentrations (Shinomura et a l , 1991; Chen 
and Murakami, 1992). The PKC isozymes also show differences in their 
catalytic activity towards substrates. The EGF receptor of A431 cells appears to 
be phosphorylated most rapidly by a PKC and more slowly by y PKC (Ido et 
a l , 1987). Also, histone III-S which is the standard PKC substrate was very 
poorly phosphorylated by PKC-e compared with a, p and y (Schaap and 
Parker, 1990). As was mentioned previously (section 1.3.3), prolonged PMA 
treatment can cause down-regulation of PKC due to an accelerated rate of 
degradation (Young et a l , 1987). However, studies have shown differences in 
phorbol ester induced down-regulation of PKC between cell lines, possibly 
reflecting different sensitivities of different PKCs to PMA (Adams and Gullick, 
1989). Additionally, activation of PKC can stimulate diametrically opposed 
processes such as proliferation and differentiation suggesting the involvemnt of 
different isozymes (Berridge, 1987a).
While PKC activation appears to be a common event of mitogenic
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stimulation, the targets of the enzyme are largely undetermined. PKC can
phosphorylate many different proteins in vitro but it has been more difficult to
identify substrates in intact cells. An important target appears to be the Na+/H+
antiporter which is responsible for cytoplasmic alkalinization (section 1.2.2).
Another substrate is vinculin; phosphorylation of this protein may be involved in
the cytoskeletal reorganisation which accompanies phorbol ester stimulation of
cultured cells (Schliwa et al., 1984). Lipocortin was also suggested to be a PKC
substrate; phosphorylation has been suggested to suppress its inhibitory activity 
towards PLA2 (Touqui et al., 1986). Caldesmon, a protein which binds actin,
calmodulin, tropomyosin and myosin, has also been shown to be 
phosphorylated by PKC. Since caldesmon was observed to be phosphorylated 
in mitotic cells at the same site phosphorylated by cdc2 kinase in vitro , it has 
been suggested that the protein may play a role in the alteration of the actin 
cytoskeleton at mitosis and therefore phosphorylation by PKC may also be an 
important regulatory mechanism (Marston and Redwood, 1991). Other possible 
PKC substrates relevant in the mitogenic response may be adenylyl cyclase 
(reviewed in Houslay, 1991), MAP kinase (Rossomondo etal., 1989), Fos 
(Barber and Verma, 1987) and Jun (Pulverer et al., 1991)
There are a number of metabolic pathways capable of removing DAG once 
it is formed. The action of DAG kinase results in the phosphorylation of DAG 
to phosphatidic acid (PtdOH) which may itself have important biological effects 
(section 1.3.4). PtdOH then combines with CTP to form CMP-phosphatidate 
which accepts a free myo -inositol molecule to reform Ptdlns. DAG kinase may 
therefore have an important role in controlling the concentration of DAG and 
hence regulating PKC activity as well as initiating resynthesis of 
phosphoinsitides (Bishop etal., 1986; reviewed in Kanoh etal., 1990). 
Activation of DAG kinase appears to involve translocation from the cytosol to 
membranes (Maroney and Macara, 1989) and it can also be phosphorylated in 
vitro by PKC suggesting that this may have a role to play in the mechanism of
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activation. DAG is also a target for hydrolysis by DAG lipase (Bishop et al., 
1986). This releases arachidonic acid which may itself have important biological 
effects or alternately be further metabolised to generate prostaglandins
1.4.4. Phosphatidylinositol 3-kinase
Recently a number of 3-phosphorylated novel inositol lipids have been
identified. Type I Ptdlns kinase (reviewed in Downes and Carter, 1991) was
found associated with a number of tyrosine kinases including pp60v' src, middle
T/pp60c' src and the PDGF receptor (Kaplan et al., 1987; Courtneidge and
Heber, 1987; Whitman etal., 1987). It was subsequently shown to make a
novel inositol lipid, phosphatidylinositol 3-phosphate (Whitman et al., 1988). A
possible role for type I Ptdlns kinase in cell proliferation is suggested by the
observation that PDGF receptors that are deficient in their ability to associate
with this kinase fail to stimulate growth (Coughlin et al., 1989). Additionally, a
novel phosphoinositide containing four phosphates, suggested to be 
phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), was observed in
activated but not in unstimulated neutrophils (Traynor-Kaplan et al., 1988), 
while both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 appeared following PDGF
stimulation of vascular smooth muscle cells (Auger et al., 1989). However, the 
role these lipids or their metabolites play in signal transduction pathways is 
unclear. PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 have been shown to be 
resistant to hydrolysis by several phospholipase Cs (Lips et al., 1989; Serunian 
et al., 1989) suggesting that the 3-phosphorylated lipids themselves may act as 
second messengers.
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1.5. Receptor-stimulated phosphatidylcholine hydrolysis
In addition to PtdIns(4,5,)P2 hydrolysis, many growth factors and
hormones also stimulate the hydrolysis of another lipid, phosphatidylcholine 
(PtdCho) (reviewed in Loffelholz, 1989; Pelech and Vance, 1989; Exton, 1990; 
Billah and Anthes, 1990). PtdCho is the main phospholipid in mammalian 
tissues. Phosphodiesteratic cleavage of PtdCho may occur via a number of 
phospholipases; a phospholipase C (PLC) activity produces DAG and 
phosphocholine, a phospholipase D (PLD) activity generates phosphatidic acid 
(PtdOH) and choline and a phospholipase A2 (PLA2) activity generates 
arachidonic acid and lysophosphatidylcholine. This section will concentrate on 
PLC- and PLD-catalysed hydrolysis of PtdCho. In addition to hydrolysis, PLD 
catalyses a unique transfer reaction whereby the phosphatidyl moiety of the 
phospholipid substrate is transferred to primary alcohols to produce 
phosphatidylalcohols.
PtdCho hydrolysis was first reported in response to phorbol esters and 
was detected as a stimulated release of labelled choline and phosphocholine from 
mouse embryo fibroblasts (Mufson et al., 1981). Hormone-stimulated PtdCho 
hydrolysis had been suggested by the kinetics of DAG ace umulation in several 
cell types and the fatty acid composition of the DAG formed, both of which 
indicated lipid sources in addition to PtdIns(4,5)P2 (see section 1.3.4). 
Quantitative discrepancies between PtdIns(4,5)P2 hydrolysed and DAG formed
were also observed (Pickford et al.y 1987). Evidence for PtdCho hydrolysis 
arose from a number of studies using [^H] choline isotopic labelling which 
showed increased release of labelled choline and/or phosphocholine in response 
to agonist stimulation (e.g.Besterman et al., 1986; Muir and Murray, 1987; Price 
et al., 1989; Cook and Wakelam, 1989)
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1.5.1. Distinguishing between PLC- and PLD-catalysed PtdCho 
hydrolysis
In order to distinguish between agonist-stimulated PLC- and PLD- 
catalysed hydrolysis of PtdCho, kinetic analysis of product formation, i.e. 
choline versus phosphocholine and PtdOH versus DAG, has been used. In 
endothelial cells stimulated with ATP an increase in [^H] choline was detected in 
the absence of any change in [^H] phosphocholine suggesting a PLD pathway 
(Martin and Michaelis, 1989). Carbachol stimulated [~H] PtdOH formation 
more rapidly than DAG in 1321 N1 astrocytoma cells also suggesting a PLD 
catalysed hydrolysis (Martinson et al.,1989). The concurrent formation of DAG 
and phosphocholine observed in 3T3 LI cells (Besterman, 1986) and A10 cells 
(Grillone et al., 1988) was suggested to be indicative of a PLC-mediated 
breakdown of PtdCho.
However, the products of PLC and PLD are rapidly interconvertible by the 
activity of specific kinases and phosphatases and therefore conclusions from 
these types of isotopic labelling experiments can only be tentative. A novel 
approach labels endogenous phospholipids selectively with ^2P without 
labelling cellular ATP. In such a system [^2P] PtdOH or [^2P] phosphocholine 
must be formed from [^2P] phospholipids exclusively by PLD or PLC 
respectively and not by kinases. HL-60 cells labelled with [^2P] lysoPtdCho 
and stimulated with formyl-Met-Leu-Phe (fMLP), PMA, OAG or A23187 
showed increased [^2P] PtdOH indicating conclusively a PLD-catalysed 
hydrolysis of PtdCho (Pai etal., 1988a; Billah etal., 1989).
Definitive assignment of PLD activity can also be achieved in the 
transphosphatidylation reaction of PLD by using primary alcohols to give rise to 
the corresponding phosphatidylalcohol. These are not substrates for further 
metabolism and therefore their accumulation can be used to conclusively detect 
PLD activity. In cultured endothelial cells ATP-dependent [14C] 
phosphatidylethanol (PtdEtOH) formation increased at the expense of [14C]
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PtdOH with increasing EtOH concentration. Also, the time course of [14C] 
PtdEtOH synthesis stimulated by ATP in the presence of EtOH paralleled that of 
[14C] PtdOH formation (Martin and Michaelis, 1989). In HL-60 cells 
stimulated with fMLP [^P] PtdEtOH formation paralleled that of [32p] PtdOH 
with respect to time course, fMLP concentration, inhibition by a specific fMLP 
antagonist and calcium concentration (Pai et al., 1988a). Similar results have 
also been demonstrated in many other systems supporting a role for PLD-
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suggest that it is a more widespread mechanism of PtdCho hydrolysis than the 
PLC-mediated pathway.
1.5.2. Regulation of agonist-stimulated PtdCho hydrolysis
Most agonists that cause PtdCho hydrolysis also stimulate PtdIns(4,5)P2
breakdown (e.g. Cook and Wakelam, 1991a) resulting in the mobilization of
intracellular calcium and activation of PKC (section 1.4). Indeed, PMA which
activates PKC and the calcium ionophore A23187 act syaeagistically in HL-60 
cells to activate PLD (Billah et al.9 1989) suggesting that prior PtdIns(4,5)P2
hydrolysis is necessary for subsequent PtdCho breakdown. Tumour promoting 
phorbol esters and exogenous DAGs promote PtdCho hydrolysis in many cell 
types (e.g. Billah e ta l , 1989; Liscovitch, 1989; Huang and Cabot, 1990a) 
while inactive phorbols are without effect (e.g. Besterman et al., 1986). Further 
support for a role for PKC-dependent activation of PtdCho hydrolysis comes 
from observations with PKC inhibitors and down-regulation of PKC by 
prolonged PMA treatment; both treatments can block the responses to agonists 
and phorbol esters. In bombesin-stimulated Swiss 3T3 cells, PtdCho hydrolysis 
is kinetically downstream of the first phase of DAG/Ins(l,4,5)P3 formation and
is abolished in cells which have been depleted of PKC activity by chronic PMA 
treatment (Cook and Wakelam, 1989; Cook et al., 1990). Similarly in
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carbachol-stimulated 132INI astrocytoma cells down-regulation of PKC blocks 
the ability of carbachol to stimulate choline generation (Martinson etal., 1989) 
while PtdEtOH formation in response to PMA in NG108-15 cells was 
completely abolished in PKC-down-regulated cells (Liscovitch, 1989). Use of 
PKC inhibitors such as staurosporine produces similar effects; for example, in 
REF52 cells the inclusion of staurosporine blocked vasopressin-induced [^H] 
PtdEtOH formation (Huang and Cabot, 1990b), and in HL-60 cells the PKC 
inhibitor K252a partially inhibited PMA-induced r~Pj PtdEtOH formation 
(Billah et al., 1989). Finally, overexpression of PKC (31 enhances PLD activity
and DAG formation in PMA-stimulated rat fibroblasts (Pai et al., 1991).
Despite the considerable evidence that prior PtdIns(4,5)P2 hydrolysis is
necessary for PtdCho breakdown, there are several systems in which this does 
not seem to be the case. Certain agonists stimulate the generation of choline 
metabolites in the absence of inositol lipid hydrolysis; e.g. in IIC9 cells, EGF 
stimulated an increase in [^H] choline metabolites without any significant change 
in inositol phosphates (Wright et al., 1990). In Swiss 3T3 cells EGF stimulated 
phosphatidylbutanol formation in the presence of 0.3% (v/v) butanol without 
stimulating inositol phosphates accumulation (Cook and Wakelam, 1992). In 
MDCK-D1 cells, al-adrenergic receptor activation promoted PtdCho hydrolysis 
more rapidly than PtdIns(4,5)P2 breakdown and was unaffected by the presence 
of neomycin, an inhibitor of PtdIns(4,5)P2 hydrolysis, and the PKC inhibitors 
sphingosine and H7 (Slivka et al., 1988). In addition, in Jurkat cells, a human 
T cell line, interleukin-1 stimulated rapid DAG and phosphocholine production 
from PtdCho in the absence of inositol lipid turnover (Rosoff et al., 1988).
Also, in neutrophils stimulated with fMet-Leu-Phe (fMLP) in the absence of 
cytochalasin B, PtdIns(4,5)P2 was maximally hydrolysed (Truett et al., 1988)
with minimal stimulation of PLD (Billah et al., 1989).
There is evidence that receptor-mediated Ca2+ flux may also be involved in 
activating PtdCho hydrolysis, although it varies markedly between cell types.
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The calcium ionophore A23187 has been shown to stimulate PLD activity in 
several cell types including HL-60 granulocytes (Billah etal.> 1989) and human 
polymorphonuclear leukocytes (Agwu et al., 1989). In HL-60 granulocytes 
fMLP-stimulated PLD activity was dependent on extracellular Ca2+ (Pai et al.,
1988) while in human platelets A23187 was able to stimulate greater increases in 
PtdOH than PDBu (phorbol 12,13-dibutyrate) (Huang e ta l, 1991). However, 
in Swiss 3T3 cells the role of Ca2+ appears to be subordinate to that of PKC as 
even A23187-stimulated PLD activity was inhibited by the PKC inhibitor Ro-31- 
8220 (Cook et al., 1991c).
A role for a guanine nucleotide-binding protein (G protein) in regulating 
PtdCho hydrolysis has been suggested from experiments using pertussis toxin 
and non-hydrolysable analogues of GTP such as GTPyS (guanosine 5'-[y-thio] 
triphosphate). Incubation of rat liver plasma membranes (Bocckino et al., 1987; 
Irving and Exton, 1987; Hurst et al., 1990) and permeabilized endothelial cells 
(Martin and Michaelis, 1989) with GTPyS has indicated G protein involvement 
in the activation of a PLC and/or PLD whose activities are regulated by P2
purinergic agonists. The non-hydrolysable GDP analogue, GDPpS (guanosine
5'-[p-thio] triphosphate), inhibited GTPyS stimulation and the response was
pertussis toxin-insensitive. Similarly, GTPyS stimulated [14C] PtdEtOH
formation in homogenates from HL-60 cells (Anthes et al., 1989) while the
fMLP-stimulated response in human neutrophils was pertussis toxin-senstitive 
suggesting the involvement of a Gj-like guanine nucleotide-binding protein
(Agwu et al., 1989). Direct activation of G proteins using aluminium fluoride 
can also stimulate PLD activity, for example in synaptosomes (Qian and Drewes,
1989) and Swiss 3T3 cells (Diaz-Meco et al., 1989). However, while there is 
evidence for a guanine nucleotide-stimulated PLD activity, it remains to be 
established that it is a direct receptor-G protein-PLD activation and not a PLD 
activity regulated downstream of another G protein-coupled signalling pathway 
such as PtdIns(4,5)P2 hydrolysis. For example, in platelet membranes PMA
34
pretreatment and the presence of Ca2+ enhanced the GTPyS-stimulated PLD 
activity suggesting that PLD is activated secondarily to Ptdlns-PLC (van der 
Meulen and Haslam, 1990).
1.6. Endothelin
Since the discovery of endothelin-1 (ET-1), the most potent 
vasoconstrictor known, there has been extensive research carried out to 
determine the physiological and pathological significance of this novel peptide. 
The following sections review what is currently known about the structure, 
biosynthesis and mechanism of action of the endothelins.
1.6.1. Structure and biosynthesis
The endothelins are a family of 21-amino acid peptides. ET-1 was 
originally isolated by Yanagisawa and colleagues from medium conditioned by 
porcine endothelial cells (Yanagisawa et al., 1988a). The corresponding cDNA 
was also isolated and sequenced and indicated that the 21-amino acid biologically 
active mature peptide was synthesised as a 203 amino acid preprotein precursor. 
A 39-amino acid residue intermediate, termed "big endothelin", is generated 
from preproendothelin by proteolytic cleavages at paired basic residues. Mature 
ET-1 is then produced through an unusual, previously unknown, processing 
between T ip^-V al^ by a putative "endothelin converting enzyme" (Yanagisawa 
etal., 1988a; Sawamura etal., 1989). Conversion of big ET-1 to ET-1 is 
essential for bioactivity; the vasoconstrictor activity of big ET-1 is about 100- 
fold lower than that of ET-1 (Kimura et al., 1989) and therefore the converting 
enzyme may be an important target for pharmacological control of ET-1 release.
Cloning and sequence analysis have now shown that there are in fact three 
ET-related genes in human, porcine and rat genomes which encode veiy similar
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peptides known as ET-1, ET-2 and ET-3 (Itoh et al., 1988; Yanagisawa et al., 
1988b; Inoue et al., 1989a). The existence of another member of this family, the 
vasoactive intestinal contractor (VIC) peptide, was reported in mouse intestine 
(Saida et al., 1989) but this peptide has now been shown to be identical to rat 
ET-2 (Bloch et al., 1991). Human and porcine ET-1 have identical sequences. 
Human and mouse/rat ET-2 (VIC) differ from one another by one amino acid 
and differ from ET-1 by two and three amino acids, respectively. Human and 
rat ET-3 have identical sequences but differ from ET-1 by six amino acids. As 
illustrated in Fig. 1.2, ET isopeptides are highly homologous and share a 
common design including, (i) two disulfide bonds (Cys^-Cys^ and Cys^- 
Cys1 J), (ii) a cluster of polar charged side chains residing within a hairpin loop 
(residues 8-10), and (iii) a hydrophobic C-terminus (residues 16-21) containing 
the aromatic indole side chain at Trp^. Experiments with synthetic derivatives 
of ET-1 demonstrated that these features are essential for the expression of 
complete biological activity (Kimura et al., 1988).
ET-1 also shows remarkable sequence similarity to a family of 21 residue 
toxins from the venom of the Israeli burrowing asp, Atractaspis engaddensis, 
known as the sarafotoxins S6 (Kloog et al., 1988; Kloog and Sokolovsky,
1989). It therefore seems likely that the two peptide families share a common 
evolutionary origin. The high degree of sequence homology between the ET 
isopeptides and between ETs and sarafotoxins suggests that the ET genes have 
evolved under strong evolutionary pressure to conserve the structure and 
function of mature ET peptides.
ET isopeptides are differentially expressed in specific tissues suggesting 
that tissue -specific factors exist to control the rate of ET gene expression. 
Northern blot analysis of porcine tissues with cloned prepro-ET-1 cDNA as a 
probe showed that the mRNA was expressed in cultured aortic cells and also in 
aortic endothelium in vivo (Yanagisawa et al., 1988a). ET-3 mRNA has been 
detected in human fetal lung, pancreas, spleen and a small amount in kidney but
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not in cultured human umbilical vein endothelial calls (HUVEC). In contrast, 
ET-1 mRNA was found in human fetal lung, pancreas, spleen, low levels in 
fetal atrium and ventricle and high levels in HUVEC (Bloch et al., 1989). In 
situ hybridization studies have also been used to analyse several rat tissues. ET- 
3 was predominandy expressed in adult kidney, eye and brain, whereas both 
ET-3 and ET-1 were abundantly expressed in the lung (MacCumber et al.,
1989). Another report (Nunez et al., 1990) has demonstrated the expression of 
ET-i mRNA in porcine aortic endothelial cells, all heart chambers, adrenals and 
kidney, aswell as human cardiac ventricular tissue, lung and cultured umbilical 
endothelial cells. Using in situ hybridization and immunocytochemistry, 
neurones of the human spinal cord, human dorsal root ganglia (Giaid et al.,
1989, Lee et al.,1990) and paraventricular and supraoptic neurones in the 
porcine and rat posterior pituitary (Yoshizawa et al., 1990) have also been found 
to contain measureable ET-1 mRNA suggesting a neuromodulator / 
neurotransmitter role for ET. ET-2 mRNA was detected in mouse intestine 
(Saida et al., 1989), the HTB119 cell line (derived from a human small cell lung 
carcinoma) and in the COS-7 cell line derived from monkey kidney (Bloche et 
al., 1991). Low levels of ET-2 mRNA were also detected in fetal human kidney 
but not in HUVEC or in fetal lung, spleen, liver or adrenal gland (Bloch et al.,
1991). The tissue distribution of gene expression is therefore distinct for each of 
the ET genes. In particular, neither the ET-2 or ET-3 gene is expressed in 
HUVEC whereas the ET-1 gene is expressed at high levels suggesting that these 
genes have biological roles outside the vasculature. Additionally, the cDNAs for 
two different ET receptors have recently been cloned and shown to encode an 
ET-1 selective and nonselective receptor, with only the selective receptor being 
expressed in aorta while the nonselective is not (Sakurai et al., 1990; Arai et al.,
1990).
The induction of ET-1 mRNA and the rate of peptide release have been 
found to be increased by a growing number of agents and mechanical stimuli
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including thrombin, transforming growth factor P (TGFp), angiotensin n, 
vasopressin, hemodynamic shear stress, interleukin 1, phorbol esters and 
calcium ionophores (Yanagisawa et al., 1988a and 1989 ; reviewed in 
Yanagisawa and Masaki, 1989a and 1989b). Some of these inducers are known 
to stimulate inositol lipid turnover resulting in increases in [Ca2+] j and activation
of protein kinase C, which may exert effects at the level of gene transcription 
and/or translation. The increase in mRNA induced by agents such as phorbol 
esters and TGF p has been suggested to result from increased transcription of 
the ET-1 gene possibly via interaction with cis -nucleotide sequences (Kurihara 
et al., 1989; Inoue et al., 1989b). The level of ET-1 mRNA may be controlled 
not only by transcriptional regulation but also by post-transcriptional regulation 
of mRNA degradation. Half-life studies have revealed that ET-1 mRNA is 
extremely labile, having an intracellular half-life of about 15min (Yanagisawa et 
al., 1989; Inoue et al., 1989b).
Plasma levels of ET-1 are extremely low in healthy volunteers (e.g. Ando 
et al., 1989) and intravenously injected labelled ET-1 was quickly eliminated 
from the blood stream of the rat (Angg&rd et al., 1989; Shiba et al., 1989). It 
therefore seems likely that ET-1 acts as an autocrine or paracrine signal, being 
produced in epithelial or endothelial cells and acting on adjacent smooth muscle, 
rather than a circulating hormone (e.g. De Nucci et al.,1988; MacCumber et al.,
1990).
1.6.2. Biological effects
ET-1 has a wide range of biological actions in diverse tissues and species 
(reviewed in Yanagisawa and Masaki, 1989b; AnggSrd et al., 1990; Simonson 
and Dunn, 1991). ET-1 is the most potent mammalian vasoconstrictor peptide 
known and has a very strong and sustained constrictor activity in vitro and 
pressor activity in vivo. Constriction of isolated arterial strips is long lasting and
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extremely difficult to wash out (Yanagisawa et al., 1988a), Intravenous bolus 
injection of ET-1 caused a transient, dose-related depressor response followed 
by a sustained, dose-dependent rise in arterial pressure both in anesthetized rats 
(Yanagisawa et al., 1988a; DeNucci et al., 1988; Inoue et al., 1989a; Wright and 
Fozard, 1988) and in intact, conscious rats (Yanagisawa et al., 1988b). The 
initial transient depressor response may be due to the ability of ET-1 to stimulate 
the release of prostaglandins and/or endothelium-derived relaxing factor (EDRF) 
from perfused tissues. ET-3 is a weaker vasoconstrictor than ET-1 or ET-2 but 
produces a significantly greater initial depressor effect (Inoue et al., 1989a). 
Other cardiovascular effects of ET-1 include positive inotropic (i.e. increase in 
contractile tension) and chronotropic (i.e. increase in the rate of contraction) 
effects on myocardium (Ishikawa et al., 1988a, 1988b). ET-1 is also a potent 
renal peptide with numerous effects including increased renal vascular 
resistance, decreased glomerular filtration rate and renal plasma flow (King et 
al., 1989) while in liver ET-1 was found to produce a sustained increase in 
portal vein pressure, an increase in glycogenolysis and alterations in hepatic 
oxygen consumption (Ganchi etal., 1990).
ET also contracts numerous nonvascular smooth muscle preparations 
including intestinal, tracheal, lung and uterine. Both ET-1 and ET-3 caused 
contraction of rat stomach strips, rat colon and guinea pig ileum (Takahashi et 
al., 1990). ET-1 produced concentration-dependent contraction of airway 
smooth muscle preparations isolated from humans, guinea pigs, rats and mice 
(Henry et al., 1990) and ET-1 and ET-2 were equally efficacious at contracting 
human isolated bronchial tissue (McKay et al., 1991). ET-1 both contracted and 
restored rhythmicity to the rhythmically quiescent rat uterus (Borges et al.,
1989).
ET-1 also has many neuroendocrine effects. In rat isolated glomerular 
preparations, ET-1 inhibited renin release (Takagi et al., 1988). Infusion into 
dogs caused a rapid increase in the plasma level of atrial natriuretic factor, renin,
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aldosterone, vasopressin and circulating catecholamines (Goetz et al., 1988;
Miller et a l , 1989) while ET-1 stimulated angiotensin I to angiotensin II
conversion in cultured pulmonary artery endothelial cells (Kawaguchi et al.,
1990). ET-1 also appears to regulate synaptic transmission in both central and
peripheral nervous systems by acting as a neuromodulater and perhaps even as a
neurotransmitter (Giaid et al., 1989; MacCumber et al., 1990; Yoshizawa et al.,
1990; Stojilkovic, 1990).
A very interesting role of ET-1, and the subject of this thesis, is its action
as a mitogen. This has been shown in vascular smooth muscle cells (Komuro et
al., 1988; Nakaki et al., 1989), vascular endothelial cells (Takagi et a l ,1990),
fibroblasts (Brown and Littlewood, 1989; Muldoon et al., 1990; Takuwa et a l,
1989), Cg glioma cells (MacCumber et a l, 1990; Zhang et al., 1991), mesangial
cells (Simonson et al., 1989) and human cancer cell lines (Shichiri et al., 1991).
Due to the wide variety of biological actions now found for ET-1 there is 
considerable interest in its role in the pathogenesis of cardiovascular, renal and 
pulmonary disease (reviewed in Yanagisawa and Masaki, 1989b; Nayler, 1990; 
Webb, 1991; Rubanyi and Parker Botelho, 1991).
1.6.3. Mechanism of action
Specific high-affinity binding sites for ET-1 have been demonstrated in 
many tissues in agreement with the wide ranging pharmacological effects of the 
peptide. High-affinity, saturable binding sites have also been characterized in 
intact cells and in membrane preparations from vascular and nonvascular smooth 
muscle, fibroblasts, glomerular mesangial cells and neurons (reviewed in 
Yanagisawa and Masaki, 1989b; Simonson and Dunn, 1990a). Most recently 
there have been two cDNA clones for ET receptors isolated from a rat and 
bovine lung cDNA library that predict typical G protein-coupled receptors 
(Sakurai et a l, 1990; Arai et al., 1990) and an ET receptor was purified from
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bovine lung (Kozuka et al.> 1991).
The mechanism of action of the ETs is unknown but ET receptor-binding
is known to activate a number of signal transduction pathways. Inositol lipid 
hydrolysis resulting in the activation of protein kinase C and increased [Ca2+]j
has been demonstrated in many systems as well as activation of the arachidonic 
acid cascade (reviewed in Simonson and Dunn 1990a, 1990b). The aim of the 
present study was to investigate the signalling pathways mediating the mitogenic 
action of ET-1 in Rat-1 cells, a rat embryo fibroblast cell line. PtdCho and 
PtdIns(4,5)P2 hydrolysis were investigated with special emphasis on their 
mechanisms of regulation.
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Fig. 1.1 Schematic representation of the role of PtdIns(4,5)P2 
and PtdCho hydrolysis in stimulating early mitogenic signals.
(M is a mitogen acting through its receptor, R.)
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Fig. 1.2 Structures of the endothelins and sarafotoxin.
Filled circles indicate residues that differ from the ET-1 sequence. (Taken 
from Sakurai et al., 1992).
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Chapter 2
Materials & Methods
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2.1 Cell lines and materials.
2.1.1 Cell lines.
Rat-1 fibroblasts were kindly donated by Dr. J. Wyke, Beatson Institute 
for Cancer Research, Glasgow.
2.1.2 Materials.
The following is a list of the sources for materials used during the course 
of this research:
Aldrich Chemical Company Ltd. Gillingham. England.
2,2,4-trimethylpentane (iso-octane).
Amersham International pic. Amersham. Buckinghamshire. England. 
[methyl-^H\ Choline chloride (specific activity 75-85 Ci/mmol),
(3-[^5I]iodotyrosyl) Endothelin-1 (specific activity -2000 Ci/mmol) 
[2-^H]myo-inositol (specific activity 10-20 Ci/mmol),
[2-^H] D-myo-inositol(l,4,5) trisphosphate (specific activity 20-60 Ci/mmol), 
[9,10(n)-^H] Palmitic acid (specific activity 40-60 Ci/mmol), 
Phosporyl[mer/iy/-^C]choline, ammonium salt (specific activity 50-60 
mCi/mmol),
[methyl-^H] Thymidine (specific activity 25 Ci/mmol)
[20(n)-^H] Phorbol-12,13-dibutyrate (specific activity 10-20 Ci/mmol). 
Glycerophospho[A-mer/iy/-^H]choline (GroPCho) had previously been 
prepared from [^H] PtdCho by transacylation with monoethylamine according to 
the method of Clarke & Dawson (1981).
BDH Chemical Company. Poole. England.
Ammonium formate, butan-l-ol, calcium chloride, EDTA, ethanol, Hepes,
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orthophosphoric acid, potassium di-hydrogen phosphate, perchloric acid, 
sodium hydroxide, sodium carbonate, trichloroacetic acid and universal 
indicator.
Biogenesis Ltd. (formerly Biomedical Technologies Inc.'). Bournemouth. 
England.
Epidermal growth factor (receptor grade) purified from mouse submaxillary 
glands.
BioMac. University of Glasgow. Glasgow. Scotland. U.K.
Endothelin-1, -2 and -3.
Boehringer (TJK) Ltd. Lewes. England.
ATP, dithiothreitol and Tris.
Cambridge Research Biomedicals. Cambridge. England.
Bombesin, [Arg^Jvasopressin.
Fisons Scientific Apparatus.
Acetic acid (glacial), chloroform, dimethyl sulphoxide, ethyl acetate, methanol, 
magnesium chloride, potassiunm chloride, Folin and Ciocalteu's phenol reagent.
Formachem (Research IntemationaPplc. Strathaven. Scotland.
D-glucose, sodium hydrogen carbonate
Gibco. Paisley. Scotland.
Dulbeccos modified eagles medium (DMEM, lOx), gentamycin, glutamine 
(lOOx), penicillin/streptomycin, sodium bicarbonate (7.5%).
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Koch-Light Ltd. Suffolk. England. 
Magnesium sulphate.
Mav and Baker. Dagenham. England.
Formic acid, hydrochloric acid and sodium tetraborate.
Riedel-DeHaenAg Seelze-Hannover. Germany.
Sodium di-hydrogen carbonate.
Roche (UK) Ltd. Welwvn Garden Citv. England.
The provision of the drug Ro-31-8220, a PKC inhibitor, by Dr. P. D. Davis is 
gratefully acknowledged.
Wellcome Diagnostics. Beckenham. England.
Streptolysin-O.
Whatman Ltd. Maidstone. England.
LK5DF glass backed thin layer chromatography plates, pre-laned with pre- 
adsorpbent strip.
All other chemicals including ion-exchange resins, phorbol esters and 
prostaglandins were obtained from the Sigma Chemical Company, Poole, 
England.
2.2 Buffer composition.
Phosphate buffered saline (PBSVCalcium and magnesium free
146mM sodium chloride, 5.4mM potassium chloride, 9.6mM di-sodium
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hydrogen orthophosphate, 1.5mM potassium di-hydrogen orthophosphate. 
When freshly prepared PBS was between pH 1.2-1 A.
Sterile trypsin solution for cell passage.
Trypsin was prepared as a solution of 0.1% (w/v) trypsin, 0.025% (w/v) 
EDTA and lOmM glucose in PBS at pH 7.4 and filtered before aliquoting 
through a sterile 0.22pm membrane (Flow pore D).
Hanks buffered saline (Hanks).
1.26mM calcium chloride, 0.5mM magnesium chloride, 0.4mM 
magnesium sulphate, 5.37 mM potassium chloride, 137mM sodium chloride, 
4.2mM sodium hydrogen carbonate, 0.35mM sodium di-hydrogen phosphate. 
When freshly prepared the pH was between 7.2 - 7.4.
Hanks buffered saline with glucose and BSA (HBG\
Buffer prepared as above containing lOmM D-glucose and 1% (w/v) BSA 
(fraction V) and pH adjusted to 7.4.
"Low Calcium" Hanks buffered saline.
0.31mm calcium chloride, 0.5mM magnesium chloride, 0.4mm 
magnesium sulphate, 5.37mM potassium chloride, 137mM sodium chloride, 
4.2mM sodium hydrogen carbonate, 0.35mM sodium di-hydrogen phosphate, 
0.33mM EGTA.
pH adjusted to 7.4 using 1M sodium hydroxide.
The free [Ca2+] of this buffer was lpM.
Permeabilisation buffer.
120mM potassium chloride, 20mM Hepes, 6mM magnesium chloride,
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2mM potassium dihydrogen orthophosphate, 2mM ATP, 0.1 mM EGTA, 
lmg/ml BSA (fraction V).
pH adjusted to 7.4 using 1M KOH.
Binding buffer for membranes.
lOmM Tris, 5mM magnesium chloride, 3mM EDTA, ImM EGTA. 
pH adjusted to 7.4 using 1M HCL.
Binding buffer for whole cells.
Hanks buffered saline containing 0.05% (w/v) BSA, lOmM Hepes, 
lOmM glucose.
pH adjusted to 7.4.
All buffers were made using distilled water and stored at 4°C.
2.3 Ion exchange resins.
2.3.1 Preparation of Dowex-formate.
Dowex 1x8-200 chloride form, strongly basic anion exchange resin, 8% 
cross-linked with a dry mesh of 100-200, was treated as described below to 
obtain the formate form for separation of inositol phosphates. A known packed 
volume of Dowex was washed with distilled water, left to setde and the 'fines' 
discarded. This wash was repeated twice. The Dowex was transferred to a 
scintered glass funnel and washed with 20 volumes of 2M sodium hydroxide. 
The Dowex was then washed with 10 volumes of water followed by 5 volumes
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of 1M formic acid. Finally, the Dowex was washed with 50 volumes of water 
until the pH of the slurry was constant at approximately 5.5. Following each 
preparation of Dowex formate it was characterised by performing ml by ml 
elutions of a mixture of [^H]Ins(l)P, [^H]Ins(l,4)P2 and [^H]Ins(l,4,5)P3.
2.3.2 Preparation of Dowex-50W-H+.
Dowex-50W-H+, strongly acidic cation exchange resin, 8% cross-linked, 
with a dry mesh of 200-400, was prepared as described below. Dowex was 
washed three times in three volumes of distilled water, allowing the resin to 
settle and discarding the 'fines' each time. The Dowex was then washed three 
times with three volumes of 1M HC1 accompanied by gentle stirring with a 
plastic rod. Washings were discarded each time. Finally, the Dowex was 
washed four or five times with three volumes of distilled water until the pH of 
the wash was constant at about pH 5.5.
Each newly prepared batch of Dowex was, characterised by performing an 
elution profile of a mixture of radiolabelled 'standards' of GroPCho, ChoP and 
Cho added to a Rat-1 cell extract.
2.4 Culture of Rat-1 fibroblast cells.
Rat-1 cells were routinely maintained in Dulbea^s modified Eagle's 
medium (DMEM) supplemented with glutamine (2mM), penicillin/streptomycin 
(100 IU/ml.) and newborn calf serum (10%). Medium was changed every two 
days as it became acidified and depleted of serum. To prevent selection of 
resistant strains of bacteria, gentamycin was used in rotation with pen/strep. 
Cells were grown in a humidified atmosphere of 5% C02 at 37°C. Except for
experimental purposes cells were grown in 75 cm^ culture flasks and were
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passaged when sub-confluent. Every two or three weeks a single flask was 
allowed to grow to confluency to ensure that cells were contact inhibiting and 
were not exhibiting aberrant morphology. Cells which exhibited transformed 
morphology, showed reduced responsiveness to given agonists or reached 
passage numbers higher than 30 were discarded.
2.4.1 Cell passage.
Cells were passaged at a ratio of 1 to 10 according to the following general 
protocol.
(1) Medium was aspirated and replaced with 3ml of sterile trypsin solution per 
75 cm2 flask.
(2) Flasks were returned to the incubator for 2-3 minutes until cells were 
detaching from the flask bottom. Trypsin activity was inhibited by addition of 
7ml of complete medium.
(3) After transfer to a sterile tube, the cell suspension was centrifuged at 800g 
for 3 minutes and the supernatant discarded.
(4) Cells were resuspended in complete medium and aliqciofed into new sterile 
flasks containing 10ml of fresh medium. Flasks were rocked gently to ensure 
even distribution of cells across the flask bottom and returned to the incubator.
2.4.2 Cryogenic preservation of cell lines.
Cell lines were stored in liquid nitrogen according to the following 
protocol.
(1) Cells were trypsinized as outlined above (cell passage 1-3)
(2) Cells were resuspended in DMEM containing 20% (v/v) newborn calf serum 
and 8% (v/v) DMSO at a density of approximately 10  ^cells per ml of freezing 
medium and aliquoted into freezing vials.
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(3) Cells were slow frozen for 24 hours at -80°C before transfer to a vat of 
liquid N2.
To bring cells up from storage, vials were removed from liquid N2 and 
thawed rapidly in a water bath at 37°C. Each aliquot of cells was plated out in 
3ml of fresh medium in a 25cm^ flask and left to attach overnight. The next day 
the medium and suspended dead cells were removed and the surviving cells 
were fed normally.
2.5 Measurement of [3H] thymidine incorporation.
Rat-1 cells were plated in 24-well plates at a density of ~1,000 cells per 
well in DMEM containing 10% (v/v) newborn calf serum. After 24h the 
medium was changed to DMEM containing 1% (v/v) newborn calf serum and 
the cells grown to quiescence over 2 days. The cells were then washed in 
serum-free DMEM and incubated in serum-free DMEM containing 1 pCi/ml [^H] 
thymidine and the agonists of choice for 24h. At the end of the labelling time 
the medium was removed and the monolayers washed twice with 0.5ml of HanKs 
followed by three 0.5ml washes with 5% (w/v) TCA and two 0.5ml washes 
with ethanol. The cells were solubilised in 0.5ml 0.3M NaOH and the samples 
transferred to 5ml insert vials. Optiphase Hi-safe scintillation fluid was added 
and the radioactivity associated with [•%] thymidine counted.
2.6 Measurement of stimulated inositol phosphate formation.
2.6.1 Preparation of samples for [^H] inositol phosphate 
measurement.
After plating on 24 well plates (~2,000 cells/well) in DMEM + 10%
newborn calf serum for 24 hours, Rat-1 cells were grown in 0.5ml of inositol- 
free DMEM containing 1% dialysed newborn calf serum with lpCi/ml of [2- 
^H]my<9-inositol for 48 hours, by which time the cells were confluent, quiescent 
and labelled to isotopic equilibrium. Labelling medium was aspirated and cells 
were washed twice with 0.5ml of HBG (pH 7.4) at 37°C and then incubated for 
lOmin with HBG containing lOmM LiCl (HBG/LiCl). Finally, cells were 
stimulated with 150pl of HBG/LiCl containing the test reagent at the final 
concentrations and for the times indicated.
Incubations were terminated by direct addition of 500 pi of ice cold 
methanol. After scraping the cell debris and transferring to a 5ml insert vial, 
each well was washed with a further 200 pi of methanol and the two washes 
pooled. Phospholipids were extracted from the cell debris by addition of 350 pi 
of chloroform followed by vortexing and standing on ice for 30 minutes or at 
4°C overnight. After addition of 500pl of distilled water and 350pl of 
chloroform samples were centrifuged at 14,000g for 3 minutes to split the 
phases and 800pl of the upper aqueOU s/methanolic phase was transferred to a 5 
ml insert vial for measurement of total inositol phosphates. In addition, an 
aliquot of the chloroform phase was removed, dried down in an insert vial and, 
after addition of 4ml of Optiphase Hi-safe scintillation fluid, the radioactivity in 
the total inositol lipids determined by scintillation counting.
2.6.2 Assay of total inositol phosphates.
Total inositol phosphates were assayed by accumulation in the presence of 
lOmM LiCl essentially by the method of Berridge et al. (1982). Samples 
(800pl) were added to insert vials containing 500pl Dowex formate (1x8 200- 
400 mesh), followed by 3 ml of distilled water to mix. After the Dowex had 
settled the supernatant was aspirated. The removal of glycerophosphoinositides 
was achieved by two washes with 3 ml of 60 mM ammonium formate/5mM
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sodium tetraborate followed by a further 3 ml wash with water. Finally total 
inositol phosphates (mainly InsPi and InsP2) were e u^te^ by a 1ml wash of 1M
ammonium formate/ 0.1M formic acid. The supernatant was removed to an 
insert vial and mixed with Optiphase Hi-safe scintillation fluid. The radioactivity 
was estimated by liquid scintillation counting.
2.6.3 Preparation of samples for analysis of individual inositol 
phosphate fractions.
Rat-1 cells were plated in 75cm^ flasks in DMEM containing 10% 
newborn calf serum. After 48h, the medium was changed to inositol-free 
DMEM containing 1% dialysed newborn calf serum and 8|iCi/ml [2-^H] myo­
inositol for 48h. Cells were harvested by scraping, preincubated for 45min in 
the conditioned DMEM and then washed twice in HBG. Aliquots (50jil) of 
resuspended cells (approx. 2x l04 cells/aliquot) were incubated with agonist or 
vehicle in assay buffer (250}il final volume) at 37°C at the final concentration 
and for the times indicated. The reaction was terminated by the additin of 50|il 
10% (v/v) perchloric acid and the samples extracted on ice for 20min. The 
samples were then neutralized by the addition of 1.5M KOH/60mM Hepes in the 
presence of Universal Indicator and the precipitated potassium perchlorate 
removed by centrifugation at 14,000g for 3min at 4°C. The supernatants were 
analysed by ion-exchange chromatography on Dowex 1x8 formate columns.
2.6.4 Assay of individual inositol phosphate fractions.
Neutralized supernatants were diluted in 5ml of 5mM sodium tetraborate/ 
0.5mM-EDTA, pH 6.7 and applied to 1 ml columns of Dowex formate (1x8; 
200-400 mesh) prepared in glass wool plugged pasteur pipettes. The columns 
were then washed with 10 ml of water followed by 14ml of 60 mM ammonium
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formate/ 5m-sodium tetraborate to remove free inositol and 
glycerophosphoinositides, respectively. Inositol mono-, bis-, tris-, and 
tetrakisphosphates were eluted with sequential 18 ml washes of O.lM-formic 
acid containing 0.2M-, 0.4M-, 0.8M- and 1.2M- ammonium formate 
respectively. Aliquots of each fraction were mixed with Optiphase Hi-safe 
scintillant and the radioactivity determined by liquid scintillation counting.
2.7 Measurement of stimulated Ins(l,4,5)P3 mass formation.
2.7.1 Preparation of samples for measurement of Ins(l,4,5)P3 
mass.
Samples were prepared from cells harvested from flasks or attached to 
plastic wells.
Rat-1 cells grown to confluency in 75cm^ flasks were harvested by
scraping into their culture medium. After a 45min incubation time at 37°C (this 
incubation period has been shown to allow full recovery of Ins(l,4,5)P3 levels
to basal) the cells were spun down and washed twice in HBG (pH 7.4). The 
cells were then resuspended in HBG and incubated at 37°C for lOmin. Aliquots 
(50pl) containing approximtely 10  ^cells were stimulated with 25pi of agonist at 
37°C in plastic polytubes and the reactions terminated by the addition of 25pi of 
ice-cold 10% (v/v) perchloric acid. The samples were extracted for 20min on ice 
and neutralized with 1.5M KOH/60mM Hepes containing Universal Indicator. 
The cell debris and precipitated potassium perchlorate were removed by 
centrifugation at 14,000g for 3min at 4°C. A 25pl aliquot of the supernatant 
was removed for assay of Ins(l,4,5)P3 mass.
Alternatively, Rat-1 cells were grown to confluency in 12-well plates. The 
medium was removed and the monolayers washed twice with 0.5ml HBG and
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Iincubated with lml of HBG for 20min at 37°C. The cells were then stimulated 
with 175|il of agonist in HBG at 37°C at the concentrations and for the times 
indicated. Incubations were terminated by the addition of 25f±l of ice-cold 16% 
(v/v) perchloric acid followed by extraction on ice for 20min. Samples were 
neutralized with 1.5M KOH/ 60mM Hepes containing Universal Indicator. The 
cells were then scraped and transferred to eppendorf tubes. The cell debris and 
precipitated potassium perchlorate were removed by centrifugation at 14,000g 
for 5min at 4°C. The supernatant (200pl) was removed for assay of 
Ins(l,4,5)P3 mass.
2.7.2 Assay of Ins(l,4,5)P3 m ass.
Samples prepared as described were assayed for Ins(l,4,5)P3 mass by the 
competitive binding assay of Palmer et al. (1989). The assay employs a bovine
adrenocortical microsomal preparation which possesses a single population of 
specific high affinity binding sites for Ins(l,4,5)P3-
Aliquots (25|il) of adrenal cortex preparation (20mg/ml of protein) were
incubated with 200|il of sample or Ins(l,4,5)P3 standard, lOOpl of binding
buffer ( lOOmM Tris, 4mM EDTA, 4mM EGTA, 4mg/ml BSA; pH 8.5), 25|il 
water and 50|il of [3H] Ins(l,4,5)P3 (approx. 3,000 cpm) on ice for 20min.
Nonspecific binding was determined in the presence of l^iM Ins(l,4,5)P3.
Incubations were teminated by centrifugation at 12,000rpm for 3min at 4°C and 
the supernatant then aspirated. The radioactivity bound to the pellet was 
determined by liquid scintillation counting after solubilisation in Hi-Safe 
scintillant. The use of a standard curve of displacement of [3H] Ins(l,4,5)P3 by 
unlabelled Ins(l ,4,5)P3with each assay allowed estimation of Ins(l ,4,5)P3 
mass in cell extracts.
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2.8 Measurement of stimulated PIP2 mass hydrolysis.
Rat-1 cells were grown to confluence and quiescence in 24-well plates. 
The medium was removed and the cells washed twice with 0.5ml HBG (pH 
7.4) and incubated with HBG for 20min. Stimulation was then carried out with 
150pl of agonist in HBG at the concentrations and for the times indicated at 
37°C and the reaction terminated by the addition of lOOpl of ice-cold 20% (w/v) 
TCA. The cells in each well were scraped and transferred to eppendorf tubes. 
The samples were spun at 14,000g for 2min at 4°C and the supernatant 
removed. The wells were then washed with 500|il of 5% (w/v) TCA/ ImM 
EDTA and this used to resuspend the cell pellet. These samples were then spun 
at 14,000g for 2min at 4°C and the supernatant removed. The pellet was washed 
with 500pl water ,spun as before and the supernatant removed. Chloroform/ 
methanol/ 12MHCL (40 : 80 : 1, by volume) (500pl) was added to the pellet and 
the samples left at room temperature for 10-20min. Then, 165|il chloroform and 
300pl 0.1M HCL was added, the samples left for a further lOmin and finally 
spun at 14,000g for 2min. An aliquot (250pl) of the lower phase was taken and 
dried down in vacuo.
The dried lipid extract was deacylated and deglycerated by the addition of 
250pl of 1M KOH and incubation of the samples at 100°C for 30min. After 
placing on ice for 5min, the samples were spun at 14,000g for 2min and then 
passed through a 0.5ml (50% w/v slurry) of Dowex 50 (H+, 200-400 mesh) 
column. The columns were washed with 3 x 0.75ml water. The resulting 
2.5ml sample was washed with 3ml butanol: petroleum ether (5:1; v/v). The 
upper phase was aspirated and the sample washed with a further 2ml of the same 
solvent. The upper phase was once again aspirated and discarded. An aliquot 
of the lower phase (1ml) was dried down, redissolved in water and assayed 
using the Ins(l,4,5)P3 mass assay described above.
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2.9 Assay of PtdCho hydrolysis.
2.9.1 Preparation of samples for mesurement of PtdCho 
breakdown.
Rat-1 cells were plated at a density of approximately 2,000 cells/ml on 24 
well plates and grown in DMEM + 10% newborn calf serum for 24 hours.
They were then labelled with 5jiCi/ml [^H] choline chloride in DMEM +1% 
newborn calf serum for 48 hours by which time they were confluent and 
quiescent. Following removal of the labelling medium, the cells were washed 
twice with 0.5ml HBG (pH 7.4) and then preincubated with 0.5ml HBG for 
30min.. Finally, cells were incubated in 150|il of HBG containing the given 
concentration of test reagent for the required time.
For experiments where intracellular or cell associated choline metabolites 
were studied, incubations were terminated by aspiration of the test solution and 
addition of 500|il of ice cold methanol. For experiments where intracellular and 
extracellular metabolites were studied incubations were terminated by addititon 
of 500|il of ice cold methanol to the incubation buffer. Cell debris was scraped, 
transferred to a 5ml insert vial and pooled with a further 200jil methanol wash. 
Phospholipids were extracted by addition of 350jil chloroform followed by 
vortexing. After standing on ice for lhour or at 4°C overnight, a further 350pl 
of chloroform and 500jil of water was added and the phases were split by 
centrifuging at 14,000g for 3 minutes. A 1ml sample of the aqueous methanolic 
phase was taken for separation of the major water soluble metabolites of choline 
by cation exchange chromatography.
2.9.2 Separation of the major water soluble metabolites of 
choline.
The 1ml aqueous methanolic samples from experiments were loaded on to
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lml Dowex-50W-H+ columns prepared in glass wool plugged pasteur pipettes. 
The flow through and a further 8 ml water wash were pooled and collected as 
the glycerophosphocholine fraction. A further wash with 20 ml of water was 
collected as the phosphocholine fraction, whilst a final wash with 20 ml of 1M 
HC1 eluted off the choline fraction. Two ml aliquots of each fraction were 
mixed with Optiphase Hi-safe scintillant and radioactivity determined by liquid 
scintillation counting.
2.9.3 Analysis of [3H] choline containing lipids.
[^HJcholine labelled Rat-1 cells were stimulated with agonist or vehicle as
described above. Following extraction in chloroform and methanol as described
above, the aqueous methanolic phase was removed and the chloroform phase
dried in vacuo. Choline-containing lipids were re-dissolved in lOOpl of
chloroform/methanol (19/1; v/v) and half the sample was applied to silica gel 60
t.l.c. plates. The t.l.c. plates were developed fully in a lined, equilibrated tank
in a solvent of chloroform:methanol:acetic acid:water (25:15:4:2, v/v) (Skipski et 
al.y 1964). PtdCho and sphingomyelin were identified by their Rf values and
co-migration with authentic standards. After excision of the appropriate spot the 
radioactivity in PtdCho was determined by scintillation counting using 4ml of 
Optiphase Hi-safe.
2.10 Measurement of Phospholipase D transferase activities in 
whole cells.
2.10.1 Assay of PtdBut formation in [3H] palmitate labelled Rat-1 
cells.
PLD catalysed phosphatidyltransferase activity was assayed by measuring
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the incorporation of butan-l-ol into phosphatidyl moieties.
Rat-1 cells were sub-cultured into 24-well culture plates and grown in 
DMEM + 10% newborn calf serum until approximately 70% confluent. The 
growth media was then replaced with 0.5ml of DMEM +1% newborn calf 
serum containing 4 p.Ci/ml of [^HJpalmitic acid and the cells were labelled for 
approximately 48 hours. For experimental purposes the labelling medium was 
removed by aspiration and cells were washed twice with 0.5ml HBG (pH 7.4) 
followed by a preincubation for 20min with 0.5ml HBG. For kinetic studies 
cells were incubated for a further 5 minutes in 0.5ml of HBG containing 30 mM 
butan-l-ol (0.3%, v/v) at 37° C prior to addition of agonists. Finally cells were 
incubated in HBG + 30mM butan-l-ol + the required concentration of test 
reagent for the indicated time. For dose dependency studies there was no pre­
incubation with butan-l-ol and the appropriate concentration of test reagent in 
HBG + 30mM butan-l-ol was added directly to the cells for 15 minutes. 
Incubations were terminated by aspiration of the incubation medium followed by 
the addition of 0.5ml of ice-cold methanol. Cell debris was scraped off the plate 
surface and transferred to screw-top glass tubes together with a further 0.2ml of 
methanol wash. Phospholipids in these pooled scrapings were extracted by the 
addition of 0.7ml of chloroform, vigorous vortexing and standing at room 
temperature for 15 minutes. After addition of 0.6ml of water the samples were 
centrifuged for 5 minutes at 14,000g, the upper aqueous/methanolic phase 
discarded and the chloroform phase dried in vacuo. Samples were routinely 
analysed by thin layer chromatography immediately.
2.10.2 Isolation and Identification of Phosphatidylbutanol.
Dried chloroform extracts were re-dissolved in 50|il of 
chloroform/methanol (19/1) with vigorous vortexing and applied to Whatman 
LK5DF, 20cm x 20cm, pre-laned silica gel thin layer chromatography plates.
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Once the samples had dried, the plates were fully developed once in the organic 
phase of 2,2,4-trimethylpentane:ethyl acetate:acetic acid:water (50/110/20/100, 
v/v) under equilibrium conditions in an un-lined chromatography tank.
After drying, plate lanes were divided into 0.5cm strips, the silica gel 
scraped into scintillation vials and radioactivity counted in 4ml of Optiphase Hi- 
safe scintillant. The band of radioactivity corresponding to PtdBut was 
identified by the following criteria: -
(a) its co-migration with an authentic [^CJPtdBut standard developed on the 
same t.l.c. plate,
(b) its unique appearance in the presence of butan-l-ol in response to a suitable 
stimulus,
(c) its dose dependent appearance with increasing butan-l-ol concentration up to 
lOOmM in response to a suitable stimulus.
2.11 Measurement of [^H] PDBu binding to intact cells.
Rat-1 cells in 24-well plates were grown to confluency. The medium was 
removed and the monolayers washed twice with 0.5ml HBG (pH 7.4). The 
cells were then incubated with 150}il of lOOnM [^H] PDBu in HBG for 20min. 
Specific binding was defined by the inclusion of 20|iM unlabelled PDBu. The 
binding reaction was terminated by aspirating the incubation medium and 
washing the cells three times with 0.5ml of ice-cold HBG. The cells were 
solubilised with 0.5ml of 0.5M NaOH/ 0.1% (v/v) Triton x-100 and bound 
radioactivity was determined by scintillation counting.
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2.12 [*2^I] Endothelin binding studies.
2.12.1 Preparation of membranes from Rat-1 cells.
Rat-1 cells were grown in 75cm2 flasks or glass burlers to confluency and 
then harvested by scraping from flasks or trysinisation from burlers. After a 
45min incubation at 37°C to allow recovery from the physical perturbation 
caused by harvesting, the cells were spun at 800g for 5min. The supernatant 
was removed and the pellet washed twice in PBS. The final pellet was 
sometimes stored at -80°C until needed.
For the preparation of membranes, the cells were resuspended in 5ml of 
lOmM Tris/ O.lmM EDTA (pH 7.4) and homogenised with 25 strokes of a Potter 
homogeniser. The homogenate was spun at 500g for lOmin in a Beckman L5- 
50B centrifuge with a Ti 50 roter and the supernatant taken and spun at 48,000g 
for lOmin. The resulting pellet was resuspended in 5ml lOmM Tris/ O.lmM 
EDTA and spun again at 48,000g for lOmin. The final pellet was resuspended 
in 1ml of lOmM Tris/O.lmM EDTA (pH 7.4) and stored in lOOjil aliquots at 
-80°C.
2.12.2 Measurement of [125I] ET-1 binding to Rat-1 membranes.
Rat-1 membranes (lOOjil; 25jig protein) were incubated with lOOjil 
binding buffer (lOmM Tris, 5mM MgCl2, 3mM EDTA, ImM EGTA; pH 7.4)
and 50|il [12^ I] ET-1 (~88,000 d.p.m.) at 25°C for 30min to reach equilibrium 
binding. Excess unlabelled ET-1 (ljiM) was included to determine nonspecific 
binding. Binding was terminated by separating bound ligand from free ligand 
by vacuum filtration through GF/C filters. The filters were washed three times 
with 4ml of ice-cold binding buffer and then counted in a gamma radiation 
counter.
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2.13 Measurement of intracellular calcium in Rat-1 cells
Rat-1 cells were grown on glass coverslips. The confluent monolayers 
were washed in HBG (pH 7.4) and incubated in HBG containing 5pM Indo-1 
AM, 0.125% (w/v) plurionic acid, 0.5% (v/v) DMSO for 20min at room 
temperature. Coverslips were placed in a perspex bath which was fixed to the 
stage of a Nikon Diaphot inverted microscope. The cells were perfused with 
HBG with or without additions at 1.5 ml/min (35-37°C) and illuminated at 
360nm. Light emitted from the cells with a wavelength greater than 385nm was 
directed at a 460nm dichroic mirror which sent longer wavelength light via a 
495nm barrier filter to a photomultiplier. Shorter wavelengths were reflected by 
the dichroic mirror and sent via a 405nm barrier filter to a second 
photomultiplier. The signals from the two photomultipliers were divided using 
analogue circuitry and a signal representing the ratio filtered at 3 Hz. No 
correction was made for cell autofluorescence which was less than 5% of a 
typical Indo loaded preparation. Due to the difficulties associated with absolute 
calibrations for [Ca2+]j from cells loaded with AM esters of Ca2+ indicators the
experimental records are presented in terms of raw fluoresc#tt& data.
2.14 Permeabilization of Rat-1 cells.
2.14.1 Electropermeabilization.
Rat-1 cells were grown to confluency in 75cm2 flasks and then harvested 
by scraping into their culture medium. After a 45min incubation at 37°C the 
cells were centrifuged at 800g for 3min and the pellet washed twice in 
permeabilization buffer (pH 7.4). The cells were then resuspended in 
permeabilization buffer and exposed to six discharges at 1 sec intervals of a 3pF 
capacitor with a field strength of 2kV/cm.
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2.14.2 Permeabilization of cells using streptolysin-O.
Rat-1 cells were grown to confluency and quiescence on 24-well plates. 
The monolayers were washed three times with 0.5ml of HBG (pH 7.4) and 
incubated with 0.5ml of permeabilization buffer containing 0.6 units/ml of 
streptolysin-O for 5min. The cells were then washed with 0.5ml of 
permeabilization buffer for 15min.
2.15 Lowry protein assay. (Lowry et al.y 1951)
Aliquots of sample (2,4,6,8pl) were incubated with 1ml of reaction 
mixture (1% Q 1SO4, 2% sodium potassium tartrate and 2% sodium carbonate in
0.1M NaOH) for lOmin at room temperature. Then, lOOjil of dilute Folin & 
Ciocalteu's phenol reagent (1:1 with water) was added and the samples 
incubated for a further 20min at room temperature. Finally, absorbance was 
measured at 750nm. Protein concentration was calculated from a standard curve 
constructed using a lmg/ml solution of BSA.
2.15 Analysis and presentation of results.
Unless otherwise stated all experiments were performed at least three times 
and each data point represents the mean ± standard deviation (S.D.) of triplicate 
determinations. Statistical significance was estimated by a paired Students't' 
test on an Apple Macintosh Stat-Works program.
EC50 and IC50 values were calculated from dose-response curves fitted to
a logistic equation (non-linear regression analysis) as defined by DeLean et al. 
(1980). However, for presentation purposes dose-response curves were 
presented as simple line graphs from the Apple Macintosh Cricket Graph 
program.
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Chapter 3
Signal transduction pathways stimulated by endothelin
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3.1. Introduction
Although the wide range of biological actions of the endothelins (ETs) is 
now appreciated (section 1.6.2), little is known about their mechanism of action. 
The original report describing ET-1-stimulated vasoconstriction demonstrated 
that extracellular calcium was needed for contraction and that vasoconstriction by 
ET-1 was inhibited by nicardipine suggesting that influx of extracellular calcium 
was required for the action of the peptide (Yanagisawa et al., 1988a). This led 
the authors to suggest that ET-1 might be acting directly on membrane calcium 
ion L-channels. Later work confirmed the importance of extracellular calcium 
both in ET-1 induced contraction (Marsault et al., 1990; Miyauchi et al., 1990) 
and in other responses such as mitogenesis (Nakaka et al., 1989; Shichiri et al.,
1991) but showed that ET-1 does not act directly on Ca2+ channels (Sugiura et 
al., 1989a; Badr et al., 1989).
It is now widely accepted that ET-1 binds to a specific membrane receptor 
leading to the activation of a number of signal transduction pathways including 
polyphosphoinositide hydrolysis and activation of the arachidonic acid cascade 
(reviewed in Simonson and Dunn, 1990a, b). The activity of Ptdlns-PLC, as 
measured by the generation of inositol phosphates, increases rapidly after 
stimulation with ET-1. ET-1 stimulated a dose-dependent accumulation of 
inositol phosphates in fibroblasts (Muldoon et al., 1989), vascular smooth 
muscle cells (Araki et al., 1989; Resink et al., 1988), mesangial cells (Simonson 
et al.,. 1989), endothelial cells (Vigne et al., 1990a), adrenal glomerulosa cells 
(Woodcock et al., 1990) and in both neurons and glial cells (Lin et al., 1990). 
The closely related peptide sarafotoxin S6b (SS6) could also stimulate 
phosphoinositide turnover in rat heart and brain (Kloog et al., 1988) and 
neurally-related cell cultures (Lin et al., 1990) suggesting that the endothelins 
and sarafotoxins share the same signalling pathways. The initial inositol 
phosphate product of Ptdlns-PLC-catalysed hydrolysis of PtdIns(4,5)P2 is 
Ins(l,4,5)P3 and its formation has been demonstrated as early as 5sec after
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stimulation with ET-1 in adrenal glomerulosa cells (Woodcock et al., 1990) and 
lOsec in rat mesangial cells (Simonson et al., 1989). Rapid generation of InsPg
(consisting of Ins(l,4,5)P3 and Ins(l,3,4)P3) has also been observed in 
vascular smooth muscle cells (Resink et al., 1990a), fibroblasts (Takuwa et al.,
1989) and endothelial cells (Vigne et al., 1990a).
The other product of PtdIns(4,5)P2 breakdown is sti-1,2-diacylglycerol
(DAG) and elevated DAG levels in response to ET-1 stimulation have been
reported in several systems. A biphasic increase in DAG that is sustained for
20min or more was observed in response to ET-1 in vascular smooth muscle
cells (Lee et al., 1989; Griendling et al., 1989) and C6 glioma cells (Zhang et
al., 1991). Sustained DAG formation was also observed in fibroblasts
(Muldoon et al., 1989; Takuwa et al., 1989). DAG is the main physiological
activator of protein kinase C (PKC) and increased PKC activity induced by ET-1
has been demonstrated by different approaches. In Swiss 3T3 cells stimulation
with ET-1 increased the incorporation of ^ 2P into an 80kDa protein which is a
PKC substrate (Takuwa et al., 1989) while in vascular smooth muscle cells
PKC activity (measured as histone HI phosphorylation) was translocated to the
plasma membrane in response to ET-1 stimulation (Lee et al., 1989). 
Ins(l,4,5)P3 mobilizes calcium from intracellular stores and much
attention has been paid to calcium signalling by the ET peptides. Ca2+ 
mobilization in response to ET-1 is typically biphasic consisting of a rapid 
transient increase followed by a smaller but sustained increase. This type of 
Ca2+ signal has been observed in Swiss 3T3 fibroblasts (Takuwa et al., 1989; 
Ohnishi et al., 1989), rat and human glomerulosa mesangial cells (Simonson et 
al., 1990, Simonson and Dunn, 1991b), vascular smooth muscle cells (Hirata et 
al., 1988; Simpson and Ashley, 1989; Marsden etal., 1989; Kai etal., 1989; 
Wallnofer et al., 1989), endothelial cells (Vigne et al, 1990b) and atrial cells 
(Vigne et al., 1990a). Generally, both intracellular release and extracellular 
influx of Ca2+ contribute to the transient phase, whereas influx is mainly
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responsible for the sustained phase. In some cases the influx of Ca2+ is 
sensitive to inhibition by dihydropyridine (DHP) and other voltage-sensitive L- 
channel blockers but in other systems it is DHP-insensitive suggesting that 
influx occurs via some type of receptor- or second-messenger-operated 
channels.
Although most attention has focused on the hydrolysis of PtdIns(4,5)P2 
as a cellular signalling pathway for ET-1, there have been reports in some
systems of other second-messenger-generating pathways. ET-1 stimulated the 
release of prostacyclin and thromboxane A2 from pig or rat isolated lungs,
suggesting activation of phospholipase A2 (PLA2) (De Nucci et al., 1988).
PLA2 activation was also demonstrated in vascular smooth muscle cells by the
ET-induced extracellular release of arachidonic acid (AA) derived from PtdCho
and Ptdlns (Resink et al., 1989; Resink et al., 1990a; Reynolds et al., 1989). 
Similarly, ET-1 stimulated AA release and prostaglandin F2(X and thromboxane
B2 synthesis in rat mesangial cells (Simonson and Dunn, 1990c). In vascular
smooth muscle cells PLA2 activity was proposed to occur independently of
PtdIns(4,5)P2 hydrolysis due to the lack of inhibition of the AA response by
neomycin (Resink et al., 1990a) or PMA (Reynolds et al., 1989) treatment.
Studies in C6 glioma cells and vascular smooth muscle cells have 
demonstrated ET-stimulated PtdCho hydrolysis measured as increased levels of 
choline and choline phosphate (Zhang et al., 1991; Resink et al., 1990a). In 
Swiss 3T3 fibroblasts ET-1 caused a decrease in cAMP levels (Takuwa et al., 
1989) while in rat nephron segments ET inhibited vasopressin-dependent cAMP 
accumulation (Tomita et al., 1990). In contrast in rat glomerulosa mesangial 
cells ET-1 potentiated P-adrenergic-mediated cAMP accumulation by a 
prostaglandin Independent mechanism (Simonson and Dunn, 1990c). Finally,
in a neuronal cell line ET-1 stimulated a rise in cGMP indicating activation of 
guanylate cyclase (Reiser, 1990).
ET-1, therefore, appears to interact with a number of signal transduction
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pathways either directly or indirectly. In this work the second messenger 
pathways mediating the mitogenic effect of ET-1 in Rat-1 cells were 
investigated. Attention was focussed on PtdIns(4,5)P2 and PtdCho hydrolysis
as both these pathways generate second messengers with potentially important 
roles in the proliferative response (section 1.3.3 and 1.3.4)
3.2. ET-1 is a complete mitogen in Rat-1 cells
When proliferation was measured as an increase in the incorporation of 
[^H] thymidine into DNA, ET-1 was found to be a complete mitogen for Rat-1 
cells. Although not as potent as 10% serum (5.7 ±1.8 fold increase, n=24), a 
maximum dose of ET-1 (lOOnM) stimulated a 2.2 ± 0.5 (n=28) fold increase in 
[^H]thymidine incorporation in quiescent cells in serum-free medium in the 
absence of any other added growth factors (Fig. 3.1). The other ET peptides, 
ET-2 (lOOnM) and ET-3 (300nM), stimulated [^H]thymidine incorporation to a 
similar extent (2.2 ± 0.5 fold for ET-2; 1.8 ± 0.3 fold for ET-3; n=4) and the 
phospholipid lysophosphatidic acid (LPA) was also equally effective (1.9 ± 0.3 
fold; n=20). Bombesin, however, did not significantly increase [^H]thymidine 
incorporation (1.0 ± 0.2 fold; n=7). The response to ET-1 was dose-dependent 
(Fig. 3.2) with a maximum response at about lOnM and with an EC50 value of
2.4 ± 1.3nM (n=3).
Long term PMA treatment has been reported to down-regulate PKC 
activity (Rodriguez-Pena and Rozengurt, 1984). In Rat-1 cells pretreated for 
48h with 400nM PMA the incorporation of [^H]thymidine in response to ET-1 
was inhibited to a variable extent. A significant inhibition (p < 0.05) was 
observed in four out of a total of six experiments (69 ± 24% inhibition, n=4) 
(Fig. 3.3a). In the remaining two experiments PMA pretreatment had no effect. 
The variable results obtained in cells treated with PMA may be due to the
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incomplete down-regulation of protein kinase C activity (see section 3.7). The 
same PMA treatment did not significantly affect the response to serum (Fig. 
3.3a) or LPA (results from a typical experiment: -PMA, 194 ± 9% of basal 
with LPA; +PMA, 212 ± 23% of basal with LPA,; n=5) in five out of six 
experiments. Chronic PMA pretreatment did not affect the basal incorporation 
of [3H] thymidine (-PMA, 1547 ± 61 d.p.m.; +PMA, 1601 ± 135 d.p.m.; 
n=6).
The effect of pertussis toxin pretreatment was also investigated. Pertussis 
toxin ADP-ribosylates the a-subunit of Gj and Go and thus inhibits productive
coupling to the effector system (Reisine, 1990). The incorporation of pH] 
thymidine in response to ET-1 was however pertussis toxin-insensitive (Fig. 
3.3b) suggesting that coupling of the ET receptor to mitogenic signalling 
pathways does not involve Gj -like G proteins. The mitogenic response to LPA 
in Rat-1 fibroblasts has been reported to be pertussis toxin-sensitive (van 
Corven, 1989); however, in the work presented here the incorporation of pH] 
thymidine in response to LPA was only inhibited by pertussis toxin in one 
experiment and otherwise was found to be insensitive to the toxin pretreatment 
(results from a typical experiment: -PTox, 163 ± 6% of basal with LPA;
+PTox, 183 ± 7% of basal with LPA; n=3).
3.3. ETs stimulate PtdIns(4,5)P2 hydrolysis
PtdIns(4,5)P2 hydrolysis was measured by the generation of the water-
soluble inositol phosphate products. ET-1 (lOOnM) stimulated a rapid increase 
in the mass of Ins(l,4,5)P3 which peaked at 5-10sec with a 7-10-fold increase
in stimulated levels over control (results from a typical experiment: 0.8 ± 0.4 
pmol in control; 7.9 ± 0.9 pmol with ET-1; n=6) and then declined towards 
basal levels (Fig 3.4). However, levels remained elevated 2-4 fold above 
controls at lOmin (results from a typical experiment: 1.3 ± 0.2 pmol in control;
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4.2 ± 0.7 pmol with ET>1; n=4).
ET-1 stimulated the accumulation of [^H] inositol phosphates (InsP) in the
presence of lOmM LiCl after a lag time of about lmin; this is probably because
lithium exerts its effect downstream of PtdIns(4,5)P2 hydrolysis by inhibiting
the metabolism of inositol phosphates at the level of the Ins(l,4)P2/Ins(l,3,4)P3
1-phosphatase and inositol monophosphatase (Nahorski etal., 1991). The
accumulation of inositol phosphates in response to ET-1 was biphasic with an
initial rapid increase up to 2-5min after which levels continued to increase at a
slower rate in a linear manner up to 30-40min (Fig. 3.5). Subsequent
measurements were carried out at 20min, a time at which ET-1 stimulated an
approximately 4-6-fold increase in InsP over controls (results from a typical
experiment: 1156 ± 75 d.p.m. in control; 6122 ± 332 d.p.m. with lOOnM ET-
1; n=3). The accumulation of [•%] InsP in response to ET-1 was dose- 
dependent with a maximum increase at approximately lOnM and an EC^q value
of 2.0 ± l.OnM (n=5) (Fig. 3.6). ET-2 and ET-3 also stimulated the
accumulation of [3H] InsP in a time-dependent manner (Fig. 3.7) with a similar
4-6-fold increase over controls at 20min (results from a typical experiment:
4758± 1120 d.p.m.in control, 21032 ± 74 d.p.m. with lOOnM ET-2, 18580 ±
1498 d.p.m. with 300nM ET-3). Pharmacological characterization of [3H] InsP 
accumulation using ET-2, ET-3 and sarafotoxin S6b (SS6) yielded EC50 values
of 1.2 ± 0.3nM, 54 ± 18nM and 1.7 ± OnM respectively (n=3) (Fig. 3.8) thus 
giving a rank order of potency of ET-1 = ET-2 = SS6 > ET-3.
3.4 ETs stimulate PtdCho hydrolysis
PtdCho hydrolysis was measured by the generation of the water soluble 
choline products in [^H] choline-labelled cells. The generation of [^H] choline 
in response to a maximum dose of ET-1 (lOOnM) was also very rapid. There 
was a significant increase (p < 0.05) in both intracellular and total (intracellular +
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extracellular) choline after lOsec which had at least doubled by lmin (Fig. 3.9a, 
c). Thereafter, the rate of production of total choline decreased and by 5min any 
further increase was paralleled by increased basals. Both stimulated and basal 
levels of total choline reached steady state after about 30min (Fig. 3.9b). The 
kinetics of intracellular choline changes were somewhat different, peaking at 
about 5min and remaining elevated for a further 5-10min before decreasing and 
returning to near-basal levels at 60min (Fig. 3.9c). The maximum obtainable 
increase in both intracellular and total choline levels in the presence of ET-1 over 
controls varied between 2-5 fold. The greater increase in basal values when total 
choline was measured rather than intracellular is probably due to the 
accumulation of choline in the extracellular medium where it is not susceptible to 
metabolism.
The generation of [3H] choline in response to ET-1 was also dose- 
dependent with a maximum response at about lOnM and an EC50 value of 0.8 ±
0.4nM (n=8), which is very close to that for stimulated pH] InsP accumulation
(Fig. 3.10). ET-2 and ET-3 were also effective at stimulating choline generation
(Fig. 3.11). pH] Choline levels increased up to about 5min with 3-5-fold
increases over controls and any subsequent increases were paralleled by
increased basal values. The dose-dependencies were very similar to that for 
InsP accumulation (Fig. 3.12). EC5Q values for ET-2, ET-3 and SS6 of 0.7 ±
0.2nM, 56 ± 18nM and 1.2 ± 0.2 nM (n=4) respectively were obtained, 
yielding the same rank order of potency ET-1 = ET-2 = SS6 > ET-3.
3.5 ET-1 stimulates PtdCho synthesis
In addition to measuring choline generation in response to ET-1 
stimulation, choline phosphate levels were also determined since this metabolite 
may also be a product of PtdCho hydrolysis. There was no significant change 
in [^H] choline phosphate content untill approximately 30min after stimulation
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with ET-1 when a decrease of 15-30% below controls was observed (Fig.
3.13). In order to determine whether this might be due to stimulated 
incorporation into parent lipid, PtdCho synthesis in response to ET-1 stimulation 
was investigated. The increased incorporation of [^H] choline into PtdCho was 
evident as early as 5min after stimulation and increased up to 20-30min, when it 
was paralleled by the basal increase (Fig. 3.14). The maximum response was 
150-180% of the basal (results from a typical experiment; 5097 ±861 d.p.m. in 
control; 8357 ± 453 d.p.m. with ET-1; 20min stimulation, n=3). [3H] 
Glycerophosphocholine generation did not change in response to ET-1 
stimulation up to 60min (results from a typical experiment: 9000 ± 1928 d.p.m. 
in control; 8738 ± 2154 d.p.m.with ET-1).
3.6. PMA-stimuIated PtdCho hydrolysis
The PKC-activating phorbol esters have been shown to stimulate PtdCho 
hydrolysis in many systems (see section 1.5.2). The ability of PMA to induce 
choline generation was therefore investigated in Rat-1 cells. The generation of 
[^H] choline in response to PMA was time- and dose-dependent. PMA 
stimulated choline generation after a lag time of l-2min and levels increased 
rapidly up to approximately 5min when the rate decreased and by 15min the 
stimulated increase was paralleled by the basal increase (Fig. 3.15). Similar to 
ET-1, PMA also caused a decrease in choline phosphate levels after 30-40min 
(results from a typical experiment: 3444 ±102 d.p.m. in control; 2600 ±142 
d.p.m. with 300nM PMA; 2747 ± 96 d.p.m. with lOOnM ET-1; 45min 
stimulation).
The EC50 value for PMA-induced choline generation was 27 ± 14nM 
(n=3) (Fig. 3.16). P-phorbol (4p,9a,12p,13a,20-Pentahydroxytiglia-l,6- 
dien-3-one) which is inactive at stimulating protein kinase C gave no response
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(results from a typical experiment: 708 ±35 d.p.m. in control; 750 ±51 d.p.m. 
with 300nM P-phorbol; 2954 ± 257 d.p.m. with 300nM PMA; lOmin 
stimulation). The magnitude of the PMA response was, however, generally 
smaller than that obtained with ET-1 (results from a typical experiment: 1106 ± 
306 d.p.m. in control; 2130 ± 38 d.p.m. with 300nM PMA; 3145 ± 248 d.p.m. 
with lOOnM ET-1; lOmin stimulation, n=4).
3.7. The role of PKC in ET-l-stimuIated PtdCho hydrolysis
The ability of PMA to stimulate pH] choline generation suggested a role 
for PKC in activating PtdCho hydrolysis. In order to investigate the role of 
PKC in mediating ET-1-stimulated PtdCho breakdown Rat-1 cells were 
pretreated for 48h prior to stimulation with 400nM PMA to down-regulate PKC. 
The effect of chronic PMA treatment on PKC activity was assessed by 
measuring the binding of pH] PDBu (Phorbol 12,13-dibutyrate) to intact Rat-1 
cells. Specific pH] PDBu binding was time-dependent reaching equilibrium 
after 20-25min (Fig. 17a) and saturable with a Kd ~ 35nM (Fig. 17b). 
Pretreatment of Rat-1 cells with 400nM PMA for 48h reduced specific binding 
to 30-40% of that in control cells. Binding of pH] PDBu to cells treated for an 
equivalent length of time with 400nM p-phorbol or vehicle was the same as in 
control cells (Fig. 3.18).
Chronic PMA pretreatment totally abolished pH] choline generation in 
response to ET-1 and PMA (Table 3.1). In control cells which had been treated 
with the inactive p-phorbol for an equivalent length of time the stimulated 
generation of choline was as observed in untreated cells (results from a typical 
experiment: 334 ± 21% of basal in control cells, 320 ± 30% of basal in p- 
phorbol-treated cells; lOmin stimulation with lOOnM ET-1). Although ET-1 
stimulated a larger increase in choline generation than PMA, the response was 
also completely inhibited by chronic PMA treatment.
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The effect of long term PMA pretreatment on InsP accumulation was also 
examined. ET-1-stimulated [3H] InsP generation remained the same in PKC- 
down-regulated cells indicating that coupling of the ET-1 receptor to the 
phosphoinositide system was still intact and unaffected by prolonged PMA 
treatment (T able 3.1)
3.8. ET-1 and PMA stimulate PtdCho hydrolysis by a 
phospholipase D-catalysed mechanism
ET-1 stimulated choline generation in the absence of any change in choline 
phosphate suggesting a phospholipase D- (PLD) catalysed hydrolysis of 
PtdCho. In order to more conclusively define a PLD-mediated pathway the 
ability of ET-1 to stimulate the phosphatidyltransferase activity of PLD was 
examined. The generation of phosphatidylalcohols is an unequivocal marker for 
PLD activity since phosphatidylalcohols can not be formed by alternative 
pathways (Pai et a l , 1988b). In the presence of 0.3% (v/v) butan-l-ol in [^H] 
palmitic acid-labelled cells, ET-1 stimulated the rapid generation of [^H] 
phosphatidylbutanol (PtdBut) with a significant increase (p < 0.05) above 
control levels after lOsec. PtdBut levels continued to rise up to 5min although 
the rate of increase was slower after 2min (Fig. 3.19a). At about 5min a 
maximum increase of approximately 8-fold was observed which remained 
unchanged for up to 30min. When a submaximal concentration of ET-1 (InM) 
was used the initial rate of accumulation of PtdBut was slower but the response 
still levelled out at 5min (Fig. 3.19b) suggesting it was a desensitization and not 
simply a situation where the [■%] label had become rate limiting. The generation 
of [^H] PtdBut was dose-dependent (Fig. 3.20) with a maximum response at 
about lOnM and an EC50 value of 2.6 ± 1.5nM (n=3). This is similar to the 
EC50 value for ET-l-stimulated choline generation (0.8 ± 0.4nM).
In keeping with its ability to stimulate choline generation PMA also
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induced the formation of pH] PtdBut in the presence of 0.3% (v/v) butan-l-ol 
in pH] palmitic acid-labelled cells. pH] PtdBut was generated with a lag time 
of approximately 2min following stimulation with 300nM PMA similar to 
choline generation, but the response was more sustained than that to ET-1 and 
lasted for up to 10-15min before levelling off (Fig. 3.21). The maximum 
response obtained was about 5-fold and in most experiments it was smaller than 
the increase obtained with ET-1 stimulation (results from a typical experiment: 
2183 ± 107 d.p.m. in control; 10316 ± 354 d.p.m. with 300nM PMA; 17250 ± 
2006 d.p.m. with lOOnM ET-1; n=3).
3.9. Regulation of ET-1- and PMA-stimulated PLD activity by 
PKC and Ca2+ influx.
The ability of long-term PMA treatment to abolish the generation of 
choline in response to ET-1 and PMA suggested a role for PKC in regulating 
PLD activity. This was further investigated by examining the effect of the PKC 
inhibitor Ro-31-8220, a staurosporine analog (Davis et al.y 1989), on the 
stimulated generation of pH] PtdBut. Pretreatment of pH] palmitic acid- 
labelled Rat-1 cells with increasing concentrations of Ro-31-8220 for lOmin 
resulted in the dose-dependent inhibition of PtdBut accumulation in response to 
both PMA and ET-1 (Fig. 3.22) thus confirming the choline results from the 
PKC-down-regulated cells. At lOpM, a concentration at which it is considered 
a specific PKC inhibitor (Davis et al., 1989), Ro-31-8220 inhibited the PMA 
response by about 80% (results from a typical experiment: 3229 ± 1097 d.p.m. 
in control; 16825 ± 3871 d.p.m. with 300nM PMA; 5629 ± 639 d.p.m. with 
300nM PMA in cells pretreated with 10|iM Ro-31-8220; 15min stimulation, 
n=3). In contrast, at the same concentration, Ro-31-8220 only inhibited the ET- 
1 response by approximately 40% (results from a typical experiment: 1309 ± 69 
d.p.m. in control; 8870 ± 2917 d.p.m. with ET-1; 5899 ±710 d.p.m. with ET-
76
1 in cells pretreated with IOjiM Ro-31-8220; lOmin stimulation, n=4). The ET- 
1 response could be further inhibited by higher concentrations of Ro-31-8220 
but at these concentrations the effect of the inhibitor becomes non-specific 
(Davis et al., 1989).
Since Ca2+ influx has also been reported to have a role to play in the 
activation of PLD in some systems (section 1.5.2) the effect of lowering the 
external [Ca2+] on ET-1-stimulated PtdCho hydrolysis was investigated. Cells 
were preincubated for 15min prior to stimulation in a low [Ca2+] buffer with 
added EGTA (0.33mM) to reduce the free [Ca2+] to lpM and then stimulated 
under the same conditions. This treatment inhibited both ET-1-induced 
formation of choline in [^H] choline-labelled cells (53 ± 8% inhibition, n=4) and 
PtdBut in [^H] palmitic acid-labelled cells (57 ± 9% inhibition, n=4) but had no 
effect on the PMA-stimulated response (Table 3.2). ET-l-stimulated PtdBut 
formation was equally inhibited by low Ca2+ conditions and Ro-31-8220 
(IO jiM ) pretreatment and the two treatments combined produced the same degree 
of inhibition as each on its own suggesting a similar site of action (57 ±9% 
inhibition in low [Ca2+], 49 ± 14% inhibition by Ro-31-8220, 61 ± 14% 
inhibition by Ro-31-8220 in low [Ca2+]; n=3-4). Basal values of choline 
generation and PtdBut accumulation were unaffected by reducing the [Ca2+]. 
Low Ca2+ conditions did not inhibit ET-l-stimulated InsP accumulation; the 
basal accumulation of [3H] InsP was decreased but the ET-l-stimulated 
response was increased by 3-4 fold when the external [Ca2+] was reduced to 
lpM .(Table 3.2)
Since these results suggested a role for Ca2+ influx in activating PLD, the 
ability of the Ca2+ ionophore A23187 to stimulate PtdCho hydrolysis was 
examined (Table 3.2). A23187 (5jiM) stimulated the formation of PtdBut 
although the response was smaller than that obtained with ET-1 (4.2 ± 0.8 fold 
increase over controls, n=4). The response to the ionophore could be totally 
inhibited by reducing the external [Ca2+] to lpM but was only inhibited to a
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small extent (24 ± 12%, n=3) by pretreatment with IOjiM Ro-31-8220.
[3H] PtdBut accumulation in response to ET-1, PMA and A23187 in 
combination with each other was also investigated (Table 3.3). PMA and 
A23187 together produced an additive response of similar magnitude to that 
obtained with ET-1. A23187 had no effect on the ET-l-stimulated PtdBut 
formation but PMA was synergistic and increased the ET-1 response by about 2- 
fold (2.0 ± 0.3 fold, n=3). The response to PMA and ET-1 in combination was 
greater than to PMA and A23187 in combination. The response to PMA and 
ET-1 in combination was not further increased by including A23187.
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Fig. 3.1 Mitogen-stimulated [3H]thymidine incorporation in Rat-1 
cells .
Rat-1 cells were grown to quiescence in DMEM +0.5% serum for 48h and 
then incubated in serum-free medium with the indicated agonist and l|iCi/ml 
[3H]thymidine for a further 24h. Concentrations of agonists used were as 
follows : 10% serum, lOOnM ET-1, lOOnM ET-2, 300nM ET-3, lOOnM 
bombesin, IOOjiM LPA. The incorporation of [3H]thymidine was measured as 
described in section 2.5. Results are expressed as means ± S.D. from a typical 
experiment where n=4. Basal value = 1604 ± 339 d.p.m. p < 0.05.
Fig. 3.2 Dose-dependence of ET-l-stimulated [3H]thymidine 
incorporation.
Rat-1 cells were grown to quiescence by incubating in the presence of 
0.5% serum for 48h. The cells were stimulated with increasing concentrations 
of ET-1 in serum-free medium containing 1 pCi/ml [3H]thymidine for 24h and 
the radioactivity incorporated was then measured as described in section 2.5. 
Results are expressed as means ± S.D. from a typical experiment where n=3. 
Basal value = 1418 ± 178 d.p.m.
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Fig. 3.3 Mitogen-stimulated [3H] thymidine incorporation in 
PMA- and pertussis toxin-treated cells.
Rat-1 cells were grown to quiescence in medium containing 0.5% serum 
for 48h. For the final (a) 48h (400nM PMA or vehicle) or (b) 16h (lOOng/ml 
pertussis toxin) the cells were pretreated with the stated agent. Stimulation was 
then carried out with the indicated agonist (10% serum, lOOnM ET-1) in serum- 
free medium containing l|iCi/ml [^H] thymidine for 24h. The incorporated 
radioactivity was measured as outlined in section 2.5. Results are expressed as 
means ± S.D. from a typical experiment where n=3-6. Basal values (d.p.m.) =
(a) -PMA, 2190 ± 738; +PMA, 1791 ± 453, (b) -PTox, 1660 ± 109; +PTox, 
16281112. ¥ ,p < 0 .0 5 .
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Fig. 3.4 Time course of ET-l-stimulated Ins(l,4,5)P3 mass 
generation.
Rat-1 cells were grown to confluency and harvested as described in
section 2.7.1. Stimulation was carried out with lOOnM ET-1 for the stated times 
and Ins(l,4,5)P3 levels were measured by the mass assay of Palmer et aL, 1989
(section 2.7.2). The results are expressed as means ± S.D. from a typical 
experiment where n=6. O, control cells; # ,  ET-l-stimulated cells.
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Fig. 3.5 Time course of ET-l-stimulated [3H] inositol phosphates 
accumulation.
pH] Inositol-labelled Rat-1 cells (l|iCi/ml for 48h) were stimulated with 
lOOnM ET-1 for the stated times in the presence of lOmM LiCl. The 
radioactivity associated with total [3H] inositol phosphates was determined as 
described in section 2.6.2. The results are expressed as means ± S.D. from a 
typical experiment where n=3. O, control cells; # ,  ET-l-stimulated cells.
Fig. 3.6 Dose-dependence of ET-l-stimulated [3H] inositol 
phosphates accumulation.
pH] Inositol-labelled Rat-1 cells (ljiCi/ml for 48h) were stimulated with 
increasing concentrations of ET-1 for 20min in the presence of lOmM LiCl and 
the radioactivity associated with pH] inositol phosphates was measured as 
described in section 2.6.2. The results are expressed as means ± S.D. from a 
typical experiment where n=5. Basal value = 5464 ±157 d.p.m.
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Fig. 3.7 Time course of ET-2- and ET-3-stimuIated [3H] inositol 
phosphates accumulation.
pH] Inositol-labelled Rat-1 cells (1 pCi/ml for 48h) were stimulated with
(a) lOOnM ET-2 or (b) 300nM ET-3 for the stated times in the presence of 
lOmM LiCl. The radioactivity associated with total pH] inositol phosphates 
was measured as described in section 2.6.2. The results are expressed as means 
± S.D from a typical experiment where n=2. O, control cells; •  (a) ET-2 - or
(b) ET-3-stimulated cells.
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Fig. 3.8 Dose-dependence of ET-2-, ET-3- and SS6-stimuIated 
[3H] inositol phosphates accumulation.
[^H] Inositol-labelled Rat-1 cells (l|iCi/ml for 48h) were stimulated with 
increasing concentrations of (a) ET-2, (b) ET-3 and (c) SS6 for 20min in the 
presence of lOmM LiCl and the radioactivity associated with total pH] inositol 
phosphates determined as outlined in section 2.6.2. The results are expressed as 
means ± S.D. from typical experiments where n=3. Basal values (d.p.m.) = (a) 
4272 ± 76, (b) 3709 ± 437, (c) 2173 ± 585.
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Fig. 3.9 Time course of ET-l-stimulated changes in intracellular 
and total [3H] choline.
Rat-1 cells were labelled with 5jiCi/ml [^H] choline for 48h and then 
stimulated with lOOnM ET-1 for the indicated times. The choline-containing 
fractions were separated as described in section 2.9.2 and the radioactivity 
associated with (a), (b) total or (c) intracellular [3H] choline was determined. 
The results are expressed as means ± S.D. from typical experiments where n=3- 
5. O, control cells; # ,  ET-l-stimulated cells.
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Fig. 3.10 Dose-dependence of ET-l-stimulated [3H] choline 
generation.
Rat-1 cells prelabelled for 48h with 5|iCi/ml pH] choline were stimulated 
with increasing concentrations of ET-1 for lOmin and the radioactivity 
associated with total pH] choline determined as described in section 2.9.2. The 
results are expressed as means ± S.D. from a typical experiment where n=8. 
Basal value = 530 ± 95 d.p.m.
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Fig. 3.11 Time course of ET-2- and ET-3-stimulated changes in 
total [3H] choline.
[^H] Choline-labelled Rat-1 cells (5jiCi/ml for 48h) were stimulated with
(a) lOOnM ET-2 or (b) 300nM ET-3 for the stated times and the radioactivity 
associated with total [3H] choline measured as described in section 2.9.2. The 
results are expressed as means ± S.D. O, control cells; # ,  (a) ET-2-, (b) ET-3- 
stimulated cells.
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Fig. 3.12 Dose-dependence of ET-2-, ET-3- and SS6-stimuIated 
[3H] choline generation.
[^H] Choline-labelled Rat-1 cells (5|iCi/ml for 48h) were stimulated with 
increasing concentrations of (a) ET-2, (b) ET-3 and (c) SS6 for lOmin and the 
radioactivity associated with total [3H] choline determined as described in 
section 2.9.2. The results are expressed as means ± S.D. from a typical 
experiment where n=4. Basal values (d.p.m.) = (a), 369 ± 85, (b), 397 ± 35, 
(c) 16461138.
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Fig. 3.13 Time course of ET-l-stimulated decrease in [3H] 
choline phosphate formation.
Rat-1 cells were labelled for 48h with 5|iCi/ml pH] choline and then 
stimulated with lOOnM ET-1 for the stated times. Choline containing fractions 
were separated as described in section 2.9.2 and the radioactivity associated 
with pH] choline phosphate determined. Results are expressed as means ± 
S.D. from a typical experiment where n=5. O, control cells; # ,  ET-l- 
stimulated cells.
Fig. 3.14 Time course of ET-l-stimulated increase in pH ]
PtdCho synthesis.
Rat-1 cells were grown to confluency and quiescence and then 
preincubated with 28|iM choline chloride and 5jiCi/ml of pH] choline for 
30min. Stimulation was carried out with lOOnM ET-1 for the stated times and 
the samples were extracted as described in section 2.9.1. The lipid phases were 
dried down, redissolved in chloroform/methanol (19:1, v/v) and separated by 
t.l.c. as described in section 2.9.3. Results are expressed as means ± S.D. from 
a typical experiment where n=3. O, control cells; • ,  ET-l-stimulated cells.
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Fig. 3.15 Time course of PMA-stimuIated [3H] choline 
generation.
pH] Choline-labelled Rat-1 cells (5pCi/ml for 48h) were stimulated with 
300nM PMA for the indicated times. The choline-containing fractions were 
separated as described in section 2.9.2 and radioactivity associated with total 
[3H] choline determined. The results are expressed as means ± S.D. from a 
typical experiment where n=3. O, control cells stimulated with vehicle; # , 
PMA-stimulated cells.
Fig. 3.16 Dose-dependence of PMA-stimulated pH] choline 
generation.
pH] Choline-labelled Rat-1 cells (5pCi/ml for48h) were stimulated with 
increasing concentrations of PMA for lOmin and the radioactivity associated 
with total pH] choline was measured as outlined in section 2.9.2. Results are 
expressed as means ± S.D. from a typical experiment where n=3. Basal value = 
925 ± 100 d.p.m.
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Table 3.1 ET-l-stimulated [3H] choline generation and [3H] 
inositol phosphates accumulation in control and PKC-down- 
regulated cells.
Rat-1 cells were labelled with [^H] choline (5jiCi/ml) or [^H] inositol 
(lpCi/ml) for 48h in the presence of PMA (400nM) or the inactive p-phorbol 
(400nM). Stimulation was carried out with lOOnM ET-1 or 300nM PMA and 
the radioactivity associated with total [3H] choline or pH] inositol phosphates 
was measured as described in sections 2.9.2 and 2.6.2 respectively.. Results 
are expressed as means ± S.D. from a typical experiment where n=3.
+PMA_______________+P-phorbol
PHI Choline generation fd.p.m.l 
488±133 521±58
433±19 1667+158
477167 12421154
PHI Inositol phosphates accumulation (d.p.m.l 
20min Control 1135214035 1571612033
20min ET-1 3781215679 4915115687
lOmin Control 
lOmin ET-1 
lOmin PMA
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Fig. 3.17 Time- and dose-dependence of [^H] PDBu binding.
Rat-1 cells were grown to confluency and quiescence and then incubated 
with (a) lOOnM [^H] PDBu ± 25jiM unlabelled PDBu for the indicated times or
(b) increasing concentrations of [^H] PDBu ± 25jiM unlabelled PDBu for 
20min. The amount of specific [3H] PDBu binding was determined as 
described in section 2.11. Results are expressed as means ± S.D. from a typical 
experiment where n=3.
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Fig. 3.18 Binding of [3H] PDBu in PKC-down-reguIated cells.
Rat-1 cells were treated for 48h with 400nM PMA, 400nM p-phorbol, 
DMSO/EtOH solvent control or medium control. Cells were then incubated with 
lOOnM pH] PDBu ± 25|iM unlabelled PDBu for 20min and the amount of 
specific pH] PDBu binding measured as described in section 2.11. Results are 
expressed as means ± S.D. from a typical experiment where n=3.
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Fig. 3.19 Time course of ET-l-stimulated [3H] PtdBut formation.
[^H] Palmitic acid-labelled cells (4jiCi/ml for 48h) were stimulated with 
(a) lOOnM or (b) InM ET-1 in the presence of 0.3% (v/v) butanol for the 
indicated times and the formation of [3H] PtdBut was determined as described in 
section 2.10. Results are expressed as means ± S.D. from typical experiments 
where n=3. O, control cells; # ,  ET-l-stimulated cells.
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Fig. 3.20 Dose-dependence of ET-l-stimulated [3H] PtdBut 
formation.
[^H] Palmitic acid-labelled Rat-1 cells (4|iCi/ml for 48h) were stimulated 
with increasing concentrations of ET-1 in the presence of 0.3% (v/v) butanol for 
lOmin and the formation of [3H] PtdBut was measured as described in section 
2.10. Results are expressed as means ± S.D. from a typical experiment where 
n=3. Basal value = 1572 ± 284 d.p.m.
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Fig. 3.21 Time course of PMA-stimuIated [3H] PtdBut formation.
[^H] Palmitic acid-labelled Rat-1 cells (4|iCi/ml for 48h) were stimulated 
with 300nM PMA in the presence of 0.3% (v/v) butanol for the indicated times 
and [3H] PtdBut formation was determined as described in section 2.10.
Results are expressed as means ± S.D. from a typical experiment where n=3.
O, control cells; # , PMA-stimulated cells.
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Fig. 3.22 Effect of Ro-31-8220 on ET-1- and PMA-stimutated 
PLD activity.
[^H] Palmitic acid-labelled Rat-1 cells (4|iCi/ml for 48h) were 
preincubated with increasing concentrations of Ro-31-8220 for lOmin and then 
stimulated with (a) lOOnM ET-1 for lOmin or (b) 300nM PMA for 15min. pH] 
PtdBut formation was determined as described in section 2.10. Results are 
expressed as means ± S.D. from typical experiments where n=3-4. control 
values (d.p.m.) = (a) basal, 2001 ± 257; ET- stimulated, 7076 ± 2046, (b), 
basal, 3229 ± 1097; PMA-stimulated, 16825 ± 3871.
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Table 3.2. Role of extracellular Ca2+ in agonist-stimulated 
PtdCho and PtdIns(4,5)P2 hydrolysis.
Rat-1 cells prelabelled for 48h with 4jiCi/ml [3H] palmitic acid were 
preincubated for 15min under normal [Ca2+] conditions (1.26mM) or with 
0.33mM added EGTA to reduce extracellular [Ca2+] to lp.M. Stimulation was 
carried out with lOOnM ET-1, 300nM PMA and 5|iM A23187 for lOmin (total 
[3H] choline and [3H] PtdBut formation) or 20min ([3H] InsP accumulation). 
Where used, Ro-31-8220 was added at 10}iM lOmin prior to stimulation. [3H] 
Choline generation and [3H] PtdBut and [3H] InsP accumulation were measured 
as described in sections 2.6.2, 2.9.2 and 2.10. Results are expressed as means 
± S.D. from typical experiments where n=3.
Control +EGTA
PHI Choline Id.p.m.')
Control 805±265 5761135
ET-1 2651±287 1187157
T3H1 PtdBut (d.p.m.)
Control 2445±524 23251674
ET-1 26437+4652 1322713641
ET-l+Ro-31-8220 12243±1640 104671647
PMA 15413±3181 1642012688
A23187 122091961 28131269
A23187+Ro-31-8220 86931569 39911426
PHI InsP Id.p.m.)
Control 31741321 5411125
ET-1 1321512495 76231776
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Table 3.3. Effect of A23187 and PMA on ET-l-stimulated [3H] 
PtdBut formation.
Rat-1 cells were labelled for 48h with 4jiCi/ml pH] palmitic acid and then 
stimulated with ET-1 (lOOnM), A23187 (5pM) and PMA (300nM) alone and in 
combination with each other in the presence of 0.3% (v/v) butanol for lOmin. 
pH] PtdBut formation was measured as outlined in section 2.9.2. Results are 
expressed as means ± S.D. from a typical experiment where n=3.
d.p.m. in PHI PtdBut
Control 3554 ±386
ET-1 30948 ± 1677
A23187 17360 ±999
PMA 15891± 1652
A23187 + PMA 37212 ±1652
ET-1 + A23187 32752 ±4167
ET-1 + PMA 54897 ± 3979
ET-1 + A23187 + PMA 57724 ±14311
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3.10 Discussion
Since the discovery of ET-1 (Yanagisawa et al., 1988a) many
investigators have sought to determine the second messenger-generating
pathways which may mediate its mechanism of action. So far most attention has 
focused on the hydrolysis of PtdIns(4,5)P2 as a means of generating
intracellular signals. However, there is accumulating evidence from other 
systems for agonist-induced PtdCho hydrolysis and many hormones and growth 
factors have now been shown to stimulate PtdCho hydrolysis in addition to 
Ptdlns(4,5)p2 breakdown (section 1.5). PtdCho hydrolysis was of interest
when investigating the signalling pathways with which the ET-1 receptor 
interacts as it could potentially generate another source of DAG or alternatively 
yield phosphatidic acid (PtdOH) which has also been implicated as an important 
signalling mediator (section 1.3.4 and section 6.1).
ET-1 has been shown to stimulate proliferation of a number of cultured 
cell lines (Komuro et al., 1988; Simonson et al., 1989; Nakaki et al., 1989; 
Brown and Littlewood, 1989; Takuwa et al., 1989; MacCumber et al., 1990; 
Shichiri et al., 1991; Yada etal., 1991) and in this study the three ET peptides 
were shown to be mitogens for Rat-1 cells (Fig. 3.1). ET-1 dose-dependently 
increased the incorporation of [^H] thymidine to a maximum of 2-fold above 
control in the absence of any other growth factors indicating that it is a complete 
mitogen. While this work was in progress Muldoon et al. (1990) also reported 
that ET-1 stimulated DNA synthesis in Rat-1 cells thus supporting the results 
presented here. Further characterization of ET-induced [3H] thymidine 
incorporation showed that in some experiments the response was sensitive to 
chronic (400nM, 48h) PMA-pretreatment (Fig. 3.3a). Since such exposure to 
PMA has been reported to down-regulate PKC activity (Rodriguez-Pena and 
Rozengurt, 1984) these results suggested an important role for PKC in the 
proliferative response to ET-1. [3H] PDBu binding studies demonstrated a large 
decrease in binding in cells pretreated with PMA (Fig. 3.18); however, binding
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was never totally inhibited suggesting residual PKC activity. This may reflect 
the presence of different isozymes of PKC with different sensitivities to PMA- 
induced down-regulation as has been suggested previously (Adams and Gullick, 
1989). This may explain why PMA pretreatment did not always inhibit ET-l- 
stimulated pH] thymidine incorporation. Similar PMA treatment has been 
shown to inhibit ET-1-induced DNA synthesis and anchorage-independent 
growth also in Rat-1 cells (Muldoon et al., 1990) while long-term PDBu 
pretreatment inhibited pH] thymidine incorporation in response to ET-1 in 
Swiss 3T3 fibroblasts (Takuwa etal., 1989). ET-l-induced pH] thymidine 
incorporation was pertussis toxin-insensitive suggesting the involvement of 
pertussis toxin-insenstive signalling pathways, i.e. signalling pathways not 
involving interaction with Gi -like G proteins. A number of novel G proteins 
have now been identified which include pertussis toxin-insensitive proteins (see 
section 1.4.1)
Since ET-1 was shown to be mitogenic for Rat-1 cells this was therefore a 
relevant model system in which to investigate further the signal transduction 
pathways stimulated by this peptide which might be important in its mechanism 
of action. A previous report demonstrated PtdIns(4,5)P2 hydrolysis stimulated
by ET-1 in Rat-1 cells (Muldoon et al., 1989) and results presented here confirm
this (Fig. 3.4). However, previous studies have employed pH] inositol- 
labelled cells and have generally measured InsP3 generation in the presence of
LiCl, often with no attempt to separate the different isomers. In this work the 
first mass measurements of Ins(l,4,5)P3 generation in response to ET-1
stimulation in any system are presented. The magnitude of the response 
observed was much greater than that reported previously (Muldoon et al., 1989) 
being approximately 10-fold above controls at 5-10sec, probably due to the 
greater sensitivity of the Ins( 1,4,5)P3 assay. The Ins( 1,4,5)P3 response was
very rapid peaking at 5-10sec and then returned towards basal levels after 30sec. 
It was however still elevated above control levels at 15min. This contrasts with
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studies using bombesin-stimulated Swiss 3T3 cells in which the Ins(l,4,5)P3
signal was completely desensitized by 30sec (Cook et al., 1990) or bradykinin-
stimulated NIH 3T3 fibroblasts and NG108-15 cells (Fu etal., 1988), possibly
reflecting differences in the mechanism of action of the peptides. However, a 
similar biphasic Ins(l,4,5)p3 response involving a transient peak and then a
sustained phase was observed with the nonpeptide, muscarinic receptor agonist 
carbachol in human neuroblastoma cells (Lambert et al., 1991). The sustained 
phase of the ET-1 response, which suggests sustained PtdIns(4,5)P2 hydrolysis
(see chapter 4, Fig. 4.4), obviously has important implications for both the
intracellular free Ca2+ concentration and DAG levels which may in turn be
important in the mitogenic activity of ET-1 in Rat-1 cells. When [^H] inositol-
labelled cells were utilized, ET-1 stimulated a biphasic increase in [3H] InsP in
the presence of lOmM LiCl consisting of an initial rapid phase followed by a
slower linear increase up to 30-40min (Fig. 3.5). The plateau observed after
40min may reflect desensitization of the response or, alternatively, a situation
were [3H] label has become limiting. This assay was used to examine the dose- 
dependency of ET-l-stimulated PtdIns(4,5)P2 hydrolysis; ET-1 stimulated InsP
accumulation with a maximum response at lOnM and an EC50 value of about
2nM (Fig. 3.6). This value is similar to that obtained for ET-l-stimulated [^H] 
thymidine incorporation (Fig. 3.2, ~2nM) and also to the EC50 values reported
in the literature for ET-l-stimulated InsP generation, DAG formation, 
arachidonic acid release and intracellular Ca2+ increases in vascular smooth 
muscle cells (Marsden et al., 1989; Van Renterghem et al., 1988; Resink et al., 
1990; Griendling et al., 1989; Araki et al., 1989) and the for ET-1 binding to
Swiss 3T3 fibroblasts (Fabregat and Rozengurt, 1990).
In common with many other mitogenic peptides ET-1 stimulated PtdCho 
hydrolysis in addition to PtdIns(4,5)P2 breakdown (Fig. 3.9). The response
was rapid with an increase in [%] choline as early as lOsec after stimulation and 
dose-dependent (Fig. 3.10) with an EC5Q value comparable with that obtained
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for InsP accumulation (2.0 ± l.OnM for InsP accumulation; 0.8 ± 0.4nM for 
choline generation). There was no change in [^H] choline phosphate levels until 
approximately 30-40min after stimulation with ET-1 when about a 30% decrease 
below controls was observed (Fig. 3.13). This may be the result of 
incorporation into lipid due to the activation of the PtdCho synthetic pathway 
since increased PtdCho synthesis was detected as early as 5min after agonist 
stimulation (Fig. 3.14). In fact, there may be generation of choline phosphate at 
these earlier time points due to choline kinase or PtdCho-specific phospholipase 
C activity but this may not be detected due to rapid reincorporation into the 
parent lipid. Price et al. (1989) have reported stimulated PtdCho synthesis in 
Swiss 3T3 cells in response to a number of growth factors but their observations 
were made only after a 30min stimulation.
The other ET peptides were also effective at stimulating both InsP
accumulation and choline generation to a similar extent as ET-1 (Fig. 3.7 and
3.11) and a comparison of their dose-dependencies with ET-1 and the related
peptide toxin, SS6, yielded the same rank order of potency i.e. ET-1 = ET-2 = 
SS6 > ET-3 for both responses, with each peptide having a similar EC5q value
for both responses (~l-2nM for ET-1, ET-2 and SS6; ~50nM for ET-3). These 
results therefore suggest that the two second messenger-generating pathways are 
controlled by activation of the same receptor subtype.
PtdCho hydrolysis in response to ET-1 has been reported for vascular 
smooth muscle cells (Resink et al, 1989; 1990) but the authors did not 
investigate the nature of the water-soluble choline products. Another study in 
C6 glioma cells (Zhang eta l, 1991) demonstrated choline and choline 
phosphate generation in response to ET-1 stimulation but did not address the 
mechanism of PtdCho hydrolysis i.e. whether it was catalysed by a PLC or a 
PLD activity. In the work presented here the hydrolysis of PtdCho was 
observed as an early lOsec increase in [3H] choline with no significant change in 
[^H] choline phosphate up to 30min. These results suggested that ET-1-
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stimulated breakdown of PtdCho in Rat-1 cells occurred via a PLD-catalysed 
mechanism. This was confirmed by the ability of ET-1 to stimulate the 
formation of j^H] PtdBut in the presence of 0.3% butanol, as 
phosphatidyltransferase activity is an unequivocal marker for PLDoctivity (Pai et 
al., 1988b). The kinetics of PtdBut formation in response to ET-1 were similar 
to choline generation with significantly elevated levels after lOsec which 
increased up to about 5min (Fig. 3.19). The response was dose-dependent 
(Fig. 3.20) with an EC50 value of ~2-3nM which is similar to that for both InsP
and choline generation. Recently, ET-1 has also been shown to activate PLD in
Rat-6 cells measured as the formation of phosphatidylethanol (Pai et al., 1991b).
PtdCho hydrolysis is frequently proposed as an alternative source of DAG 
to maintain DAG levels once PtdIns(4,5)P2 hydrolysis has been desensitized.
Indeed, Griendling et al. (1989) observed a biphasic accumulation of DAG in
response to ET-1 in rat aortic vascular smooth muscle cells which was sustained 
for at least 20min while InsP3 generation in the same cells was transient and had
returned to basal levels by 5min (Sugiura et al., 1989b). Similarly, in C6 
glioma cells the ET-l-stimulated increase in DAG was sustained for at least 
15min while Ins(l,4,5)P3 formation had returned to resting levels at 3min
(Zhang et al., 1991). Although transient InsP3 generation does not necessarily 
imply transient PtdIns(4,5)P2 hydrolysis, these reports might suggest other 
sources of DAG. DAG accumulation in Rat-1 cells is also a sustained process 
and levels were still elevated 2-fold above controls even after 24h (Muldoon et 
al., 1990). However, the results presented here suggest that PtdCho hydrolysis 
could only contribute an early transient role to this DAG accumulation since the 
PLD response levels off after approximately 5min stimulation with ET-1. In 
addition, intracellular choline levels were only maintained for 10-15 min and 
then began to decrease. Similar transient activation of PLD has also been 
observed in bombesin-stimulated Swiss 3T3 fibroblasts (Cook et al., 1991c; C. 
Briscoe, personal communication), vasopressin-stimulated A10 smooth muscle
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cells (Plevin and Wakelam,1992) and carbachol-stimulated 1321N1 cells 
(Martinson et al., 1990). The possibility exists that the phosphatidic acid which 
is the initial product of PLD-catalysed PtdCho hydrolysis is only slowly 
converted to DAG as was suggested for carbachol-stimulated 132INI cells 
(Martinson et al., 1990). However, PtdIns(4,5)P2 is more likely to contribute
significantly to prolonged DAG formation in Rat-1 cells due to the sustained 
nature of Ins(l,4,5)P3 generation and the prolonged accumulation of InsP. This
therefore raises the possibility that PtdOH itself functions as a second messenger
(this is discussed further in chapter 6).
PtdCho hydrolysis in Rat-1 cells could also be stimulated by the PKC-
activating phorbol ester PMA (Fig. 3.15 and 3.21) suggesting that activation of
PKC in these cells can lead to breakdown of PtdCho. This is supported by the
inability of the inactive B-phorbol to elicit a response. In order to investigate
further the role of PKC in stimulating PLD activity, cells were treated with
400nM PMA for 48h prior to stimulation since this treatment has been reported
to down-regulate PKC (Rodriguez-Pena and Rozengurt, 1984). The PMA- and
ET-l-stimulated generation of choline was abolished in the down-regulated cells
but not in cells which had been treated with the inactive control, S-phorbol
(Table 3.1). These results imply that stimulation of PLD activity may be 
secondary to the activation of PKC, for example as a result of PtdIns(4,5)P2
hydrolysis. This is supported by comparing the kinetics of Ins(l,4,5)P3 and
choline generation as the former appears to precede the later. The loss in PKC 
activity was confirmed by [3H] PDBu binding; specific binding of [^H] PDBu 
was decreased in PMA-treated cells but remained the same as controls in B- 
phorbol-treated cells. Long term PMA pretreatment did not affect the ability of 
ET-1 to stimulate inositol phosphates accumulation suggesting that it had not 
affected events upstream from PKC such as receptor function or coupling to the 
inositol phosphate pathway. This contrasts with the effect of phorbol ester 
treatment in human vascular smooth muscle cells where pretreatment of the cells
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for 24h with PMA resulted in decreased ET-1 binding and inhibited both the 
inositol phosphates and DAG responses to ET-1 (Resink et al., 1990b) or in rat 
vascular smooth muscle cells where preexposure for 18h with PDBu resulted in 
a decrease of ET-1 binding sites (Roubert et al., 1989). It is noteworthy that in 
the Rat-1 cells the magnitude of the choline and PtdBut responses stimulated by 
PMA were usually smaller than that obtained with ET-1. Also, although PMA 
pretreatment totally abolished the ET-l-stimulated choline response, not all the 
PKC activity as defined by [3H] PDBu binding was down regulated, though it 
may be that the residual activity is incapable of stimulating PLD. Billah and 
Anthes (1990) have suggested that PMA may directly interact with PLD in the 
same way as it does with PKC and therefore it may be possible that the 
inhibition of ET-l-stimulated choline generation is due to PMA-induced down- 
regulation of PLD aswell as PKC. In lymphocytes there is evidence for protein 
kinase C-independent activation of PLD by phorbol esters (Cao et al., 1990) 
while in HL-60 granulocytes the PKC inhibitor K252a inhibited PMA-induced 
protein phosphorylation but caused only partial inhibition of PLD activation 
(Billah et al., 1989a) suggesting that PKC does not solely mediate the action of 
PMA. Therefore, these results may suggest two possible mechanisms of ET-l- 
stimulated PLD activation, a PKC-dependent and -independent pathway. This is 
supported by studies investigating the ability of the PKC inhibitor, Ro-31-8220, 
to inhibit PMA- and ET-l-stimulated PtdBut formation. Used at a concentration 
(10|iM) at which it is considered a selective PKC inhibitor, Ro-31-8220 
inhibited PMA-stimulated PLD activity by about 80% which is consistent with a 
predominantly PKC-mediated activation of PLD by PMA. In contrast, at the 
same concentration, ET-l-stimulated PLD activity was only inhibited by 
approximately 40%. Although the involvement of distinct isoforms of PKC 
with different sensitivities to PMA induced down-regulation and inhibition by 
Ro-31-8220 is possible, these results suggest an additional PKC-independent 
pathway of PLD activation. Similar results have also been reported for
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bombesin-stimulated Swiss 3T3 fibroblasts (Cook etal., 1991). Likewise, the 
PKC inhibitors sphingosine (20}iM) and H7 (IOOjiM) had no effect on 
epinephrine-stimulated choline phosphate generation in MDCK-D1 cells (Slivka 
etal., 1988).
In some systems Ca2+ has also been proposed to have a role in regulating 
PLD activity. When ET-l-stimulated choline and PtdBut formation was 
examined under conditions where the extracellular [Ca2+] was buffered at I jiM  
both responses were inhibited by 40-50% (Table 3.2). Reducing the [Ca2+] 
further (lOOnM) did not produce any further inhibition. In contrast PMA- 
stimulated PLD activity was unaffected which is consistent with its 
predominantly PKC-mediated mechanism of action. Consistent with the ability 
of Ca2+ influx to activate PLD, the Ca2+ ionophore A23187 stimulated PtdBut 
formation by a mechanism that was totally dependent on the extracellular [Ca2+]. 
The effect of the PKC inhibitor Ro-31-8220 was also investigated under normal 
and low Ca2+ conditions. Ro-31-8220 inhibited ET-l-stimulated PLD activity 
to a similar extent as EGTA treatment but both treatments combined did not 
produce any further inhibition. This suggests a similar site of action and may 
indicate that Ca2+ is required as a cofactor for PKC activation in addition to 
acting as a primary activator of PLD. The importance of Ca2+ as a cofactor for 
PKC activity is also suggested by the increased InsP response to ET-1 under 
low [Ca2+] conditions, possibly due to the removal of negative feedback 
inhibition mediated by PKC. Ro-31-8220 inhibited the A23187-stimulated 
response by approximately 25% supporting the possibility that the role of Ca2+ 
influx is partly to act as a cofactor for PKC activation but also demonstrating that 
it can stimulate PLD activity in a PKC-independent manner. Similar results have 
also been reported for bombesin-stimulated Swiss 3T3 cells (Cook et al., 1991) 
although in that case EGTA and Ro-31-8220 together produced a greater 
inhibition than either alone but it was still less than additive.
The regulation of PLD activity by ET-1 stimulation was further
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investigated by additivity experiments with A23187 and PMA. A23187 and 
PMA together gave an additive or greater than additive response approximately 
of the same magnitude as that stimulated by ET-1 suggesting that Ca2+ influx 
and PKC activation can regulate PLD by different mechanisms in Rat-1 cells. 
A23187 in combination with ET-1 did not produce a greater response than ET-1 
alone suggesting that they share a similar pathway of PLD activation and 
therefore implying that the ET-stimulated response is partly mediated by influx 
of Ca2+. ET-1 and PMA together were synergistic and produced a greater 
response than PMA + A23187. Since experiments using cells where PKC 
activity had been down-regulated by PMA pretreatment or inhibited by Ro-31- 
8220 suggested that PLD activation by both agonists involved PKC, the 
synergism observed when both were used together may indicate that ET-1 and 
PMA activate different isoforms of PKC and possibly different isoforms of 
PLD. Also, it appears that ET-1 regulates PLD by another unidentified pathway 
as evidenced by the phosphatidyltransferase activity still measured in the 
presence of Ro-31-8220 in low Ca2+ conditions. In rat macrophages, colony 
stimulating factor-1 (a receptor tyrosine kinase agonist) activation of PtdCho- 
specific phospholipase C required tyrosine phosphorylation (Ghosh Choudhury 
et al., 1991). Similarly, in human neutrophils, PLD activity stimulated by fMet- 
Leu-Phe, platelet-activating factor and leukotriene B4 was inhibited by tyrosine 
kinase inhibitors which did not inhibit PLD per se (Uings et al., 1992). The 
fMet-Leu-Phe receptor does not have a tyrosine kinase activity; therefore, it is 
likely that a non-receptor tyrosine kinase(s) is responsible for the activation of 
PLD by fMet-Leu-Phe in the neutrophil. ET-1 has been shown to stimulate 
tyrosine phosphorylation of a number of proteins in rat mesangial cells (Force et 
al., 1991), Swiss 3T3 cells (Zachary etal., 1991) and Rat-1 cells (R. Plevin, 
personal communication) and it is therefore tempting to speculate that tyrosine 
phosphorylation may have a role to play in ET-l-stimulated PLD regulation.
In summary therefore, this chapter shows that ET-1 is a complete mitogen
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in Rat-1 cells and effective in stimulating both the PtdIns(4,5)P2 and PtdCho 
second messenger-generating pathways. Pharmacological characterization of 
both responses using ET-1 and the analogous peptides ET-2, ET-3 and SS6
suggested that both pathways are controlled by the same receptor. PtdCho 
hydrolysis appears to take place kinetically downstream from Ins(l,4,5)P3
generation by a PLD-catalysed mechanism that involves both PKC-dependent 
and independent pathways. This would generate PtOH which may itself be an 
important second messenger thus generating a greater diversity of potential 
mitogenic mediators.or, alternatively, it may be further metabolized to DAG by 
phosphatidate phosphohydrolase.
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Chapter 4
Regulation of ET-l-stimulated Ins(l,4,5)P3 form ation;
comparison with LPA
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4.1. In troduction .
It is now generally accepted that many receptors linked to the 
phospholipase C-catalysed hydrolysis of PtdIns(4,5)P2 do so by interaction with 
a G protein referred to as Gp (reviewed in Cockcroft, 1987; Fain et al., 1988; 
Boyer et al., 1989a; Litosch, 1990). Although as yet the system is not as well 
defined as agonist-stimulated adenylyl cyclase or rhodopsin activation, a number 
of approaches have been used to investigate the involvement of a G protein in 
coupling receptors to polyphosphoinositide hydrolysis.
Studies into the adenylyl cyclase system have shown that the interaction of 
a receptor with a G protein following stimulation with an appropriate agonist 
results in the dissociation of GDP and the subsequent binding of GTP to the G 
protein. A consequence of this is that the affinity of the receptor for the agonist 
is decreased (Casey and Gilman, 1988). The effects of guanine nucleotides on 
the binding of hormones and growth factors which stimulate PtdIns(4,5)P2 
breakdown have therefore been studied to investigate for the involvement of a G 
protein. Receptors exist as high and low affinity components and the efficacies 
of agonists acting through G protein-coupled receptors to stimulate 
polyphosphoinositide hydrolysis have been correlated with their capacity to form 
a GTP-sensitive high affinity binding state (Evans etal., 1985; Taylor and 
Merritt, 1986). Guanosine 5'-[pY-imido] triphosphate (Gpp[NH]p), a non- 
hydrolysable analogue of GTP, decreased the affinity of pH] vasopressin for its 
receptor on hepatic plasma membranes which was reflected by an increase in its 
rate of dissociation (Bojanic and Fain, 1986). In permeabilized human 
neuroblastoma cells the binding affinity of carbachol was significantly reduced 
by GppNHp (Wojcikiewicz et al., 1990). Guanine nucleotides have also been 
shown to decrease the binding of other hormones that stimulate PtdIns(4,5)P2 
breakdown (reviewed in Fain et al., 1988). In order to recycle back to an 
inactive state an intrinsic GTPase activity hydrolyses the bound GTP to GDP 
which promotes reassociation of the a-subunit with Py. Activation of GTPase
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activity has been observed in vasopressin-stimulated hepatic plasma membrane 
preparations and GTPase activity migrated with bound [3H] vasopressin when 
solubilized membranes were subjected to sucrose gradient centrifugation 
(Fitzgerald etal., 1986).
More direct evidence for G protein regulation of Ptdlns-PLC has come 
from reports of the ability of fluoride and stable analogues \ of GTP to stimulate 
polyphosphoinositide turnover. Activation by fluoride is caused by interaction 
of aluminium fluoride (AIF4-) with bound GDP so that it mimics the role of the 
y phosphate of GTP (Bigay et al., 1985). AIF4- and GTP[S] (guanosine 5'-[y- 
thio] triphosphate) stimulated InsP3 production in hepatocyte membranes in a 
manner that could be inhibited by GDP[S] (guanosine 5'-[p-thio] diphosphate) 
(Cockcroft and Taylor, 1987). Similarly, in plasma membrane preparations 
from human neutrophils GTP[S] stimulated the breakdown of 
polyphosphoinositides (Cockcroft and Gomperts, 1985) and in turkey 
erythrocyte membranes GTP[S]-induced inositol phosphates accumulation was 
accompanied by a corresponding decrease in polyphosphoinositides (Harden et 
al., 1988). Guanine nucleotides can potentiate hormone effects on Ptdlns-PLC 
activity. GTP[S] potentiated bombesin-stimulated InsP3 generation in 
permeabilized Swiss 3T3 cells while GDP[S] had an inhibitory effect (Cattaneo 
and Vincentini, 1989; Plevin et al., 1990). Similar effects were also reported for 
angiotensin II-stimulated membranes from rat mesangial cells (Pfeilschifter and 
Bauer, 1987) and carbachol- and histamine-stimulated rat brain cortical 
membranes (Claro et al., 1989). A requirement for guanine nucleotides for 
receptor coupling to Ptdlns-PLC is also supported by the observations that 
purinergic agonist-stimulated inositol phosphates accumulation in turkey 
erythrocyte membranes (Boyer et al., 1989b) and carbachol-stimulated inositol 
phosphates accumulation in membranes from astrocytoma cells (Orellana et al,
1987) occurred only in the presence of added guanine nucleotides.
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The rate-limiting step in the activation process is thought to be the 
dissociation of GDP from the G protein and agonist-receptor occupation is 
believed to accelerate GTP/GDP exchange thus enhancing the onset of 
PtdIns(4,5)P2 hydrolysis. In turkey erythrocyte membranes activation of 
polyphosphoinositide turnover by GTP[S] occurred with a considerable lag time 
which was decreased in a concentration-dependent manner by a P2y-purinergic 
agonist. Increasing concentrations of agonist also increased the rate constant in a 
saturable manner indicating that the rate of activation was increased by receptor 
stimulation (Boyer et al., 1989b). Plevin et al.. (1990) also reported similar 
effects with bombesin in Swiss 3T3 cells where a potentiating effect with 
GTP[S] on InsP3 generation was observed at early time points after stimulation 
when GTP[S] on its own had no effect.
The p2 -adrenergic receptor which couples to adenylyl cyclase can be 
uncoupled from G protein activation by phosphorylation of the receptor via the 
(3-adrenergic receptor kinase (pARK) (reviewed in Palczewski and Benovic, 
1991). Similarly, many receptors which couple to the inositol lipid signalling 
pathway via a G protein also seem to be regulated by phosphorylation and a 
feature of many agonists which stimulate polyphosphoinositide hydrolysis is the 
sensitivity of the response to inhibition by PKC-activating phorbol esters such as 
PMA. PMA pretreatment for 15min inhibited bombesin-stimulated inositol 
phosphates accumulation in Swiss 3T3 cells with no effect on bombesin 
binding. Supporting a role for PKC in mediating a negative-feedback pathway 
was the observation that in cells where PKC had been down-regulated, basal and 
bombesin-stimulated production of inositol phosphates were elevated (Brown et 
al., 1987). The third cytoplasmic loop of the bombesin receptor, which is the 
proposed site involved in the receptor/G protein interaction (Kobilka et al.,
1988), has serine residues which potentially could be phosphorylated by 
serine/threonine protein kinases (Battey et al., 1991), suggesting that receptor 
function may be regulated by protein kinases. Such inhibition of
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polyphosphoinositide turnover by short exposures to PMA seems to be a general 
feature of agonists whose receptors couple to Ptdlns-PLC by a G protein 
interaction, for example: carbachol-stimulated astrocytoma cell membranes, 
angiotensin II-stimulated mesangial cell membranes, f-Met-Leu-Phe-stimulated 
polymorphonuclear leukocytes and HL60 cells, vasopressin-stimulated Swiss 
3T3 cells, angiotensin II- and thrombin-stimulated vascular smooth muscle cells, 
bombesin-stimulated Swiss 3T3 cells (Orellana et al., 1987; Pfeilschifter and 
Bauer, 1987; Smith etal., 1987; Cockcroft and Stutchfield, 1989; Blakeley et 
al., 1989; Kawahara etal., 1988; Huang and Ives, 1989; Cook and Wakelam, 
1991a). In membranes from astrocytoma cells the addition of purified PKC 
mimicked the ability of PMA pretreatment to inhibit GTP[S]-stimulated L1SP3 
production (Orellana et al., 1987) while in membrane preparations from 
mesangial cells angiotensin H+GTP[S]-stimulated InsP3 generation was 
similarly inhibited with OAG or PMA pretreatment (Pfeilschifter and Bauer,
1987). In contrast PDGF, which mediates its effects via a receptor with intrinsic 
tyrosine kinase activity, stimulated polyphosphoinositide turnover in a manner 
which was insensitive to PMA inhibition (Kawahara et al., 1988; Blakeley et al., 
1989; Huang and Ives, 1989). PKC-mediated inhibition of agonist-stimulated 
polyphosphoinositide turnover is thought to be due to impaired coupling of the 
receptor to Ptdlns-PLC caused by PKC-mediated phosphorylation at several 
sites, possibly including the G protein itself. Both receptor-G protein coupling 
(Pfeilschifter and Bauer, 1987; Plevin et al., 1990) and G protein-Ptdlns-PLC 
coupling (Orellana et al., 1987; Smith et al., 1987) have been proposed as sites 
of inhibition as well as Ptdlns-PLC itself (Geny et al., 1989; Ryu et al., 1990).
Heterogeneity in the G proteins (Gp) coupling receptors to Ptdlns-PLC 
was suggested by the ability of pertussis toxin to inhibit the response in some 
systems but not in others (reviewed in Fain et al., 1988; Cockcroft, 1987). In 
HL60 cells f-Met-Leu-Phe-stimulated polyphosphoinositide breakdown was 
pertussis toxin-sensitive and in membranes from these cells the formyl peptide
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receptor was shown to functionally interact with both G& and Go (Gierschik et 
al., 1989). Similarly, the f-Met-Leu-Phe-stimulated response in 
polymorphonuclear leukocytes was also pertussis toxin-sensitive (Smith et al.,
1987). Prior treatment with pertussis toxin had little or no effect on inositol 
phosphates accumulation in response to vasopressin+GTP[S] in hepatocyte 
plasma membranes (Uhing et a l , 1986), PGF2a, bombesin and vasopressin in 
Swiss 3T3 cells (Taylor et al., 1988), bradykinin in NG108-15 cells (Fu etal.,
1988) or angiotensin II in rat liver epithelial cells (Hepler et al., 1990) therefore 
arguing against a major role for a pertussis toxin substrate in coupling any of 
these agonist receptors to Ptdlns-PLC. A number of pertussis toxin-insensitive 
G proteins have now been identified (section 1.4.1). Among these Gq and G n 
are widely expressed and highly homologous. In reconstitution experiments 
Gotq was shown to specifically activate PLC-pl (Martin et al., 1991; Taylor et 
al., 1991; Wu etal., 1992).
Increasing interest is being shown in the receptor-G protein-effector 
interactions for two important mitogens, ET-1 and lysophosphatidic acid (LPA). 
Both ET-1 and LPA have been reported to stimulate inositol phosphates 
accumulation which was dependent on the presence of GTP[S] in A10 
membranes and permeabilized Rat-1 cells respectively (Takuwa et al., 1990; van 
Corven etal., 1989) while in permeabilized rat mesangial cells ET-1-stimulated 
inositol phosphates accumulation was potentiated in the presence of GTP[S] 
(Thomas et al., 1991). Having established that ET-1 potently stimulated the 
hydrolysis of PtdIns(4,5)P2 in Rat-1 cells (see section 3.3) it was therefore of 
interest to characterize the nature of the receptor-G protein-Ptdlns-PLC 
interaction involved in this system using the criteria discussed above. Since 
LPA has already been reported to stimulate polyphosphoinositide hydrolysis in a 
GTP-dependent manner in these cells a more rigorous investigation of the nature 
of the G protein interaction using the same criteria could reveal important 
differences in the way these agonists function as mitogens. LPA has been
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suggested to exert its mitogenic effect in Rat-1 cells via the inhibition of adenylyl 
cyclase (van Corven et a l 1989) but ET-1 has no effect on adenylyl cyclase 
activity in these cells (F. McKenzie and E. Adie, personal communication) and 
therefore must have a different mode of action. In the studies presented here a 
comparison of the characteristics of ET-1- and LPA-stimulated PtdIns(4,5)P2 
hydrolysis and Ins(l,4,5)P3 formation in both intact and electropermeabilized 
Rat-1 cells is presented.
4.2. Comparison of PtdIns(4,5)P2 hydrolysis stimulated by ET-1 
and LPA in intact cells.
In Rat-1 cells LPA stimulated the accumulation of [3H] inositol phosphates 
in a dose-dependent manner with a maximum increase at about 10|iM and an 
EC50 value of 3.0 ± 2.3 {iM (n=7) (Fig. 4.1). LPA is therefore a far less potent 
agonist at stimulating polyphosphoinositide hydrolysis than ET-1 (EC50 ~2nM). 
The maximum response to LPA was also smaller than that obtained with ET-1 
with a 2-3 fold increase in [3H] inositol phosphates accumulation over controls 
after 20min. When the formation of Ins(l,4,5)P3 mass stimulated by a 
maximum concentration of LPA (IOOjiM) was measured further differences to 
the ET-1-stimulated response were observed. LPA stimulated the rapid 
generation of Ins(l,4,5)P3 with a peak response at about 10s which was 6-10 
fold (n=5) above basal values (results from a typical experiment: 2.94 ± 0.85 
pmol in control; 21.2 ± 3.3 pmol with 100|iM LPA; n=5) (Fig. 4.2). Stimulated 
levels then quickly declined to basal and by 2min were not significantly different 
from control values (results from a typical experiment: 3.26 ± 0.26 pmol in 
control; 4.10 ± 0.42 pmol with IOOjiM LPA; n=5). This is in contrast with ET-
1-stimulated formation of Ins(l,4,5)P3 where stimulated levels were maintained
2-4 fold above controls up to lOmin (Fig. 4.3). The sustained phase of ET-1-
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stimulated Ins(l,4,5)P3 generation was dependent on the extracellular [Ca2+] 
and could be abolished by including 0.33mM EGTA to reduce the extracellular 
[Ca2+] to l|iM  (Fig. 4.3a). Furthermore, if Ca2+ was re-added once stimulated 
levels had returned to basal, a further 3-4 fold increase in Ins(l,4,5)P3 was 
stimulated; this response had returned to basal after about 2 min (Fig. 4.3b). 
Thus ET-1 appears to stimulate an additional Ca2+-dependent pathway of 
polyphosphoinositide hydrolysis compared with LPA.
Since these differences in Ins(l,4,5)P3 formation in response to LPA and 
ET-1 suggested differences in the rates of Ins(l,4,5)P3 degradation or the 
hydrolysis of PtdIns(4,5)P2 , mass levels of this lipid were measured following 
stimulation with both agonists (Fig. 4.4). LPA stimulated a rapid decrease in the 
mass of PtdIns(4,5)P2 with a maximum reduction of 40-50% in lipid levels 
after 10s (results from a typical experiment: 9.5 ±1.8 pmol in control; 4.8 ± 0.5 
pmol with lOOpM LPA; n=4). However, in parallel with Ins(l,4,5)P3 
formation, the response was transient and lipid levels had returned to control 
values within 2min after stimulation with LPA and, in some experiments, 
subsequently increased above control values before returning to basal (8.5 ± 0.6 
pmol in control; 11.0 ± 0.6 pmol with IOOjiM LPA; 5min stimulation; n=2).
This is probably due to the time it takes to regulate the activity of the enzymes 
responsible for re-synthesizing PtdIns(4,5)P2 once lipid levels have returned to 
control values. ET-1 also stimulated a rapid decrease in PtdIns(4,5)P2 mass but 
a maximum reduction was only observed after nearly lmin following stimulation 
when a 70-85% reduction in stimulated levels below control was observed 
(results from a typical experiment: 8.6 ± 1.0 pmol in control; 1.5 ± 0.3 pmol 
with lOOnM ET-1; n=4) which is greater than the decrease obtained with LPA. 
The stimulated decrease was also more sustained than that obtained with LPA 
thus paralleling the formation of Ins(l,4,5)P3 and stimulated levels only returned 
to control values after about 20min.
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The inositol phosphates responses to LPA and ET-1 in intact cells were 
further characterized by investigating the sensitivity to inhibition by short 
pretreatments with PMA (Fig. 4.5). Following a 15min preincubation with 
300nM PMA, dose-dependent [3H] inositol phosphates accumulation stimulated 
by LPA was decreased at all concentrations of agonist and the inhibition was 60- 
90% at a maximum dose of LPA (Fig. 4.5b). In contrast, the response to ET-1 
was unaffected by PMA pretreatment (Fig. 4.5a). Increased concentrations of 
PMA up to I j jM  or a prolonged preincubation time up to 60min were also 
without any effect on the ET-1-stimulated accumulation of inositol phosphates 
(379 ± 56% of basal with ET-1 in control cells, 446 ± 14% of basal with ET-1 
in cells pretreated with ljiM for 15min; 310 ± 20% with ET-1 in control cells, 
360 ± 20% with ET-1 in cells pretreated with 300nM PMA for 60min). When 
cells were exposed to lOOng/ml pertussis toxin for 18-20h prior to stimulation 
this treatment had little effect on subsequent inositol phosphates accumulation in 
response to either LPA or ET-1 (Fig. 4.6). Pertussis toxin has been shown to 
ribosylate a ~40kD substrate in Rat-1 cells transfected with the 0C2 -CIO 
adrenergic receptor (Milligan et al., 1991).
4.3. Differences in Ca2+ mobilization stimulated by ET-1 and 
LPA.
Since the primary function of Ins(l,4,5)P3 is to release stored Ca2+, 
intracellular Ca2+ mobilization in response to both ET-1 and LPA was also 
measured. Changes in intracellular Ca2+ levels were measured by the 
fluorescence emitted from cells loaded with the Ca2+ indicator Indo-1 AM. Due 
to the difficulty in calibrating the fluorescence emitted as a Ca2+ concentration, 
the results are presented as florescence data. Both ET-1 and LPA stimulated a 
biphasic increase in intracellular Ca2+ levels consisting of a rapid transient phase 
and a second smaller but sustained phase (Fig. 4.7). However, in LPA- 
stimulated cells the level of Ca2+ immediately returned to basal if the cells were
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washed with buffer and a rechallenge with LPA could again elicit a biphasic 
response similar to the first one recorded (Fig. 4.7b). In contrast, Ca2+ levels in 
response to ET-1 remained high despite washing with buffer and a rechallenge 
with the peptide could not elicit any further increases (Fig. 4.7a). For both 
agonists the initial peak increase in intracellular Ca2+ was independent of the 
extracellular [Ca2+]; however, if EGTA was included to buffer the extracellular 
[Ca2+] to lpM the sustained phase of the response was abolished (Fig. 4.8). 
Re-adding a 1.26mM Ca2+-containing buffer elicited a second, sustained 
increase in the level of Ca2+ similar to the second phase of the biphasic response, 
suggesting that both ET-1 and LPA increase the intracellular [Ca2+] by release 
from intracellular stores and entry of external Ca2+. In some experiments 
changing to a lpM Ca2+ buffer in the absence of agonist resulted in an increase 
in intracellular Ca2+ (e.g. Fig. 4.8a), but the significance and mechanism of this 
is unclear.
4.4. The role of guanine nucleotides in ET-1- and LPA-stimulated 
inositol phosphates accumulation.
In order to investigate potential differences in the interaction of both LPA 
and ET-1 receptors with the inositol lipid signalling pathway experiments were 
performed using electropermeabilized cells. Electropermeabilization was carried 
out by exposing cells in suspension to six discharges of a 3 |iF capacitor with a 
field strength of 2kV/cm; approximately 95% of cells were found to be 
permeable to Hoescht stain following this procedure (Fig. 4.9).
The involvement of a G protein in receptor-effector coupling was assessed 
by studying the effect of the non-hydrolysable GTP analogue, GTP[S], on pH] 
inositol phosphates accumulation. In permeabilized cells LPA gave a maximum 
response 2-3-fold over basal values, but the addition of 30pM GTP[S] clearly 
potentiated LPA- stimulated inositol phosphates accumulation at all 
concentrations of the agonist employed (results from a typical experiment: 1495
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±183 d.p.m. in control; 2320 ± 66 d.p.m. with IOOjiM LPA; 2596 ± 143 
d.p.m. with 30pM GTP[S]; 5356 ± 206 d.p.m. with LPA + GTP[S]) (Fig. 
4.10b). Potentiation of the response was specific for non-hydrolysable 
analogues of GTP; Gpp[NH]p was less effective than GTP[S] (54 ± 3 % of the 
GTP[S] response, n=2) whereas GTP, GDP, GMP and ATP were without 
effect (n=3). In contrast, GTP[S] had little effect on ET-1-stimulated pH] 
inositol phosphates accumulation in permeabilized cells. ET-1 alone stimulated a 
maximum response which was not significantly enhanced by the addition of 
30pM GTP[S] (Fig. 4.10a). In subsequent experiments examining nucleotide 
effects on ET-l-stimulated inositol phosphates accumulation, the peptide was 
used at a submaximum concentration (0.3nM or InM) to ensure that the system 
was not being stimulated to its full capacity by the peptide alone
The effect of LPA and ET-1 on the dose-dependent accumulation of pH] 
inositol phosphates in response to GTP[S] in permeabilized cells was also 
investigated. GTP[S] stimulated a maximum increase of about 2-fold above 
basal and the response was substantially increased at all concentrations of the 
nucleotide by a maximum concentration of LPA (results from a typical 
experiment: 1323 ±81 d.p.m. in control; 2206 ±102 d.p.m. with IOOjiM 
GTP[S]; 2187 ± 120 d.p.m. with 30pM LPA; 4455 ± 506 d.p.m. with GTP[S] 
+ LPA). LPA also shifted the EC50 value for the nucleotide to the left (-LPA, 
86.9 ± 15.6 |iM; +LPA, 31.2 ± 8.6 i^M; n=3) (Fig. 4.11b). In contrast, ET-1 
had little effect on the magnitude or EC50 value of the GTP[S] response (Fig.
4.1 la). Similar experiments were also carried out in cells which had been 
permeabilized by streptolysin-0 treatment. Cells permeabilized with 
streptolysin-0  were grown as monolayers while cell suspensions were used for 
electropermeabilization. In agreement with the results obtained in 
electropermeabilized cells, the GTP[S] response was also not affected by ET-1 
in toxin-permeabilized cells (results from a typical experiment: 963 ± 22 d.p.m. 
in control; 2378 ± 262 d.p.m. with lOpM GTP[S]; 3640 ± 419 with InM ET-1;
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5529 ± 761 d.p.m. with GTP[S] + ET-1; n=3). The GTP[S]-stimulated 
accumulation of inositol phosphates was potentiated by LPA but the increase 
was not as great as that obtained in electropermeabilized cells (results from a 
typical experiment: 311 ± 60 d.p.m. in control; 1172 ± 193 d.p.m. with 10|iM 
GTP[S]; 773 ± 83 d.p.m. with 30pM LPA; 2306 ± 97 d.p.m. with GTP[S] + 
LPA). Therefore, electroporation was used as the preferred method for 
permeabilization.
4.5. Effect of GTP[S] on the kinetics of InsP3 formation in 
response to ET-1 and LPA in permeabilized cells.
For G protein-coupled receptors, agonist-receptor occupation is thought to 
accelerate GTP/GDP exchange and thus enhance the onset of PtdIns(4,5)P2 
hydrolysis. In permeabilized Rat-1 cells GTP[S] alone stimulated the formation 
of pH] InsP3 but only after a lag time of about 30s (Fig. 4.12). However, in 
the presence of LPA (30jiM), a potentiating effect of GTP[S] was observed as 
early as 10s after stimulation indicating that the lag time for the onset of the 
nucleotide response had been decreased by LPA (Fig. 4.12a). A similar effect 
was observed for the kinetics of pH] InsP2 formation (results from a typical 
experiment: 2004 ± 132 d.p.m. in control; 2128 ± 156 d.p.m. with GTP[S]; 
4928 ±116 d.p.m. with LPA; 6912 ± 180 d.p.m. with LPA + GTP[S]; 10s 
stimulation). However, InsP3 generation in response to a maximum 
concentration of ET-1 (lOnM) was not enhanced by GTP[S] and the agonist did 
not reduce the lag time for the onset of a GTP[S] response (Fig. 4.12b). At 
submaximal concentrations (InM ) of ET-1 a potentiating effect with GTP[S] 
was observed and the presence of ET-1 reduced the lag time for the onset of the 
GTP[S] effect (Fig. 4.12c). The ET-1-stimulated generation of pH] InsP3 was 
increased about 2-fold in the presence of GTP[S] as early as lOsec following 
stimulation with a submaximum concentration of the peptide. The sustained 
generation of pH] InsP3 stimulated by InM ET-1 compared with the transient
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response stimulated by a maximum concentration probably reflects differences in 
the activation of the kinases and phosphatases responsible for InsP3 metabolism.
4.6. Effect of GDP[S] and PMA pretreatment on ET-1 and LPA- 
stimulated inositol phosphates accumulation in permeabilized cells.
Despite the lack of potentiation of ET-l-stimulated inositol phosphates 
accumulation by GTP[S] when a maximum concentration of agonist was used, 
the ability of submaximal concentrations of the peptide to reduce the lag time for 
the onset of GTP[S]-stimulated [3H] InsP3 generation suggested a role for a G 
protein in coupling the receptor to Ptdlns-PLC. In order to investigate this 
further the effect of the nonhydrokable GDP analogue, GDP[S], on agonist -
v
stimulated [3H] inositol phosphates accumulation was studied. Following a 
preincubation with ImM GDP[S] the responses to both ET-1 and LPA, alone 
and in combination with GTP[S], were inhibited (Fig. 4.13). GDP[S] was 
equally effective against ET-1 in the presence or absence of GTP[S] inhibiting 
inositol phosphates accumulation by 40-55% (n=5). However, although the 
response to LPA in combination with GDP[S] was substantially inhibited by 
-50%, GDP[S] had little effect on stimulation by LPA alone (10-20%, n=5).
Since short PMA pretreatment was shown to inhibit the LPA-stimulated 
inositol phosphates accumulation in intact cells but to have no effect on the ET-1 
response, similar experiments were carried out in permeabilized cells (Fig.
4.14). Following preincubation with 300nM PMA for 15min the accumulation 
of [3H] inositol phosphates stimulated by LPA was decreased by about 50%.
The response to GTP[S] was not significantly affected and, in agreement with 
the results obtained from intact cells, stimulation by ET-1 was also not inhibited 
(results from a typical experiment: 151± 11% basal with GTP[S]; 138 ± 3% 
basal with GTP[S] + PMA; 232 ± 14% basal with ET-1; 257 ± 6% basal, with 
ET-1 + PMA).
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Fig. 4.1 Dose dependence of LPA-stimuIated inositol phosphates 
accumulation.
Rat-1 cells labelled for 48h with ljiCi/ml [3H] inositol were stimulated 
with increasing concentrations of LPA for 20min in the presence of lOmM LiCl 
and the radioactivity associated with total inositol phosphates was measured as 
described in section 2.6.2. The results are expressed as means ± S.D. from a 
typical experiment where n=7. The basal value was 5363 ± 880 d.p.m.
Fig. 4.2 Time course of LPA-stimuIated Ins(l,4,5)P3 mass 
formation.
Rat-1 cells were grown to confluency and quiescence. Stimulation was 
then carried out with IOOjiM LPA ( • )  or vehicle (O) for the indicated times and 
Ins(l,4,5)P3 levels were measured by mass assay (section 2.7). Each point 
represents the mean ± S.D. of triplicate determinations from a typical experiment 
where n=5.
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Fig. 4.3 Ca2+-dependency of ET-l-stimuIated Ins(l,4,5)P3 mass 
formation.
(a) Rat-1 cells were grown to confluency and quiescence. Cells were then 
preincubated in normal HBG containing 1.26mM Ca2+ (O, • )  or HBG low in 
Ca2+ containing 0.33mM EGTA to give a ljiM free [Ca2+] (□, ■) for 20min 
and then stimulated with vehicle (O, □) or lOOnM ET-1 (# , ■ ) in the same 
buffers. In (b) a 1.26mM Ca2+-containing buffer was added after a 5min 
preincubation with lOOnM ET-1 in low Ca2+ buffer. Ins(l,4,5)P3 levels were 
measured as described previously (section 2.7). O, ljiM Ca2+; • ,  1.26mM 
Ca2+.
Results are expressed as means ± S.D. from typical experiments where n=3-6.
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Fig. 4.4 Time course of ET-1- and LPA-stimulated PtdIns(4,5)P2 
breakdown.
Rat-1 cells were grown to confluency and quiescence. Stimulation was 
then carried out with (a) lOOnM ET-1 or (b) IOOjiM LPA for the stated times. 
Samples were deacylated and deglycerated as described in section 2.8 and 
PtdIns(4,5)P2 mass levels determined by measuring the mass of Ins(l,4,5)P3. 
Results are expressed as means ± S.D. from a typical experiment where n=3. 
(O), basal levels; ( • ) , stimulated levels.
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Fig. 4.5 Effect of PMA on ET-1 and LPA dose-dependent 
stimulation of [3H] inositol phosphates accumulation.
Rat-1 cells labelled for 48h with ljiCi/ml [3H] inositol were preincubated 
with vehicle (O) or 300nM PMA ( • )  for 15min prior to incubation for a further 
20min with increasing concentrations of (a) ET-1 or (b) LPA. Samples were 
assayed for inositol phosphates as described in section 2.6.2. Results are 
expressed as the mean ± S.D. of triplicate determinations from a typical 
experiment where n=3. Basal values were (d.p.m.) (a) -PMA, 4954 ± 323; 
+PMA, 5491 ± 483; (b) -PMA, 2778 ± 192; +PMA, 2232 ± 315.
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Fig. 4.6 Effect of pertussis toxin treatment on ET-1- and LPA- 
stimulated [3H] inositol phosphates accumulation.
Rat-1 cells were labelled for 48h with 1 jiCi/ml [3H] inositol and for the 
final 18-20h lOOng/ml pertussis toxin was included. Stimulation was carried out 
with lOOnM ET-1 or IOOjiM LPA for 20min and [3H] inositol phosphates were 
assayed as outlined in section 2.6.2. The results are expressed as means ± S.D. 
from a typical experiment where n=5. Basal values were (d.p.m.): - 
PTox,4852 ± 480; +PTox, 5508 ± 676.
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Fig. 4.7 Time course of ET-1- and LPA-stimulated changes in 
intracellular Ca2+ levels.
Rat-1 cells were grown to confluency on glass coverslips and loaded with 
5|iM Indo-1 AM for 20min at room temperature. The cells were then perfused 
with HBG containing agonist (a)lOOnM ET-1 or (b)100pM LPA, and the 
emitted fluorescence measured as described in section 2.13. The results are 
expressed as the ratio of the light emitted at 405nM and 495nM from a typical 
experiment where n=3.
Shaded boxes indicate times when cells were exposed to agonist; during the 
remaining time cells were washed with buffer.
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Fig. 4.8 Contribution of release of intracellularly stored Ca2+ and 
the influx of extracellular Ca2+ to the ET-1- and LPA-induced 
changes in intracellular free Ca2+ levels.
Cells were grown to confluency on glass coverslips and loaded with 5}iM 
Indo-1 AM for 20min at room temperature. The cells were perfused with (a) 
lOOnM ET-1 or (b) IOOjiM LPA in normal HBG (1.26mM Ca2+) or low Ca2+ 
HBG containing 0.33mM EGTA (ljiM free Ca2+) and the emitted fluoresence 
measured as described in section 2.13. The results are expressed as the ratio of 
the light emitted at 405nM and 495nM from a typical experiment where n=3. 
Shaded boxes indicate times when the cells were exposed to agonist; during the 
remaining time cells were washed with buffer.
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Fig. 4.9 Permeabilizatlon of Rat-1 cells by electroporation.
Rat-1 cells in suspension were exposed to six discharges at lsec intervals 
of a 3jjF  capacitor with a field strength of 2 kV/cm. Hoechst reagent (1 mg/ml) 
was added to a sample of the cell suspension and the cells viewed under UV 
light for-uptake of the dye. The photographs show p&meabilized cells (a) under 
normal light, (b) under UV light.
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Fig. 4.10 Effect of GTP[S] on ET-1- and LPA-stimuIated pH ] 
inositol phosphates accumulation in permeabilized cells.
Rat-1 cells prelabelled for 48h with ljiCi/ml pH] inositol and then 
permeabilized were incubated with increasing concentrations of (a) ET-1 and (b) 
LPA in the presence ( • )  or absence (O) of 30jiM GTP[S] for 5min. Results are 
expressed as the d.p.m. in pH] inositol phosphates due to agonist stimulation 
minus the basal d.p.m. Each point is the mean ± S.D. from triplicate 
determinations of a typical experiment where n=3-5. Basal values were (d.p.m.) 
(a) -GTP[S], 456 ± 13; +GTP[S], 734 ± 53; (b) -GTP[S], 1495 ± 83;
+GTP[S], 2596 ± 143.
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Fig. 4.11 Effect of ET-1 and LPA on dose-dependent GTP[S]- 
stimulated [3H] inositol phosphates accumulation in permeabilized 
cells .
Rat-1 cells prelabelled for 48h with ljiCi/ml [3H] inositol and then 
permeabilized were incubated with increasing concentrations of GTP[S] in the 
presence ( • )  or absence (O) of (a) 0.3nM ET-1 or (b) 30jiM LPA for 5min. 
Results are expressed as the d.p.m. in [3H] inositol phosphates due to agonist 
stimulation minus the basal d.p.m. Each point is the mean ± S.D. of triplicate 
determinations from a typical experiment where n=3. Basal values were 
(d.p.m.): (a) -ET-1, 473 ± 60; +ET-1, 1958 ± 48; (b) -LPA, 1312 ± 81; +LPA, 
2187 ±120.
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Fig. 4.12 Kinetics of agonist- and GTP[S]-stimuIated [3H] InsP3 
formation in permeabilized cells.
Rat-1 cells prelabelled for 48h with 8|iCi/ml pH] inositol and then 
electroporated were stimulated with (a) 30jiM LPA, (b) lOnM ET-1 or (c) InM 
ET-1 in the presence or absence of 200pM GTP[S] for the indicated times. (O), 
vehicle; (□), GTP[S]; ( • ) ,  agonist; (■) agonist + GTP[S]. Results are 
expressed as means ± S.D. from a typical experiment where n=3.
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Fig. 4.13 Effect of GDP[S] on agonist- and GTP[S]-stimulated 
[3H] inositol phosphates accumulation in permeabilized cells.
pH] Inositol-labelled cells (ljj.Ci/ml for 48h) which had been 
electropermeabilized were preincubated with vehicle or ImM GDP[S] for 5min 
prior to stimulation for 5min with LPA (30|iM), ET-1 (0.3nM) and GTP[S] 
(30|iM), alone and in combination. Basal values were (d.p.m.): control, 1511 
± 93; +GDP[S], 717 ± 21. Results are expressed as the mean ± S.D. of 
triplicate determinations from a typical experiment where n=5.
Fig. 4.14 Effect of PMA on agonist- and GTP[S]-stimuIated pH ] 
inositol phosphates accumulation in permeabilized cells.
pH] Inositol-labelled cells (ljiCi/ml for48h) were preincubated for 15min 
with vehicle or 300nM PMA and then permeabilized by electroporation. 
Stimulation was carried out for 5min with 30jiM LPA, 0.3nM ET-1 or 30|iM 
GTP[S], alone and in combination. Basal values were (d.p.m.): control, 629 ± 
83; +PMA, 474 ± 14. Results are expressed as means ± S.D. from a typical 
experiment where n=3.
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4.7. Discussion.
The previous chapter demonstrated that ET-1 could stimulate both 
PtdIns(4,5)P2 and PtdCho hydrolysis; both these pathways generate DAG and 
thus could activate protein kinase C. Indeed, ET-l-stimulated DNA synthesis 
appears to be dependent on protein kinase C activity to some extent (Fig. 3.3; 
Muldoon et al., 1990). In some systems a decrease in cAMP seems to be 
important for stimulating cell proliferation and this has been proposed to be the 
mechanism underlying the mitogenic response to LPA in Rat-1 cells based on the 
pertussis toxin-sensitivity of LPA-stimulated DNA synthesis and adenylyl 
cyclase activity (van Corven et al., 1989). In contrast, the results presented here 
show that both LPA- and ET-l-stimulated [3H] thymidine incorporation were 
pertussis toxin-insensitive arguing against a role for the inhibition of adenylyl 
cyclase in the mitogenic response to both these agonists. Although ET-1 has 
been shown to have no effect on adenylyl cyclase activity in Rat-1 cells, an 
inhibition was observed in response to LPA (F. McKenzie and E. Adie, 
unpublished observations). Since this suggested differences in the signalling 
pathways stimulated by ET-1 and LPA, the regulation of PtdIns(4,5)P2 
hydrolysis in response to both mitogens was investigated and compared in an 
attempt to gain further insight into the mechanism of ET-1-induced mitogensis in 
Rat-1 cells.
The accumulation of inositol phosphates in response to LPA in intact cells 
was considerably less than that observed with ET-1 with about a 2-3-fold 
increase above basal, in agreement with results reported elsewhere (van Corven 
et al., 1992). The generation of Ins(l,4,5)P3 mass was transient which was 
reflected in the transient decrease in PtdIns(4,5)P2 mass (Fig.4.4). This was in 
contrast to the ET-l-stimulated response which consisted of an initial peak of 
Ins(l,4,5)P3 generated independently of the external [Ca2+] and a second 
sustained Ca2+-dependent phase. Similar results have also been reported for 
carbachol-stimulated human neuroblastoma cells where the inclusion of EGTA
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significantly reduced the plateau phase of a biphasic Ins(l,4,5)P3 response 
(Lambert et al., 1991). In fact, in the Rat-1 cells, re-addition of Ca2+ (1.26mM) 
once stimulated levels had returned to basal could elicit another phase of 
Ins(l,4,5)P3 generation (Fig.4.3 ). Thus, ET-1 appears to activate an additional 
Ca2+-dependent pathway of Ins(l,4,5)P3 generation compared with LPA. The 
sustained nature of the Ins(l,4,5)P3 response was reflected in the sustained 
hydrolysis of PtdIns(4,5)P2. Although these results suggest that ET-1 and LPA 
stimulate the hydrolysis of PtdIns(4,5)P2 to different extents, it is important to 
realise that mass measurements do not necessarily reflect the flux through the 
pathway. Indeed, at any time the mass of PtdIns(4,5)P2 and Ins(l,4,5)P3 
reflect both the rate of synthesis and degradation. Although LPA-stimulated 
levels appear to return to control values this may simply reflect a steady state in 
which rates of formation and degration are balanced. However, the results do 
imply differences in the regulation of PtdIns(4,5)P2 hydrolysis by LPA and ET- 
1.
The generation of Ins(l,4,5)P3 almost certainly results in the release of 
Ca2+ from intracellular stores and therefore changes in intracellular Ca2+ levels 
in response to both LPA and ET-1 were compared in Indo-1-loaded cells. Both 
agonists stimulated a biphasic increase in intracellular [Ca2+] reflecting initial 
mobilization from intracellular stores and subsequent entry of external Ca2+. 
Similar patterns of Ca2+mobilization in response to ET-l-stimulation have been 
observed in other systems including fura-2-loaded rat mesangial cells (Simonson 
and Dunn, 1991b) and Swiss 3T3 cells (Takuwa et al., 1989). Chan and 
Greenberg (1991) used the inhibitor SK&F 96365 to provide evidence of 
receptor-mediated Ca2+ entry in response to ET-1 in NG108-15 cells while 
Mn2+-quenching of Indo-1 fluorescence was taken as evidence of Ca2+ entry in 
LPA-stimulated human fibroblasts (Jalink et al., 1990). Although both LPA and 
ET-1 stimulated a sustained phase of Ca2+ increase in Rat-1 cells, the LPA 
response could be washed out while the ET-1 response remained high. In
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addition, the LPA-mediated Ca2+ mobilization was not desensitized and further 
challenges with the agonist could elicit an additional response. This is unlike the 
LPA-stimulated increase in Ca2+ in human fibroblasts which showed 
homologous desensitization and may therefore involve different regulatory 
pathways or a different receptor (Jalink et al., 1990). The ET-l-stimulated 
response in Rat-1 cells is, however, insensitive to further challenges with the 
peptide in agreement with the homologous desensitization of Ca2+ mobilization 
reported for ET-1 in Swiss 3T3 cells (Fabre^tand Rozengurt, 1990). The 
relationship between the second phase of ET-l-stimulated Ins(l,4,5)P3 
generation and the second phase of the Ca2+ increase is however unclear. Both 
ET-1 and LPA stimulated biphasic Ca2+ responses which were reduced to a 
single transient phase in the presence of EGTA, while re-addition of a normal 
(1.26mM) external [Ca2+] could elicit a second phase. Clearly, however, only 
ET-1 stimulated a sustained, Ca2+-dependent phase of Ins(l,4,5)P3 generation. 
This, therefore, suggests that the second phase of Ca2+ mobilization is not 
dependent on Ins(l,4,5)P3 generation. In addition, since both agonists 
stimulated Ca2+ entry this explanation is not sufficient to account for the 
sustained phase of Ins(l,4,5)P3 in response to ET-1 stimulation and suggests 
the involvement of an additional component. The two phases of Ins(l,4,5)P3 
generation may reflect activation of different Ptdlns-PLCs. The pertussis toxin- 
insensitive G protein, Gq, has been shown to activate phospholipase CPi while 
phospholipase Cyhas been shown to be activated by tyrosine phosphorylation 
(section 1.4.1). The possible role of phospholipase Cy in the secondary phase 
of Ins(l,4,5)P3 generation is discussed further in chapter 6. The inability to 
wash out the ET-l-stimulated Ca2+response may be due to the tight association 
between the peptide and its receptor and will be discussed further in chapter 5.
Comparison of ET-1- and LPA-stimulated responses in intact cells 
therefore clearly showed differences between the effects of these two mitogens. 
Sustained Ins(l,4,5)P3 formation is not usually associated with peptide
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receptors linked to the inositol phosphates pathway but rather is rapidly 
desensitized as with the LPA response. Thus, in bombesin-stimulated Swiss 
3T3 cells Ins(l,4,5)P3 generation had returned to basal by 30s (Cook et al., 
1990) while in NIH3T3 and NG108-15 cells the bradykinin-stimulated increase 
in Ins(l,4,5)P3 mass was also transient (Fu et al., 1988). Similarly, in fMet- 
Leu-Phe-stimulated neutrophils Ins(l,4,5)P3 levels determined by both HPLC 
and competition binding studies had returned to basal by 2min (Bradford and 
Rubin, 1986). In contrast, in adrenal glomerulosa cells angiotensin II stimulated 
a biphasic increase in [3H] Ins(l,4,5)P3 generation and the secondary increase 
was sustained for up to 30min (Balia et al., 1988). It is not possible to compare 
the action of ET-1 in Rat-1 cells with that in other systems since previous studies 
measured the kinetics of labelled InsP3 generation without separating the 
different isomers. Since the sustained phase of Ins(l,4,5)P3 does not appear to 
be required for Ca2+ mobilization this therefore raises the question of why it is 
generated. It may simply reflect sustained PtdIns(4,5)P2 hydrolysis where DAG 
is the important mediator produced. Alternatively, it may be further metabolized 
to Ins(l,3,4,5)P4 which may then have a second messenger role; for example in 
regulating Ca2+ influx as has been suggested in other systems (see section 
1.4.2). Another characteristic of the ET-1 response which distinguished it from 
other agonists which act through G protein-coupled receptors was the 
insensitivity of inositol phosphates accumulation to a short PMA pretreatment. 
This appears to be a feature of the response in Rat-1 cells since ET-l-stimulated 
inositol phosphates formation in other systems has been reported to be inhibited 
by PMA pretreatments of 10-15min with inhibition of up to 80% (Reynolds et 
al., 1989; Araki et al., 1989; Galron etal., 1990; Resink etal., 1990). In 
contrast, preincubation with PMA markedly decreased the subsequent LPA- 
stimulated inositol phosphates response in a manner characteristic for an agonist 
acting through a receptor linked to Ptdlns-PLC via a G protein. It is worth 
mentioning again that the site of protein kinase C-mediated inhibition varies
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among cell types and agonists used (section 4.1). However, G protein-receptor 
kinases have been identified involved in the desensitization of adenylyl cyclase 
responses, e.g. pARK (reviewed in Palczewski and Benovic, 1991), and it is 
possible that similar enzymes may exist involved in desensitizing the inositol 
lipid pathway.
The receptor-G protein-effector interaction for both ET-1 and LPA was 
further investigated in permeabilized Rat-1 cells in combination with guanine 
nucleotide analogues. In permeabilized cells the characteristics of LPA- 
stimulated inositol phosphates formation in the presence of guanine nucleotides 
agreed with the criteria expected for an agonist acting through a G protein- 
coupled receptor. LPA-stimulated inositol phosphates accumulation was 
enhanced by GTP[S] in agreement with the findings of van Corven et a l .
(1989). The results presented here also demonstrate that LPA enhanced the 
GTP[S] response and that the presence of LPA decreased the EC50 value for 
GTP[S]-stimulated inositol phosphates accumulation. Similar results have also 
been reported in other systems where G protein interactions have been 
suggested, for example histamine- and carbachol-stimulated rat brain cortical 
membranes and P2y purinergic receptor activation in turkey erythrocytes (Claro 
et aLy 1989; Boyer et a l , 1989b). In addition, kinetic studies demonstrated that 
LPA decreased the lag time for the onset of the GTP[S] response suggesting that 
LPA accelerates GTP/GDP exchange, an essential criterion for defining the 
involvement of a G protein in coupling a receptor to a second messenger 
pathway (Boyer et a l , 1989b). Consistent with this finding GDP[S], which 
maintains the G protein in an inactive state, inhibited the potentiation of the LPA 
response by GTP[S] although it had little effect on the LPA response alone. The 
PMA inhibition studies carried out in intact cells were extended to permeabilized 
cells with similar results; the response to LPA in the presence or absence of 
GTP[S] was inhibited by a similar amount. The site of protein kinase C- 
mediated inhibition appeared to be upstream of the G protein-Ptdlns-PLC
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interaction since the response to GTP[S] alone was unaffected by PMA 
pretreatment. Although lack of a suitable labelled ligand prevented any 
investigation of the effect of protein kinase C on agonist affinity, modifications 
of the receptor or the G protein may be the site of protein kinase C-mediated 
inhibition causing impaired coupling without affecting the function of either 
receptor or G protein. Similar results have also been reported in other systems 
including bombesin-stimulated permeabilized Swiss 3T3 cells (Plevin et a l ., 
1990) and angiotensin D-stimulated rat mesangial cell membranes (Pfeilschifter 
and Bauer, 1987). As yet a receptor for LPA has not been identified. However, 
the results presented here demonstrating the rapid and transient nature of LPA- 
stimulated Ins(l,4,5)P3 generation and the effect of guanine nucleotide 
analogues on second messenger formation are consistent with the existence of a 
specific LPA receptor which interacts with Ptdlns-PLC via a G protein.
As with intact cells, ET-l-stimulated responses in permeabilized cells 
showed a number of differences compared with LPA and did not conform to all 
the criteria expected for an agonist binding to a receptor linked to a G protein. 
GTP[S] did not potentiate the ET-l-stimulated accumulation of inositol 
phosphates and the peptide had little effect on the nucleotide response. This is in 
contrast with reports of ET-1 responses in other systems. In A10 smooth 
muscle cell membranes and permeabilized rat mesangial cells GTP[S] potentiated 
ET-l-stimulated inositol phosphates formation (Takuwa et a l ., 1990; Thomas et 
a l ., 1991). However, in the Rat-1 cells GDP[S] substantially inhibited the 
response to ET-1 alone and in combination with GTP[S]. The different effects 
seen with GDP[S] on ET-1- and LPA-stimulated inositol phosphates 
accumulation may reflect differences in the ability of these agonists to stimulate 
guanine nucleotide exchange. Since GDP[S] inhibits both responses in the 
absence of GTP[S], this suggests that residual GTP remaining after 
permeabilization can support a response stimulated by both LPA and ET-1. 
However, the greater inhibition seen with ET-1 may be due to the greater
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efficacy of ET-1 to stimulate guanine nucleotide exchange. Measurements of 
GTPase activity might give some indication of the relative abilities of ET-1 and 
LPA to stimulate GTP/GDP exchange. Despite the inability of a maximum 
concentration of ET-1 to accelerate GTP/GDP exchange as measured by the 
kinetics of agonist- and nucleotide-stimulated InsP3 generation, a submaximum 
concentration of the peptide did reduce the lag time for the onset of the nucleotide 
response. This is probably because there is a limit to the extent to which 
agonists can stimulate polyphosphoinositide turnover governed by the activity of 
Ptdlns-PLC and the availability of substrate. Since the efficacy of ET-1 to 
stimulate inositol phosphates accumulation is greater than LPA, a maximum 
concentration of ET-1 may already reach this limit and therefore an effect with 
GTP[S] can only be detected with a submaximum concentration. Taken together 
these results suggest a G protein involvement in the ET-l-stimulated response 
but the nature of the receptor-G protein interaction for the peptide may be 
different from the accepted model. This is con firmed by the lack of effect of 
PMA in permeabilized cells as well as in intact cells.
Due to the lack of effect of GTP[S] on the ET-1 response in 
electropermeabilized cells, similar experiments were performed with cells 
permeabilized with streptolysin-0 in case electroporation hadn't allowed for full 
equilibration of nucleotide pools within the cells. LPA could stimulate inositol 
phosphates accumulation in the absence of added GTP[S] suggesting that there 
was enough residual GTP following electroporation to sustain a response. 
However, in streptolysin-O-permeabilized cells essentially the same results were 
obtained but the potentiation of the LPA response was not as great as that 
observed in electropermeabilized cells suggesting that the latter method allowed 
better equilibration of nucleotide pools. Indeed, the LPA-stimulated response 
was generally greater in toxin-permeabilized cells compared with electroporated 
cells supporting this hypothesis.
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Despite possible artifacts with the permeabilization method the results 
still suggest differences in the G protein input required for LPA and ET-1 
responses. The ET-l-stimulated hydrolysis of PtdIns(4,5)P2 may involve two 
mechanisms only one of which requires a receptor-G protein interaction. This 
could explain why an effect with GTP[S] was only observed when pH] InsP3 
generation was measured at early time points (as against total inositol phosphates 
acumulation after 5min) in response to a submaximum concentration of ET-1; a 
possible candidate responsible for Ins(l,4,5)P3 generated at later times could be 
phospholipase Cy which is activated by tyrosine phosphorylation. The proposal 
that there are two pathways of PtdIns(4,5)P2 hydrolysis stimulated by ET-1 is 
supported by the Ca2+ sensitivity of the second phase of Ins(l,4,5)P3 
generation. As discussed previously the simple model of Ca2+ influx stimulating 
PtdIns(4,5)P2 breakdown is inadequate since LPA also stimulates Ca2+ entry. 
The nature of receptor-G protein coupling for ET-1 and LPA also appears to be 
different due to the different effects obtained with PMA in both intact and 
permeabilized cells. The inability of PMA to inhibit the ET-l-stimulated 
response may suggest that the ET-1 receptor exists in a precoupled state with the 
G protein and hence the site for protein kinase C-mediated inhibition is masked. 
Alternatively, if ET-l-stimulated Ins( 1,4,5)P3 generation involves two pathways 
then it is possible that only the earlier pathway is PMA-sensitive so that when 
PMA-sensitivity is investigated at later times the inhibitory effect of PMA is no 
longer detected. Finally, ET-1 may interact with the G protein itself in a manner 
similar to that described for certain venoms, toxins and neuropeptides such as 
mastoparan and bradykinin (Mousli et a l ., 1990).
Although the nature of the interaction of the ET-1 receptor with the 
inositol phosphate signalling pathway remains unclear, the unusual 
characteristics of the ET-l-stimulated response may be significant in relation to 
its physiological effect. The novel receptor-G protein interaction together with a 
second pathway may underlie the sustained PtdIns(4,5)P2 hydrolysis in
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response to ET-1. This clearly has important implications for the level of DAG 
within the cell and hence activity of protein kinase C which may in turn be 
important for the mitogenic respone to the peptide.
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Chapter 5
Characterization of binding sites for [125I] ET-1 on 
Rat-1 cell membranes.
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5.1 Introduction.
The distribution of ET receptors has been mapped using radiolabelled 
ETs and autoradiography, and saturable, specific binding sites for [125I] ETs 
have been identified in numerous tissues including lung, kidney, heart, 
intestine, adrenal gland, eye and nervous system (Koseki et al., 1989; 
reviewed in Simonson and Dunn, 1990a). Studies in vitro using intact cells 
and membrane preparations have also characterized specific, high affinity and 
saturable binding which was not displaced by other vasoactive peptides or 
Ca2+ channel antagonists suggesting the presence of a specific ET receptor(s) 
(Kanse etal., 1989; Sugiuraetal., 1989; Badretal., 1989). ET-1 had 
originally been suggested to be an endogenous agonist for L-type Ca2+ 
channels due to its sequence similarity with biological toxins that are known to 
interact with ion channels and the ability of the L-channel blocker, 
dihydropyridine, to inhibit ET-1-induced contraction (Yangisawa et al., 
1988a), but this is now clearly not the case. In general, the dissociation of 
bound [125I] ETs was extremely slow suggesting a tight association between 
agonist and receptor (Hirata etal., 1988; Kanse et al., 1989; Serradeil-Le Gal 
et al., 1991). Competition binding studies using a variety of ET and 
sarafotoxin (SS6) analogs in different tissues or cell types suggested the 
existence of multiple ET receptors with different affinities for the ET 
isopeptides (Kloog et al., 1989; Watanabe et al., 1989; Martin et al., 1990b). 
Cross-linking studies also supported the existence of multiple receptor 
subtypes and proteins with a range of molecular weights have been reported: 
73kD and 60kD (Martin et al., 1990b); 58kD and 34kD in rat mesangial cells 
(Sugiura etal., 1989); 53kD, 46kD and 34kD in chick cardiac membranes 
(Watanabe et al., 1989); 34kD and 52kD in bovine lung plasma membranes 
(Hagiwara et al., 1990); 53kd and 38kD in rat brain membranes (Ambar et al.,
1990). The ET binding sites/receptors characterized can be divided into three 
groups; those that bind ET-1 and ET-2 with higher affinity than ET-3, those
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that bind ET-1, ET-2 and ET-3 with equal affinity and those that show highest 
affinity for ET-3.
Most recently the cloning and sequencing of two different ET receptors 
termed ETa and ETb has been reported (Arai et al., 1990; Sekurai et al., 1990; 
reviewed in Sekurai et al., 1992). The ETa receptor (Mr = 48.5kD) was 
cloned from bovine lung and showed highest selectivity to ET-1 in COS cells 
transfected with the cloned cDNA while the ETb receptor (Mr = 46.9kD) 
cloned from rat lung encoded a non-isopeptide-selective receptor subtype with 
equal affinity for ET-1, ET-2 and ET-3. Interestingly, the ETa receptor 
mRNA was detected in vascular smooth muscle while the ETb receptor was 
not. Both receptors contained seven membrane-spanning domains similar to 
other G protein-coupled receptors. Both receptors also contained potential N- 
glycosylation sites within the N-terminal region and serine residues in the third 
cytoplasmic loop and cytoplasmic C-terminal tail which may be 
phosphorylated by serine/threonine kinases and therefore are potential target 
sites for receptor regulation. The cloning of ET receptors from other sources 
has now also been reported including the ETb receptor from human liver and 
jejunum (Nakamuta etal., 1991; Sakamoto etal., 1991), the ETa and ETb 
receptors from human placenta (Cyr et al., 1991; Ogawa et al., 1991; Hosada 
et al., 1991; Adachi et al., 1991), the ETa receptor from a rat heart cell line 
(Lin et al., 1991) and the ETb receptor from bovine lung (Saito et al., 1991). 
The ETb receptor has also been purified from bovine lung (Kozuka et al.,
1991). There is a high degree of homology between the receptor subtypes 
cloned from the different species.
ET-1 was shown to stimulate PtdIns(4,5)P2 hydrolysis in Rat-1 cells 
but the nature of the interaction of the ET-1 receptor with the inositol lipid 
signalling pathway appeared to be different to other receptors which couple to 
Ptdlns-PLC via a G protein (Chapter 4). A preliminary characterization of the 
ET-1 receptor on Rat-1 cells was therefore carried out by examining the
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binding of [125I] ET-1 to membranes from these cells in an attempt to further 
clarify the unusual characteristics of the ET-l-stimulated inositol phosphates 
response.
5.2 Time course of [125I] ET-1 binding to Rat-1 cell membranes
At 25° C specific binding of [125I] ET-1 to membranes from Rat-1 cells 
increased in a time-dependent manner and reached equilibrium after 15-20min 
(Fig. 5.1). Equilibrium binding experiments were therefore carried out for 
30min at 25° C. Binding increased linearly with protein concentration up to 
30-40|ig of membrane protein (Fig. 5.2) and 25pg of membrane protein was 
therefore used in subsequent experiments. The total radioactivity bound was 
-10% of the amount added and nonspecific binding was ~ 30% of total 
binding. There was no difference in binding whether fresh or freeze-thawed 
membranes were used or whether membranes were prepared from scraped or 
trypsinized cells.
5.3 Saturation binding of [125I] ET-1 to membranes.
Binding of [125I] ET-1 to Rat-1 cell membranes under equilibrium 
conditions was saturable and showed high affinity (Fig. 5.3). When the data 
was fitted to a rectangular hyperbola (y = A x / B + x where A = Bmax and B 
= Kd) by computer-assisted non-linear regression analysis the Bmax was 
found to be 3.7 ± 1.1 pmoles bound ET-1 / mg of protein and the Kd value 
was 2.7 ±1.3 nM (Fig. 5.3a). Scatchard analysis (Fig. 5.3b) showed that 
there was a single class of binding sites and yielded similar apparent Bmax 
(4.0 ± 1.2 pmoles ET-1 bound / mg of protein, n=4) and Kd (3.5 ± 0.7 nM) 
values as were obtained from curve fitting. The latter method is however 
more accurate for calculating saturation binding parameters as scatchard
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analysis involves manipulation of the data such that there are errors in both the 
x- and y-axis directions.
Dissociation of bound ligand was determined by addition of lfiM 
unlabelled ET-1 once equilibrium binding had been reached and was found to 
be minimal (Fig. 5.4). Only 10-20% of bound [125I] ET-1 had dissociated up 
to 2h after addition of excess unlabelled ET-1. Guanine nucleotide analogs 
had no effect on binding (Fig. 5.5). When membranes were preincubated for 
lOmin with increasing concentrations of GTP[S] or GDP[S] prior to addition 
of [125I] ET-1, binding was the same as in control membranes. When lower 
concentrations of ET-1 (InM) or shorter incubation times (1,2 and 5min) 
were used GTP[S] still had no effect.
5.4 Competition binding with ET isopeptides.
The ability of ET-1, ET-2 and ET-3 to displace [125I] ET-1 binding was 
investigated by including increasing concentrations of each isopeptide in binding 
assays containing 2nM (~ Kq value) [125I] ET-1 (Fig. 5.6). Each isopeptide 
competed with labelled ET-1 for binding and yielded IC50 values as follows : 
ET-1, 4.2 ± 3.1 nM; ET-2, 5.7 ± 3.1 nM; ET-3, 112 ± 60 nM. The 
corresponding Kj values, calculated from the Cheng and Prusoff equation Kj = 
IC50 /  1 + ([ligand]/ KD), were : ET-1, 2.4 ± 1.8 nM; ET-2, 3.4 ± 1.9 nM; ET- 
3, 58 ± 28 nM thus giving a rank order of potency for displacing [125I] ET-1 
binding of ET-1 ~ ET-2 > ET-3. The competition curves had slopes of 
approximately -1 which is consistent with [125I] ET-1 and the competing 
unlabelled ET isopeptides interacting with a single receptor population by a 
reversible bimolecular reaction which obeys mass action law.
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Fig. 5.1 Time course of [125I] ET-1 binding to Rat-1 cell 
membranes.
Membranes (25Jig) were incubated with lOnM [125I] ET-1 at 25 °C for 
the indicated times. An excess of unlabelled ET-1 (ljiM) was included to 
determine nonspecific binding. Bound ligand was separated from free ligand 
by vacuum filtration through GF/C filters. Results are expressed as the mean 
± S.D. of triplicate determinations from a typical experiment where n=4. (O). 
total binding; (□), nonspecific binding; ( • ) , specific binding.
Fig. 5.2 Effect of protein concentration on [125I] ET-1 binding 
to membranes.
Membranes with increasing protein concentration were incubated with 
lOnM [125I] ET-1 ± ljiM unlabelled ET-1 at 25 °C for 30min. Bound ligand 
was separated from free ligand by vacuum filtration through GF/C filters. 
Results are expressed as means ± S.D. from a typical experiment where n=3. 
(O), total binding; (□), nonspecific binding; ( • ) ,  specific binding.
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Fig. 5.3 Saturation binding of [125I] ET-1 to membranes.
Membranes (25jig) were incubated with increasing concentrations of 
labelled ET-1 for 30min at 25 °C. Nonspecific binding was determined by 
including ljiM unlabelled ET-1. The data was analysed by (a) computer- 
assisted non-linear regression analysis and (b) scatchard analysis. Results are 
expressed as means ± S.D. from a typical experiment where n=4.
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Fig. 5.4 Time course of dissociation of bound [125I] ET-1 from 
membranes.
Membranes (25}ig) were incubated with lOnM [125I] ET-1 ± IjiM 
unlabelled ET-1 for 30min at 25 °C. lfiM unlabelled ET-1 was then added for 
the indicated times. Bound and free ligand were separated by vacuum filtration 
through GF/C filters. Results are expressed as the mean ± S.D. of triplicate 
determinations from a typical experiment where n=3.
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Fig. 5.5 Effect of guanine nucleotides on [12SI] ET-1 binding to 
membranes.
Membranes (25[Xg) were preincubated with increasing concentrations of 
(a) GTP[S] or (b) GDP[S] for lOmin at 25 °C and then incubated for a further 
30min with lOnM [125I] ET-1. Nonspecific binding was determined by 
including l|iM unlabelled ET-1. Results are expressed as means ± S.D. from 
typical experiments where n=3-4.
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Fig. 5.6 Competitive inhibition of [125I] ET-1 binding by ET 
isopeptides.
Membranes (25|ig) were incubated with lOnM [125I] ET-1 ± IjiM 
unlabelled ET-1 for 30min at 25 °C in the presence of increasing 
concentrations of unlabelled ET-1 (O), ET-2 ( • )  and ET-3 (□). Bound and 
free ligand were separated by vacuum filtration. Results are expressed as 
means ± S.D. from a typical experiment where n=3.
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5.5 Discussion
These studies demonstrated that [125I] ET-1 binds to a single class of 
high affinity sites on Rat-1 cell membranes in a saturable manner. The Kd 
value obtained (2.7 ±1.3 nM) is similar to the values reported for [125I] ET-1 
binding to Swiss 3T3 cells (Fabregat and Rozengurt, 1990), brain capillary 
endothelial cells (Vigne et al., 1990) and human melanocytes (Yada et al., 
1991) although it is higher than the Kd reported for [125I] ET-1 binding to 
vascular smooth muscle cells (Hirata et al., 1988). The Kd is also very 
similar to the EC50 values (~2nM) for ET-1-stimulated inositol phosphates 
accumulation, choline generation and PtdBut accumulation in Rat-1 cells 
(Chapter 3).
There is an extremely tight association between the peptide and its 
receptor with very little dissociation even after 2h washing with excess 
unlabelled ET-1. This is in agreement with studies in other systems (Hirata et 
a l , 1988; Kanse et al., 1989; Marin et al., 1991; Serradeil-Le Gal et al.,
1991). The slow dissociation of ET-1 from its receptor almost certainly 
explains why the ET-1-stimulated increase in intracellular Ca2+ levels cannot 
be washed out compared with the LPA response which is easily washed out 
(section 4.3). The tight association between ligand and receptor may also be 
important for the sustained nature of ET-1-stimulated PtdIns(4,5)P2 
hydrolysis. It does not, however, appear to explain the unusual characteristics 
of ET-l-stimulated inositol phosphates accumulation (chapter 4) since in other 
systems where the dissociation of ET-1 from its receptor has been shown to 
be slow the inositol phosphates responses have been characteristic of G 
protein-coupled receptors in terms of their sensitivity to PMA and GTP[S] 
(Baldi and Dunn, 1990; Thomas et al., 1991; Takuwa et al., 1990; Resink et 
al., 1990, Hirata et al., 1988; Reynolds et al., 1989).
As discussed previously (chapter 4), receptors which couple to G 
proteins generally show an apparent decrease in affinity for their agonist in the
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presence of GTP[S]. In bovine endothelial cell membranes GTP[S] inhibited 
the binding of both [125I] ET-1 and ET-3 in a dose-dependent manner (Eguchi 
et al., 1991) and, similarly, in vascular smooth muscle cell membranes ET-1 
binding was also inhibited by GTP[S] (Takuwa et al., 1990). However, 
GTP[S] and GDP[S] had no effect on [125I] ET-1 binding in the studies 
presented here. Similar results have also been reported for ET-1 binding 
studies in porcine aortic and rat lung membranes (Kanse et al., 1989) and rat 
liver plasma membranes (Serradeil-Le Gal etal., 1991) and also for 
sarafotoxin S6b binding to rat atrial membranes (Kloog et al., 1988). The 
capacity of agonists to form a guanine nucleotide-sensitive high affinity 
binding complex has been correlated with their efficacy for stimulating 
polyphosphoinositide breakdown. Although ET-1 appeared to be very 
efficacious at stimulating Ins(l,4,5)P3 generation and inositol phosphates 
accumulation, GTP[S] clearly had no effect on [125I] ET-1 binding to 
membranes. This may reflect an unusual interaction of the ET-1 receptor with 
a G protein or, alternatively, it may suggest that only a small part of the ET-1 
inositol phosphates response is generated by a G protein-regulated Ptdlns- 
PLC activity. Both these proposals have previously been suggested by the 
characteristics of ET-1-stimulated inositol phosphates generation (chapter 4).
Competition binding studies yielded a rank order of potency of ET-1 ~ 
ET-2 > ET-3 in displacing [125I] ET-1 binding. The Kj values obtained (~ 2- 
4nM for ET-1 and ET-2; ~ 60nM for ET-3) are similar to the EC50 values for 
inositol phosphates accumulation and choline generation in response to each of 
the isopeptides (~ 2nM for ET-1 and ET-2; ~ 50nM for ET-3).
Although the characteristics of the binding site on Rat-1 cell membranes 
suggests an ETa type receptor with highest affinity for ET-1, this receptor has 
been shown to have seven membrane spanning domains and putative sites for 
protein kinase C-mediated phosphorylation consistent with a receptor which is 
coupled to a G protein in the accepted manner (Arai et al., 1990). Since the
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characteristics of ET-l-stimulated inositol phosphates accumulation in Rat-1 
cells do not corresponsd to these structural observations, this may suggest the 
presence of another subtype of ET receptor on Rat-1 cells with a different 
receptor-G protein interaction. It is worth noting that the nonselective ET 
receptor subtype contains unusual sequences within the third cytoplasmic loop 
(Sekurai et al., 1990) which is the putative site of the G protein interaction 
suggesting that not all subtypes of the ET receptor may interact with G 
proteins in the same way. Alternatively, an ETa -like receptor may control 
both G protein-regulated and non-G protein-regulated Ptdlns-PLC isozymes.
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Chapter 6
Conclusions
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6.1 Conclusions.
The object of the work presented here was to investigate the signal 
transduction pathways stimulated by ET-1 in Rat-1 cells which might be 
important in the mitogenic response to the peptide. ET-1-stimulated DNA 
synthesis was reported to be dependent on protein kinase C activity (Muldoon 
et al., 1990). The inhibitory effect of chronic PMA treatment, which down- 
regulates protein kinase C, on pH] thymidine incorporation into DNA in 
response to ET-1 confirmed this (chapter 3) and therefore suggests that 
stimulation of cell proliferation by the peptide is at least partly dependent on 
activation of one or more isozymes of protein kinase C. Generation of DAG 
would therefore appear to have a central role since it is the physiological 
activator of the enzyme. Sustained elevation of DAG levels in response to ET- 
1 stimulation in Rat-1 cells has been reported (Muldoon et al., 1990; P. Kaur, 
personal communication) and both PtdIns(4,5)P2 and PtdCho hydrolysis 
could be potential sources of this second messenger. In other cell types 
stimulated Ca2+ influx has also been implicated in the proliferative response to 
ET-1 based on the inhibitory effects of Ca2+ L-channel blockers such as 
nifedipene (Nakaki et a l , 1989; Shichiri et al., 1991). Similarly, a role for 
Ca2+ influx has also been suggested in bombesin-stimulated pH] thymidine 
incorporation into DNA in Swiss 3T3 cells (Takuwa et a l , 1991). Ca2+ influx 
has been proposed to occur by several different mechanisms including direct 
receptor activation of Ca2+ channels or activation by second messengers 
generated as a result of PtdIns(4,5)P2 hydrolysis (see section 1.4.2).
The results presented in this thesis provide evidence for ET-1-stimulated 
PtdIns(4,5)P2 hydrolysis by a Ptdlns-PLC and PtdCho hydrolysis via PLD in 
Rat-1 cells. Mass measurement of Ins(l,4,5)P3 and PtdIns(4,5)P2 levels 
suggested sustained hydrolysis of PtdIns(4,5)P2 in response to ET-1.
Clearly, this may result in the prolonged generation of DAG which has 
important implications for the activation of protein kinase C. Measurement of
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intracellular Ca2+ changes demonstrated two phases of Ca2+ mobilization 
following stimulation with ET-1; the initial increase is probably due to 
Ins(l,4,5)P3-mediated release from intracellular stores while the scond phase 
is dependent on Ca2+ influx (chapter 4). As discussed earlier, Ca2+ influx has 
been implicated in the mitogenic response to ET-1 in other cell types and may 
also contribute to the response in Rat-1 cells. Measurement of DNA synthesis 
and cell division in low Ca2+ buffers or in the presence of Ca2+channel 
blockers would provide more evidence on the potential role of Ca2+ influx in 
the initiation of cell proliferation by ET-1. A comparison of the changes in 
Ins(l,4,5)P3 levels and intracellular [Ca2+] in response to ET-1 and LPA 
suggested that the second phase of Ca2+ mobilization was not dependent on 
the generation of Ins(l,4,5)P3 and therefore questions the role of the sustained 
formation of this second messenger. In some systems Ins(l,3,4,5)P4f which 
is generated from Ins(l,4,5)P3 by an InsP3-3-kinase, has been implicated in 
stimulating Ca2+ influx (see section 1.4.2); measurements of Ins(l,3,4,5)P4 
levels following stimulation with ET-1 might therefore provide more 
information on the significance of sustained Ins(l,4,5)P3 generation.
PtdCho hydrolysis is increasingly being recognized as an important 
second messenger generating pathway; in particular, it is often put forward as 
an additional source of DAG. ET-1 stimulated PtdCho hydrolysis in Rat-1 
cells by a PLD-catalysed mechanism (chapter 3). Although this appeared to be 
a transient response based on the accumulation of PtdBut, the generation of 
choline was more sustained suggesting another pathway of PtdCho 
breakdown. This could involve a PtdCho-specific PLC. The products of 
such a hydrolysis would be DAG and phosphocholine. The inability to detect 
any increase in phosphocholine levels following ET-1 stimulation may be due 
to the rapid resynthesis of the parent lipid (chapter 3) or further metabolism to 
choline by a phosphatase.
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In many systems where prolonged DAG formation has been observed 
Ins(l,4,5)P3 generation has been transient so that PtdCho hydrolysis has been 
considered as an alternative source to maintain DAG levels at later times 
(Wright et al., 1988; Pessin and Raben, 1989; Matozaki and Williams, 1989; 
Huang and Cabot, 1990). In vitro experiments have shown that protein 
kinase C activity can be stimulated by molecular species of DAG identical to 
those generated by PtdCho hydrolysis (Go et al., 1987) while ai-adrenergic 
receptor stimulation in MDCK cells has been shown to activate protein kinase 
C under conditions when polyphosphoinositide hydrolysis was inhibited 
(Slivka et al., 1988). Studies such as these suggest an important role for 
PtdCho hydrolysis in maintaining elevated DAG levels and thus prolonging 
protein kinase C activation. However, since in Rat-1 cells PtdIns(4,5)P2 
hydrolysis stimulated by ET-1 is sustained and could therefore maintain 
elevated DAG levels, this questions the role of PtdCho breakdown. Indeed, 
PtdCho hydrolysis by a PLD-catalysed pathway yields phosphatidic acid 
which must be further metabolized by phosphatidate phosphohydrolase to 
generate DAG. PtdIns(4,5)P2 hydrolysis is therefore a more direct source of 
DAG. In addition, there have been some reports where protein kinase C 
activation has been dissociated from PtdCho-derived DAG. In IIC9 
fibroblasts low concentrations of thrombin which stimulated PtdCho 
hydrolysis but not PtdIns(4,5)P2 breakdown did not result in the activation of 
protein kinase C despite the generation of DAG from PtdCho (Leach et al., 
1991). Similarly, thyrotropin-releasing hormone treatment of GH3 cells 
resulted in a rapid but transient activation of protein kinase C although the 
increase in DAG was sustained (Martin et al., 1990b). In addition, the 
mitogenic response of Swiss 3T3 fibroblasts to exogenous PtdCho- 
hydrolysing phospholipase C was independent of protein kinase C (Larrodera 
et al., 1990). These studies question the relevance of DAG derived from 
PtdCho as an activator of protein kinase C in the systems mentioned.
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However, it is also important to realize the difficulties in fully measuring 
protein kinase C activity. The studies by Martin et al. (1990) measured the 
activation of protein kinase C by the translocation of the enzyme to the 
membrane. However, other studies have shown that redistributuion of protein 
kinase C can be dissociated from phosphorylation of its substrates (Trilivas et 
al., 1991). But even where phosphorylation of substrates is measured as was 
done by Leach et al. (1991) interpretation is also not clear cut since different 
protein kinase C isozymes may have different substrate specificities (reviewed 
in Kikkawa et al., 1989). In order to conclusively determine the sources of 
DAG in response to ET-1 stimulation in Rat-1 cells it would be necessary to 
determine the molecular species of DAGs formed and compare them with the 
molecular species contained in cellular phospholipids as has been done in other 
systems (Pessin and Raben, 1989; Divecha et al., 1991). Different isozymes 
of protein kinase C show differences in their regulation by phospholipid 
metabolites and in their substrate specificities and therefore the generation of 
DAGs with different molecular structures may provide for a greater diversity 
in controlling cellular processes dependent on protein kinase C.
It is possible that DAG is not always the relevant mediator generated as a 
result of PtdCho hydrolysis. The results presented in chapter 3 provide 
evidence for PLD-catalysed hydrolysis of PtdCho which would yield 
phosphatidic acid (PtdOH) as the initial product rather than DAG. There is 
increasing evidence for a second messenger role for PtdOH. In A431 
carcinoma cells and mesangial cells PtdOH increased polyphosphoinositide 
turnover, raised intracellular [Ca2+], induced expression of c-fos and c-myc 
and stimulated DNA synthesis (Moolenaar et al., 1986; Knauss etal.> 1990).
In Swiss 3T3 cells PtdOH inhibited adenylyl cyclase (Murayama and Ui,
1987) while in neuroblastoma cells cGMP levels were elevated (Ohsako and 
Deguchi, 1981). Most recently, PtdOH-dependent protein phosphorylation 
has been demonstrated in soluble extracts from rat liver, brain, lung and testis.
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The profiles of proteins phosphorylated were distinct from those 
phosphorylated in response to protein kinae C activation (Bocckina et al., 
1991) suggesting a PtdOH-dependent protein kinase. The ability of PtdOH to 
stimulate DNA synthesis is of particular interest due to the mitogenic response 
to ET-1 in Rat-1 cells. Thus the stimulation of PtdCho hydrolysis via 
phospholipase D by ET-1 in Rat-1 cells may generate PtdOH as another 
mediator in addition to the Ins(l,4,5)P3 and DAG generated from 
PtdIns(4,5)P2 breakdown. In addition, results presented here and previous 
reports (van Corven et al., 1989; Jalink et al., 1990; van Corven et al., 1992) 
also provide evidence for LPA as a mitogenic stimulus for cells although the 
physiological relevance of this is not known. Since most studies have 
investigated the effect of exogenously added PtdOH or LPA it is not clear 
whether PtdOH or LPA produced as a result of stimulated phospholipid 
turnover exert their effects within the cell or are released to act in an autocrine 
or paracrine manner.
Although the work presented here has focussed on PtdIns(4,5)P2 and 
PtdCho hydrolysis as potential mitogenic signalling pathways mediating the 
action of ET-1 in Rat-1 cells it is highly likely that other pathways are also 
involved. In vascular smooth muscle cells and rat mesangial cells ET-1 has 
been shown to activate PLA2 resulting in the release of arachidonic acid (AA) 
(Resink et al., 1989a; Resink etal., 1990; Reynolds etal., 1989; Simonson 
and Dunn, 1990c) and preliminary experiments suggest that ET-1 also 
stimulates A A release in Rat-1 cells (S. Currie and A. Stewart, personal 
communication). AA is increasingly being recognized as a potentially 
important second messenger molecule and has been reported to activate protein 
kinase C (a, P and y isozymes to different extents) and Ptdlns-PLC and to 
mimic the action of InsP3 on Ca2+ mobilization (reviewed in Naor, 1991; 
Shinomura et al., 1991; Chen and Murakami, 1992). A mitogenic role has 
also been proposed for AA and it has been shown to stimulate pH] thymidine
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incorporation into DNA in the presence of insulin in Swiss 3T3 cells (Takuwa 
et al., 1988; Gil et al,, 1991). Activation of AA release via PLA2 or another 
enzymic pathway may therefore contribute in eliciting a mitogenic response to 
ET-1 in Rat-1 cells.
In addition to release of AA, agonist stimulation may also result in the 
release of other unsaturated fatty acids such as oleic acid. Indeed, ET-1 can 
stimulate release of oleic acid in Rat-1 cells (A. Stewart, personal 
communication). This is of relevance due to the reported ability of oleic acid 
to activate protein kinase C (El Touny et al,, 1990; Shinomura et al,, 1991) 
and phospholipase D in vitro (Chalifour and Kanfer, 1982). Results from 
experiments investigating the regulation of phospholipase D by ET-1 
stimulation suggested the involvement of a pathway in addition to protein 
kinase activation and Ca2+ influx (chapter 3) and this could potentially be 
achieved by the stimulated release of oleic acid.
Tyrosine kinase activity is recognized to be important for the mitogenic 
response to growth factors such as PDGF and EGF (Escobedo and Williams, 
1988; Escobedo et al., 1988; Pandiella et al,, 1989). In addition, a number of 
proteins which have been implicated in the control of cell proliferation are 
regulated by phosphorylation at tyrosine residues e.g. cdc2 kinase (see section 
1.1), MAP kinase and Raf-1 kinase (see section 1.2.3). Phosphorylation of 
proteins on tyrosine residues has now been demonstrated in response to 
stimulation by a number of mitogenic peptides whose receptors do not possess 
intrinsic tyrosine kinase activity. In rat mesangial cells ET-1 rapidly enhanced 
tyrosine phosphorylation of a number of proteins which were also 
phosphorylated in response to EGF suggesting that these agents share a 
common signalling pathway (Force et al., 1991). Similarly, in Swiss 3T3 
cells ET-2 stimulated rapid tyrosine phosphorylation of a set of substrates also 
phosphorylated in response to bombesin and vasopressin (Zachary et al., 
1991a, 1991b). Agonists have frequently been classified into different
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groups, those whose receptors have intrinsic tyrosine kinase activity and those 
which couple to effector systems via G proteins. The above reports, however, 
suggest an interaction between G protein-coupled systems and tyrosine 
kinases. This is supported by some reports of G protein involvement in the 
transduction of signals by receptor tyrosine kinases (reviewed in Ives, 1991). 
In permeabilized vascular smooth muscle cells GTP[S] potentiated PDGF- 
stimulated InsP3 generation (Huang and Ives, 1989) while EGF-stimulated 
proliferation in a human breast cancer cell line and EGF-stimulated 
Ins(l,4,5)P3 generation in hepatocytes were inhibited by pertussis toxin 
(Church and Buick, 1988; Johnson and Garrison, 1987). Also, in rat 
macrophages colony stimulating factor 1-stimulated phosphatidylcholine- 
specific phospholipase C activity was reduced by pertussis toxin and enhanced 
by GTP[S] (Ghosh Choudhury, 1991).
Preliminary studies indicate that ET-1 can stimulate tyrosine 
phosphorylation of a number of proteins in Rat-1 cells (R. Plevin and M. 
Saville, personal communication). Since the ET receptors characterized so far 
contain seven membrane-spanning domains similar to other G protein-coupled 
receptors, this suggests the activation of a non-receptor tyrosine kinase which 
may constitute an additional mitogenic signalling pathway for ET-1. A 
common substrate of EGF and PDGF receptor tyrosine kinases is 
phospholipase Cy (Meisenhelder et al., 1989; Wahl et al., 1989; Nishibe et al., 
1990). PtdIns(4,5)P2 hydrolysis in response to PDGF in Balb c/3T3 cells and 
Swiss 3T3 cells has been shown to be sustained (Fukami and Takenawa,
1989; Plevin et al., 1991) and is therefore similar to the response to ET-1 in 
Rat-1 cells. The results presented here for ET-1 suggested two pathways of 
PtdIns(4,5)P2 hydrolysis, a Ca2+-independent and a Ca2+-dependent pathway 
(chapter 4). It is therefore tempting to speculate that in addition to stimulating 
a Ca2+-independent pathway of polyphosphoinositide turnover involving a G 
protein ET-1 might also stimulate PLCy via the activation of a tyrosine kinase
164
in a Ca2+-dependent manner. Since activation of PLCy is believed to involve 
tyrosine phosphorylation rather than interaction with a G protein this 
hypothesis could also account for the unusual characteristics of the ET-1- 
stimulated inositol phosphates response regarding the effects of guanine 
nucleotide analogs and PMA (chapter 4). Tyrosine phosphorylation of PLCy 
has been demonstrated in response to stimulation by agonists which exert their 
effects via receptors which do not possess intrinsic tyrosine kinase activity; for 
example, IgE stimulation of rat basophilic leukemia cells (Park et al., 1991).
It would therefore be of interest to investigate the effect of selective tyrosine 
kinase inhibitors such as genistein (Akiyama et al., 1987) or phosphotyrosine 
phosphatase inhibitors on ET-1-stimulated Ins(l,4,5)P3 generation and DNA 
synthesis in Rat-1 cells. Using this approach, tyrosine phosphorylation has 
been implicated in the activation of phospholipase D in response to fMet-Leu- 
Phe, platelet-activating factor and leukotriene B4 in human neutrophils (Uings 
et al., 1992). An alternative pathway which might explain the Ca2+ 
dependency of the second phase of ET-1-stimulated Ins(l,4,5)P3 generation 
and the lack of effect of GTP[S] and PMA on inositol phosphates 
accumulation is that the influx of Ca2+ in response to the peptide activates a 
particular species of Ptdlns-PLC. Arguing against this, however, is the 
observation that LPA also appears to stimulate Ca2+ influx, yet responses to 
this lipid are typical of an agonist acting through a G protein-coupled receptor.
Results presented in chapter 6 provide a preliminary characterization of 
the ET receptor on Rat-1 cells. Although the order of potency of ET 
isopeptides in competing for bound, radiolabeled ET-1 suggested an ET-1- 
selective receptor, the lack of effect of GTP[S] on the binding of the peptide 
may distinguish the binding site on Rat-1 cells from the previously identified 
ETa receptor which has the structure expected of a G protein-coupled receptor 
(Arai et al., 1990). The inability of guanine nucleotides to affect ET-1 binding 
may simply be due to an unusual interaction of the ET receptor with a G
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protein; alternatively, it may suggest the existence of another type of ET 
receptor.
Mitogenesis is clearly a complex event involving the interaction of many 
different signalling pathways. This work has investigated the regulation of 
PtdIns(4,5)P2 and PtdCho hydrolysis by ET-1 in Rat-1 cells. Both these 
pathways can give rise to a number of second messengers which might initiate 
or facilitate the onset of cell proliferation. Given the existence of numerous 
species of protein kinase C and Ptdlns-PLC (and possibly also PLD although 
as yet none have been completely purified) and the probable involvement of 
other signal transduction pathways such as activation of PLA2 or non-receptor 
tyrosine kinases, there is clearly considerable potential for great diversity in the 
regulation of cellular processes.
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